Drug(s);Gene;Variant/Haplotypes;Alleles;Outcome;Effect;Notes;Sentence
KETANSERIN;HTR1B;rs130060;C;Associated  with  decreasedaffinity toHTR1B with  ➔ KETANSERIN;PD;C allele is referred to as the Cys-124 allele in the paper and was mapped to rs130060 by PharmGKB.;Allele C is associated with decreased affinity to HTR1B with ketanserin in COS-7 cells as compared to allele G.
THIOXANTHINE;XDH;rs2295474;T;Associated  with  decreasedclearance of XDH with  ➔ THIOXANTHINE;Metabolism/PK;;Allele T is associated with decreased clearance of XDH with thioxanthine as compared to allele C.
PAROMOMYCIN;MT-RNR1;rs267606617;G;Associated  with  decreased activity  of MT-RNR1 with  ➔ PAROMOMYCIN;PD;In vitro study of LCLs derived from symptomatic and asymptomatic members of an Arab-Israeli pedigree carrying A1555G and married-in members without the mutation. Growing the LCLs in medium containing paromomycin found that cells from individuals with A1555G had significantly longer doubling times (i.e. slower growth) than controls. Pulse labeling of translation products with [35S] methionine showed that cell lines with A1555G had decreased mitochondrial translation compared to controls.;Allele G is associated with decreased activity of MT-RNR1 with paromomycin.
THIOXANTHINE;XDH;rs45442092;T;Associated  with  decreasedclearance of XDH with  ➔ THIOXANTHINE;Metabolism/PK;;Allele T is associated with decreased clearance of XDH with thioxanthine as compared to allele C.
DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;HTR1B;rs130060;C;Associated  with  increased affinity toHTR1B with  ➔ DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;PD;C allele is referred to as the Cys-124 allele in the paper and was mapped to rs130060 by PharmGKB.;Allele C is associated with increased affinity to HTR1B with dihydroergotamine, methysergide or sumatriptan in COS-7 cells as compared to allele G.
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Associated  with  increased  expression of TYMS when treated  with  ➔ FLUOROURACIL;Metabolism/PK;compared to the 2R/2R-2R/3RC-2R/3RG genotypes (3RC has the additional SNP in the repeat).;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased expression of TYMS when treated with fluorouracil in colonic mucosa of colorectal cancer patients as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.
CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;Associated  with  increased  expression of SAE1 when treated  with  ➔ CISPLATIN, IRINOTECAN;Metabolism/PK;;Genotype CG is associated with increased expression of SAE1 when treated with cisplatin and irinotecan non-small-cell lung cancer tumors.
METHOTREXATE;SHMT1;rs1979277;AA;Associated  with  increased catalytic  activity  of TYMS when treated  with  ➔ METHOTREXATE;Metabolism/PK;indicating decreased in vitro methotrexate sensitivity.;Genotype AA is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.
IVACAFTOR;CFTR;rs113993960;del;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;F508del allele. 14.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele del is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs397508139;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;I336K allele. 4 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
FLUOROURACIL;DPYD;rs1335150891;C;Associated  with  decreasedcatalytic  activity  of DPYD when treated  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate.;Allele C is associated with decreased catalytic activity of DPYD when treated with fluorouracil in 293FT cells as compared to allele T.
IVACAFTOR;CFTR;rs141033578;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;S977F allele. 3.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs121909011;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R334W allele. 3.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs77409459;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;T338I allele. 5.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs397508510;C;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;H1054D allele. 5.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
PHENYTOIN;CYP2C9;rs12782374;A;Associated  with  decreased expression of CYP2C9 when treated  with  ➔ PHENYTOIN;;when co-transfected with CAR (NR1I3) or PXR (NR1I2), suggesting this variant disrupts a binding site responsive to CAR and PXR in the CYP2C9 promoter.;Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells.
IVACAFTOR;CFTR;rs397508435;C;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;L927P allele. 52 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs77010898;A;Associated  with  increased  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;;Allele A is associated with increased activity of CFTR when treated with ivacaftor as compared to allele G.
ESTRADIOL;TCL1A;rs7158782;G;Associated  with  increased  expression of IL17RA when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7159713,rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to  = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele A.
IVACAFTOR;CFTR;rs397508328;G;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;M1V allele. 8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs77932196;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R347H allele. 9.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
NIMESULIDE;PTGS2;rs5272;C;Associated  with  increased enzyme  activity  of PTGS2 when treated  with  ➔ NIMESULIDE;Metabolism/PK;using arachidonate as substrate. ie. it had higher residual activity in the presence of the inhibitor (nimesulide) compared to wild type.;Allele C is associated with increased enzyme activity of PTGS2 when treated with nimesulide.
IVACAFTOR;CFTR;rs75527207;A;Associated  with protein stability of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;G551D allele. CFTR proteins with the A allele are thermally unstable. Ivacaftor does increases the stability of these proteins.;Allele A is associated with protein stability of CFTR when treated with ivacaftor.
IVACAFTOR;CFTR;rs1800111;C;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;L997F allele. 3.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs74551128;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;A455E allele. 2.8 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs186045772;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;F1074L allele. 3.1 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs78769542;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R1070Q allele. 1.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs397508537;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;D110E allele. 4.1 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs397508256;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;E56K allele. 4 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs121908751;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;E92K allele. 7 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs75527207;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;G551D allele. 55.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;Associated  with  increased  expression of TLR4 when treated  with  ➔ CISPLATIN;Other;HEI-OC1 cells expressing TPMT*1 or TPMT*3A were treated with 25 ‘M cisplatin or left untreated and TLR4 expression was only higher in response to cisplatin in TPMT*3A expressing cells.;TPMT *3A is associated with increased expression of TLR4 when treated with cisplatin in HEI-OC1 cells as compared to TPMT *1.
IVACAFTOR;CFTR;rs368505753;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;P67L allele. 5.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
NIMESULIDE;PTGS2;rs5273;G;Associated  with  increased enzyme  activity  of PTGS2 when treated  with  ➔ NIMESULIDE;Metabolism/PK;using arachidonate as substrate. ie. it had 60% higher residual activity in the presence of the inhibitor (nimesulide) compared to wild type.;Allele G is associated with increased enzyme activity of PTGS2 when treated with nimesulide.
IVACAFTOR;CFTR;rs115545701;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R74W allele. 2.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
SACUBITRIL;CES1;rs71647871;CT;Associated  with  decreasedcatalytic  activity  of CES1 when treated  with  ➔ SACUBITRIL;Efficacy;The G143E variant appears to contribute to approximately 10% variation of sacubitril activation. E variant has null function. Studies in transfected human cells and isolated liver cells.;Genotype CT is associated with decreased catalytic activity of CES1 when treated with sacubitril as compared to genotype CC.
IVACAFTOR;CFTR;rs1800100;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R668C allele. 2.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
ESTRADIOL;TCL1A;rs7158782;A;Associated  with  increased  expression of IL12RB2 when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7159713,rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant""and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.
ESTRADIOL;TCL1A;rs7158782;G;Associated  with  increased  expression of TCL1A when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7159713,rs2369049 and rs11849538.  Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"".  dbSNP has G as the minor allele in Europeans so  variant was understood to = G.  Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.  Also, after ER blockade, U2OS cell lines with variant SNPs demonstrated elevated NFKB1 transcriptional activity and a dramatic drop in TCL1A expression, while  TCL1A expression was elevated in wt cell lines.";Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele A.
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AG;Associated  with  activity  of CYP19A1 when treated  with  ➔ ANASTROZOLE, EXEMESTANE, LETROZOLE;Other;The AG genotype was associated with greater change in aromatase activity in people with breast cancer. This is suggestive of higher levels of aromatase inhibition and therefore increased drug efficacy in carriers of the AG genotype. However, the variant allele (A) was associated with a significant increase in Estradiol (E2) plasma levels post-anastrozole treatment, in a followup study of 200 postmenopausal women with Breast Neoplasms. The multiplicative effect of 1 rare allele (A allele) = 12.58 fold increase in E2 levels, p=0.0002. The group concluded that allele A may result in higher expression of CYP19, providing increased targets for aromatase inhibitors thus higher changes in aromatase activity, but not resulting in higher reduction in E2 levels. This variant was shown to be in tight LD with rs7176005, which had similar association patterns.;Genotype AG is associated with activity of CYP19A1 when treated with anastrozole, exemestane and letrozole.
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs7176005;CT;Associated  with  activity  of CYP19A1 when treated  with  ➔ ANASTROZOLE, EXEMESTANE, LETROZOLE;Other;The CT genotype was associated with greater change in aromatase activity in people with breast cancer. This is suggestive of higher inhibition levels of aromatase activity and therefore increased drug efficacy in carriers of the CT genotype. However, the variant allele (T) was associated with a significant increase in Estradiol (E2) plasma levels post-anastrozole treatment, in a followup study of 200 postmenopausal women with Breast Neoplasms. The multiplicative effect of 1 rare allele (T allele) = 10.88 fold increase in E2 levels, p=0.0002. The group concluded that allele T may result in higher expression of CYP19, providing increased targets for aromatase inhibitors thus higher changes in aromatase activity, but not resulting in higher reduction in E2 levels. This variant was shown to be in tight LD with rs6493497, which had similar association patterns.;Genotype CT is associated with activity of CYP19A1 when treated with anastrozole, exemestane and letrozole as compared to genotype CC.
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;Associated  with  decreased activity  of TPMT when treated  with  ➔ MERCAPTOPURINE, THIOGUANINE;Metabolism/PK;"In children with acute lymphoblastic leukemia, those heterozygous for a TPMT variant allele had increased levels of thioguanine nucleotides (TGNs), and decreased levels of methylmercaptopurine nucleotides (MeMPNs), as compared to wild-type; this indicates reduced TPMT activity for these genotypes. n=425 taking thioguanine and n=707 taking mercaptopurine. Note that not all heterozygote genotypes appeared in both the thioguanine and mercaptopurine cohorts, see paper for details. Also, the authors note that within the mercaptopurine cohort, those with the *1/*3C genotype had borderline-significantly lower TGN and MeMPN concentrations as compared to those with the *1/*3A genotype, despite similar drug doses (p=0.05 and p=0.06, respectively).";TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34 are associated with decreased activity of TPMT when treated with mercaptopurine or thioguanine as compared to TPMT *1/*1.
SITAGLIPTIN;DPP4;rs759717;CC;Associated  with  increased  activity  of DPP4 when treated  with  ➔ SITAGLIPTIN;PD;"""Three genotypes were associated with higher DPP4 activity during placebo (rs6733162 GG) or during sitagliptin (rs2909451 TT and rs759717 CC) (Table 3; Fig. 3).""";Genotype CC is associated with increased activity of DPP4 when treated with sitagliptin as compared to genotypes CG + GG.
SITAGLIPTIN;DPP4;rs2909451;TT;Associated  with  increased  activity  of DPP4 when treated  with  ➔ SITAGLIPTIN;PD;"""Three genotypes were associated with higher DPP4 activity during placebo (rs6733162 GG) or during sitagliptin (rs2909451 TT and rs759717 CC) (Table 3; Fig. 3).""";Genotype TT is associated with increased activity of DPP4 when treated with sitagliptin as compared to genotypes CC + CT.
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*21, CYP2D6*41;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;Associated  with  increased  expression of MKI67 when treated  with  ➔ TAMOXIFEN;Efficacy;Decrease in MK167 was measure of tamoxifen efficacy. Patients with two variant CYP2D6 decreased and null alleles had less response to tamoxifen as measured by MKI67 decreases compared to patients with zero or one CYP2D6 decreased and null alleles. *14 was determined as CYP2D6*14 (1758G>A).;CYP2D6 *5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41 is associated with increased expression of MKI67 when treated with tamoxifen in tumor biopsy tissue as compared to CYP2D6 *1/*1 + *1/*5 + *1/*10 + *1/*14 + *1/*18 + *1/*21 + *1/*41.
ESTRADIOL;TCL1A;rs7158782;A;Associated  with  increased  expression of IL1R2 when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7159713,rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant""and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.
ESTRADIOL;TCL1A;rs7158782;A;Associated  with  increased  expression of IL17A when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7159713,rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant""and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL17A when treated with estradiol as compared to allele G.
ESTRADIOL;TCL1A;rs7159713;A;Associated  with  increased  expression of IL1R2 when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant""and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.
ESTRADIOL;TCL1A;rs7159713;A;Associated  with  increased  expression of IL12RB2 when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782 ,rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant""and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.
ESTRADIOL;TCL1A;rs7159713;A;Associated  with  increased  expression of IL17A when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant""and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL17A when treated with estradiol as compared to allele G.
ESTRADIOL;TCL1A;rs7159713;G;Associated  with  increased  expression of TCL1A when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles forrs7158782,rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.  Also, after ER blockade, U2OS cell lines with variant SNPs demonstrated elevated NFKB1 transcriptional activity and a dramatic drop in TCL1A expression, while TCL1A expression was elevated in wt cell lines.";Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele A.
IVACAFTOR;CFTR;rs78655421;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R117H allele. 4.1 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs397508759;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;E193K allele. 6.1 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs150212784;G;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;F1052V allele. 2.3 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs34911792;G;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;S1235R allele. 2.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs397508513;C;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;K1060T allele. 2.7 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
ESTRADIOL;TCL1A;rs7159713;G;Associated  with  increased  expression of IL17RA when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782,rs2369049 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele A.
METHOXSALEN;CYP2A6;CYP2A6*15, CYP2A6*21, CYP2A6*22;*15 + *21 + *22;Associated  with  decreasedenzyme  activity  of CYP2A6 when treated  with  ➔ METHOXSALEN;Other;"The authors transfected plasmids with human CYP2A6*15, *21 or *22 and NADPH-CYP coenzyme into ""E. coli"" and prepared the membrane fractions to asses CYP2A6 enzyme activity. Enzyme activity was assessed with a fluorescence-based coumarin 7-hydroxylase assay (an assay of metabolic activity). The authors then quantified mean IC50 (‘M) values of methoxsalen (a CYP2A6 inhibitor) needed to decrease coumarin 7-hydroxylation.";CYP2A6 *15 + *21 + *22 are associated with decreased enzyme activity of CYP2A6 when treated with methoxsalen in E. coli membrane fractions from cells expressing human CYP2A6 *15, *21 or *22.
ATORVASTATIN;SCAP;rs12487736;TT;Associated  with  decreasedtranscription of SCAP when treated  with  ➔ ATORVASTATIN;Other;This reduction was not observed in cells from patients with the TC+CC genotype. Variant described as SCAP A2386G Ile796Val, and was genotyped using the HpyCH4 IV restriction enzyme. Here, alleles have been complemented and this rsID maps to a position where the T allele abolishes the restriction site.;Genotype TT is associated with decreased transcription of SCAP when treated with atorvastatin in PBMCs.
IVACAFTOR;CFTR;rs202179988;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R1070W allele. 6.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;Associated  with  decreased activity  of CYP2D6 when treated  with  ➔ TAMOXIFEN;Other;Individual alleles in the EM group had distinct metabolic activity (p<0.0001). Fixing the wild-type (*1) allele activity=1.00, the *2 allele had an estimated scaled activity of 0.63, which was significantly different from the *1 allele (p=<0.0001, 95% CI: 0.021-0.041) while the *35 allele had activity of 1.03, which was similar to *1. Please note, UM alleles (composite, not specifically reported in this study had a scaled activity of 0.73).;CYP2D6 *2 is associated with decreased activity of CYP2D6 when treated with tamoxifen as compared to CYP2D6 *1.
VITAMIN E;CYP4F2;rs3093105;C;Associated  with  increased catalytic  activity  of CYP4F2 when treated  with  ➔ VITAMIN E;Metabolism/PK;;Allele C is associated with increased catalytic activity of CYP4F2 when treated with vitamin e in Sf9 insect cells transfected with CYP4F2 as compared to allele A.
ESTRADIOL;;rs11849538;C;Associated  with  increased  expression of IL17A when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713, and rs2369049. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G, but this is not completely clear due to possibility of strand switch. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele C is associated with increased expression of IL17A when treated with estradiol as compared to allele G.
ESTRADIOL;;rs11849538;C;Associated  with  increased  expression of IL1R2 when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713, and rs2369049. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G, but this is not completely clear due to possibility of strand switch. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele C is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.
IVACAFTOR / LUMACAFTOR;CFTR;rs78655421;A;Associated  with  increased  activity  of CFTR when treated  with  ➔ IVACAFTOR / LUMACAFTOR;Efficacy;;Allele A is associated with increased activity of CFTR when treated with ivacaftor / lumacaftor as compared to allele G.
IVACAFTOR, NPPB;CFTR;rs75527207;A;Associated  with  increased  activity  of CFTR when treated  with  ➔ IVACAFTOR, NPPB;Efficacy;NPPD and VX-770 applied together resulted in an overall 46-fold increase of G551D-CFTR currents (46.6 ¤ 8.5 fold, n = 18), which larger than the sum of the effects from individual reagents (~12-fold). However, the effects of NPPB and VX-770 together are smaller than the product of individual effects (~110-fold).;Allele A is associated with increased activity of CFTR when treated with ivacaftor and nppb Chinese hamster ovary cells as compared to allele G.
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;Associated  with  increased  activity  of CYP3A4 when treated  with  ➔ EFAVIRENZ;Metabolism/PK;as measured by plasma 4beta-OHC/Chol ratio;CYP2B6 *6 is associated with increased activity of CYP3A4 when treated with efavirenz.
FLUOROURACIL;DPYD;rs56005131;T;Associated  with  decreasedcatalytic  activity  of DPYD when treated  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate.;Allele T is associated with decreased catalytic activity of DPYD when treated with fluorouracil in 293FT cells as compared to allele G.
ESTRADIOL;;rs2369049;G;Associated  with  increased  expression of IL17RA when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele A.
ESTRADIOL;;rs2369049;A;Associated  with  increased  expression of IL12RB2 when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.
ESTRADIOL;;rs2369049;A;Associated  with  increased  expression of IL17A when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL17A when treated with estradiol as compared to allele G.
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG;Associated  with  increased  activity  of CFTR when treated  with  ➔ ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;PD;"""To study the effects of CFTR modulators in vitro, we have established four intestinal organoid cultures compound heterozygous for CFTR: N1303K with class I variants 2143delT (two patients), 3821delT (one patient) and with the rare variant G461E (one patient). Variants 2143delT and 3821delT induce frameshifting and are classified as ©severeî; G461E (p.Gly461Glu) is a rare pathogenic missense variant, which leads to the substitution of glycine for glutamine acid; the class of this variant is unknown. As a control of morphological features, we used intestinal organoids derived from a CF patient with the F508del/F508del genotype, as well as a healthy donor possessing the normal CFTR gene (wt/wt CFTR). """;Genotype CG is associated with increased activity of CFTR when treated with elexacaftor / tezacaftor / ivacaftor in intestinal organoid.
CORR-4A, IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;Associated  with  increased  activity  of CFTR when treated  with  ➔ CORR-4A, IVACAFTOR, LUMACAFTOR;Efficacy;Including corr-4a with vx-809+vx-770 therapy offsets the negative effect of vx-770.;Genotype del/del is associated with increased activity of CFTR when treated with corr-4a, ivacaftor and lumacaftor as compared to genotype CTT/CTT.
ESTRADIOL;;rs2369049;A;Associated  with  increased  expression of IL1R2 when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele A is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.
IVACAFTOR;CFTR;rs397508288;G;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;D579G allele. 8.9 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs75541969;C;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;D1152H allele. 2.4 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
ESCITALOPRAM;IL11;rs1126757;CT + TT;Associated  with  decreased expression of IL11 when treated  with  ➔ ESCITALOPRAM;Other;"Mean relative expression of IL11. After 8 weeks of treatment with escitalopram. No significant difference between the genotypes was seen at baseline (week 0). Note that IL11 expression was significantly higher in patients who were responders to escitalopram treatment than non-responders after 8 weeks of treatment (p < 0.05); refer to paper for definition of responders.";Genotypes CT + TT is associated with decreased expression of IL11 when treated with escitalopram as compared to genotype CC.
ESTRADIOL;;rs11849538;G;Associated  with  increased  expression of TCL1A when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713, and rs2369049. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G, but this is not completely clear due to possibility of strand switch. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.  Also, after ER blockade, U2OS cell lines with variant SNPs demonstrated elevated NFKB1 transcriptional activity and a dramatic drop in TCL1A expression, while TCL1A expression was elevated in wt cell lines.";Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele C.
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;Associated  with  increased catalytic  activity  of TYMS when treated  with  ➔ METHOTREXATE;;indicating decreased in vitro methotrexate sensitivity.;Genotypes AG + GG are associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.
ESTRADIOL;;rs11849538;G;Associated  with  increased  expression of IL17RA when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713, and rs2369049. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G, but this is not completely clear due to possibility of strand switch. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele C.
ESTRADIOL;;rs11849538;C;Associated  with  increased  expression of IL12RB2 when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713, and rs2369049. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G, but this is not completely clear due to possibility of strand switch. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.";Allele C is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.
IVACAFTOR;CFTR;rs11971167;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;D1270N allele. 1.9 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
ESTRADIOL;;rs2369049;G;Associated  with  increased  expression of TCL1A when treated  with  ➔ ESTRADIOL;Other;"3 transfected (with a pcDNA4.1-ERalpha construct) LCLs were used which also had ""variant"" alleles for rs7158782, rs7159713 and rs11849538. Alleles were not mentioned specifically but were listed only as ""variant"" and ""wt"". dbSNP has G as the minor allele in Europeans so variant was understood to = G. Several increasing concentrations of estradiol were used - stated to be in the range found in plasma of post-menopausal women.  Also, after ER blockade, U2OS cell lines with variant SNPs demonstrated elevated NFKB1 transcriptional activity and a dramatic drop in TCL1A expression, while TCL1A expression was elevated in wt cell lines.";Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele A.
IVACAFTOR;CFTR;rs121909019;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R1066H allele. 2.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs121908753;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R352Q allele. 15.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
PHENYTOIN;CYP2C9;rs71486745;del;Associated  with  decreased expression of CYP2C9 when treated  with  ➔ PHENYTOIN;;when co-transfected with CAR (NR1I3), suggesting this variant disrupts the CAR binding site in the CYP2C9 promoter.;Allele del is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells.
METHOTREXATE;MTHFR;rs1801131;GT;Associated  with  increased catalytic  activity  of TYMS when treated  with  ➔ METHOTREXATE;;indicating decreased in vitro methotrexate sensitivity.;Genotype GT is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.
IVACAFTOR;CFTR;rs77834169;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;R117C allele. 5.7 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs397508442;T;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;S945L allele. 12.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs121909047;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;A561E allele. Iodide efflux assays were used to measure CFTR activity. Ivacaftor is believed to stabilize CFTR proteins with the A561E mutation.;Allele A is associated with activity of CFTR when treated with ivacaftor in BHK cells.
GLYBURIDE;KCNJ11;rs5219;T;Associated  with  decreased activity  of KCNJ11 when treated  with  ➔ GLYBURIDE;Metabolism/PK;as measured by insulin secretion in response to glucose and glibenclamide;Allele T is associated with decreased activity of KCNJ11 when treated with glibenclamide pancreatic islet cells.
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;Associated  with  decreased expression of YEATS4 when treated  with  ➔ HYDROCHLOROTHIAZIDE;Metabolism/PK;as compared to whole blood RNA from TT or CT individuals where expression did not change significantly compared to at baseline.;Genotype CC is associated with decreased expression of YEATS4 when treated with hydrochlorothiazide in whole blood RNA.
IVACAFTOR;CFTR;rs121908752;G;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;L206W allele. 3.6 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs75527207;A;Associated  with  increased  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;compared to no treatment. Ivacaftor stimulated CFTR activity in CFTR-G551D expressing CHO cells (as measured by iodine efflux).;Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.
VITAMIN E;CYP4F2;rs2108622;T;Associated  with  decreasedenzyme  activity  of CYP4F2 when treated  with  ➔ VITAMIN E;Other;;Allele T is associated with decreased enzyme activity of CYP4F2 when treated with vitamin e in Sf9 insect cells transfected with CYP4F2.
IVACAFTOR;CFTR;rs121909020;A;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;A1067T allele. 2.9 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
IVACAFTOR;CFTR;rs113993958;C;Associated  with  activity  of CFTR when treated  with  ➔ IVACAFTOR;Efficacy;D110H allele. 6.2 fold increase in chloride transport upon ivacaftor treatment as compared to baseline (no ivacaftor treatment).;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.
DISOPYRAMIDE;KCNH2;rs104894021;T;Associated  with  decreasedinhibition of KCNH2 when exposed to ➔ DISOPYRAMIDE;Efficacy;"Although the decrease in KCNH2 inhibition was statistically significant, the authors describe the decrease as ""modest"" and suggest that disopyramidine may be a suitable treatment for idiopathic short QT syndrome associated with the N588K mutation. Please note that alleles have been complemented to the positive strand. Both the C and T alleles cause the N588K amino acid substitution studied in the paper. However, it is unclear whether the authors specifically looked at the C or T allele.";Allele T is associated with decreased inhibition of KCNH2 when exposed to disopyramide as compared to allele G.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Associated  with  decreasedcatalytic  activity  of CYP2C19 when exposed to ➔ MEPHENYTOIN;Metabolism/PK;"Genomic DNA was prepared from 92 different lymphoblastoid cell lines from healthy volunteers (Coriell Genetic Cell Repositories). Each exon, intron-exon junction, and -1.46 kb of the upstream region of CYP2C19 was amplified and products were directly sequenced. ""Novel"" SNPs were then introduced into plasmids with regions of cDNA flanking the mutated nucleotides were excised and subcloned into new pCW 2C191.B plasmid, transfected into E. coli, expressed and purified. Variant proteins were then assayed for catalytic activity on mephenytoin.";CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.
QUINIDINE;KCNH2;rs104894021;T;Associated  with  decreasedinhibition of KCNH2 when exposed to ➔ QUINIDINE;Efficacy;Please note that alleles have been complemented to the positive strand. Both the C and T alleles cause the N588K amino acid substitution studied in the paper. However, it is unclear whether the authors specifically looked at the C or T allele.;Allele T is associated with decreased inhibition of KCNH2 when exposed to quinidine as compared to allele G.
CHLOROCRESOL;RYR1;rs193922803;T;Associated  with  increased  activity  of RYR1 when exposed to ➔ CHLOROCRESOL;Other;B-lymphocytes were isolated from individuals from the pedigree that were carriers of the SNP. Lymphocytes were immortalized (Epstein-Barr) and assayed for calcium release in response to the RYR1 agnost chlorocresol.;Allele T is associated with increased activity of RYR1 when exposed to chlorocresol in lymphoblastoid cell lines as compared to allele C.
TAMOXIFEN;NCOA1;rs1804645;T;Associated  with  decreased activity  of NCOA1 when exposed to ➔ TAMOXIFEN;;In multiple cell lines, the T construct showed a decreased ability to coactivate Estrogen Receptor compared to C. [stat_test: two-way ANOVA].  This result was also seen without tamoxifen. Cell lines were MCF-7 and T47D, which are hormone-responsive.;Allele T is associated with decreased activity of NCOA1 when exposed to tamoxifen.
CYTARABINE;CDA;rs60369023;AA + AG;Associated  with  decreasedcatalytic  activity  of CDA when exposed to ➔ CYTARABINE;Metabolism/PK;Carriers of the A allele had decreased catalytic efficiency of cytarabine (also referred to as Ara-C in the paper) deamination, as shown by decreased Km and Vmax values, as compared to GG homozygotes.;Genotypes AA + AG are associated with decreased catalytic activity of CDA when exposed to cytarabine as compared to genotype GG.
GENTAMICIN;MT-RNR1;rs267606619;T;Associated  with  decreased activity  of MT-RNR1 when exposed to ➔ GENTAMICIN;PD;"In vitro study of cybrid lines from three matrilineal relatives with the C1494T mutation and three control subjects. Levels of mitochondrial proteins were reduced in C1494T lines compared to control in both the presence and absence of gentamicin.; In the absence of gentamicin, there was a 21% reduction in ATP production in C1494T cybrids compared to controls. Further reduction was seen when C1494T cybrids were treated with gentamicin. Exposure to gentamicin had no effect on ATP production in control cybrids.; In the presence of gentamicin, the efficiency of ATP production in control lines was increased (stress response), while efficiency in the C1494T lines was decreased. The presence of the C1494T mutation and gentamicin together also resulted in a reduction in mitochondrial membrane potential and an increase in cellular ROS levels.; Untreated C1494T cybrids showed increased mitochondrial ROS levels compared to controls. However, these levels decreased upon exposure to gentamicin.; Mitochondria in the C1494T cybrids were found to be elongated, with many of them fused together. Mitophagy was also increased when C1494T cybrids were treated with gentamicin.";Allele T is associated with decreased activity of MT-RNR1 when exposed to gentamicin.
QUINIDINE;KCNH2;rs104894021;C;Associated  with  decreasedinhibition of KCNH2 when exposed to ➔ QUINIDINE;Efficacy;Please note that alleles have been complemented to the positive strand. Both the C and T alleles cause the N588K amino acid substitution studied in the paper. However, it is unclear whether the authors specifically looked at the C or T allele.;Allele C is associated with decreased inhibition of KCNH2 when exposed to quinidine as compared to allele G.
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;Associated  with  decreased activity  of CYP2B6 when exposed to ➔ BUPROPION;Other;in human hepatocytes.;CYP2B6 *1/*30 is associated with decreased activity of CYP2B6 when exposed to bupropion as compared to CYP2B6 *1/*1.
GEMCITABINE;DCTD;rs35932500;C;Associated  with  decreasedenzyme  activity  of DCTD when exposed to ➔ GEMCITABINE;Metabolism/PK;Human subjects' genes encoding DCTD were resequenced and then transfected into mammalian cells for functional genomic studies. This SNP was presented as Asn58Asp (172A>G), and was only seen in the Caucasian cohort. Recombinant Asp58 resulted in enzymes with approximately 11% of the activity for gemcitabine as a substrate as compared to wild-type.;Allele C is associated with decreased enzyme activity of DCTD when exposed to gemcitabine in transfected cells as compared to allele T.
BUPROPION;POR;rs2868177;AG + GG;Associated  with  increased  activity  of CYP2B6 when exposed to ➔ BUPROPION;Metabolism/PK;CYP2B6 activity was measured through bupropion hydroxylation. POR g.6593A > G AA homozygotes had a significantly lower mean ratio of AUC hydroxybupropion/AUC bupropion than AG and GG genotypes in the CYP2B6*1/*1, CYP2B6*1/*6, and CYP2B6*6/*6 groups (10.9 ¤ 1.82 vs. 19.7 ¤ 5.53, P < 0.001, 6.18 ¤ 0.284 vs. 12.1 ¤ 4.31, P = 0.011, and 6.94 ¤ 1.48 vs. 10.9 ¤ 2.39, P = 0.043, respectively).;Genotypes AG + GG are associated with increased activity of CYP2B6 when exposed to bupropion as compared to genotype AA.
GEMCITABINE;CDA;rs2072671;C;Associated  with  decreasedenzyme  activity  of CDA when exposed to ➔ GEMCITABINE;Metabolism/PK;Human subjects' genes encoding CDA were resequenced and then transfected into mammalian cells for functional genomic studies. This SNP was presented as Lys27Gln (79A>C). Recombinant Gln27 resulted in enzymes with approximately 2/3 activity for gemcitabine as a substrate as compared to wild-type.;Allele C is associated with decreased enzyme activity of CDA when exposed to gemcitabine in transfected cells as compared to allele A.
ADALIMUMAB;TNF;rs1800629;AG;Associated  with  decreasedsteady-state level of TNF when exposed to ➔ ADALIMUMAB;Metabolism/PK;Individuals with the AG genotype were found to have lower median serum TNFalpha levels as compared to those with the GG genotype at 8 and 24 weeks of adalimumab treatment. The authors also noted that responders to treatment had a significant overall increase in TNFalpha over time (p<0.000001).;Genotype AG is associated with decreased steady-state level of TNF when exposed to adalimumab as compared to genotype GG.
PAROMOMYCIN;MT-RNR1;rs267606617;G;Associated  with  decreased activity  of MT-RNR1 when exposed to ➔ PAROMOMYCIN;PD;Growing human cells carrying the A1555G mutation in the presence of paromomycin decreased the growth rate of the cells, while the quantity and activity level of the OXPHOS complex IV was reduced.;Allele G is associated with decreased activity of MT-RNR1 when exposed to paromomycin.
SIMVASTATIN;HLA-G;rs1063320;GG;Associated  with  increased  expression of HLA-G when exposed to ➔ SIMVASTATIN;Other;Gene expression was compared between cells administered 2 micro molar simvastatin or sham buffer for the GG, GC and CC genotypes. Only the GG genotype was associated with increased HLA-G expression in response to simvastatin.;Genotype GG is associated with increased expression of HLA-G when exposed to simvastatin in lymphoblastoid cell lines.
ACETAMINOPHEN;CYP2E1;rs2515641;T;Associated  with  increased  expression of CYP2E1 when exposed to ➔ ACETAMINOPHEN;Other;;Allele T is associated with increased expression of CYP2E1 when exposed to acetaminophen as compared to allele C.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Associated  with  decreasedcatalytic  activity  of CYP2C19 when exposed to ➔ MEPHENYTOIN;Other;A mutation for CYP2C19*1C (991A > G) was introduced using pcDNA3.1/CYP2C19*1A as a template, resulting in pcDNA3.1/CYP2C19*1C (*1B and *1C is used interchangeably in the article). Mutations for CYP2C19*19 (991A>G and 151A>G) was successively introduced using pcDNA3.1/CYP2C19*1C as a template. All CYP2C19 plasmids were sequenced to confirm successful mutagenesis. The cDNAs of CYP2C19*1C, CYP2C19*19 were subsequently subcloned into the pGYR1 yeast expression vector and heterologously expressed in yeast cells and proteins were purified from yeast microsomes. Proteins were then assayed for catalytic activity. Kinetic parameters were estimated using Michaelis-Menten plots and mephenytoin hydroxylation was assayed by HPLC.;CYP2C19 *19 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in yeast microsomes heterologously expressing CYP2C19*19 as compared to CYP2C19 *1.
BUPRENORPHINE;OPRM1;rs1799971;G;Associated  with  decreased activity  of OPRM1 when exposed to ➔ BUPRENORPHINE;Efficacy;Variant referred to as 'N40D' in the paper, reflecting the amino acid change caused by the SNP. Cells were transfected with the human OPRM1 cDNA containing either the A or G allele at rs1799971.;Allele G is associated with decreased activity of OPRM1 when exposed to buprenorphine in COS cells as compared to allele A.
TAMOXIFEN;UGT1A4;rs8330;CC;Associated  with  decreased activity  of UGT1A4 when exposed to ➔ TAMOXIFEN;Metabolism/PK;Microsomes from individuals homozygous for the C allele had significantly lower 4-OH-tamoxifen-O-glucuronidation, as compared to those with the CG or GG genotype. A borderline significant result (p=0.053) was seen when considering 4-OH-toremifene-O-glucuronidation. No significant result was seen when considering Tamoxifen-N-glucuronidation (p = 0.79), 4-OH-tamoxifen-N-glucuronidation (p = 0.67), Toremifene-N-glucuronidation (p = 0.47), or 4-OH-toremifene-N-glucuronidation (p = 0.49). UGT enzymes like UGT1A4 are responsible for the glucuronidation of compounds such as tamoxifen, leading to metabolites like the ones mentioned above.;Genotype CC is associated with decreased activity of UGT1A4 when exposed to tamoxifen in human liver microsomes as compared to genotypes CG + GG.
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Associated  with  increased catalytic  activity  of CYP2C19 when exposed to ➔ OMEPRAZOLE;Metabolism/PK;Comparison was to construct the has Ile331Val. Article states CYP2C19.1B having Ile331Val-however, according to definition would be *1C.  The kinetic parameters of CYP2C19*19 were assessed at increasing concentrations of omeprazole. Kinetic parameters included V(max) and intrinsic clearance [the ratio of K(m)/V(max)]. V(max) and intrinsic clearance were assayed relative to level of holoprotein as well as holo and apoforms of the protein.;CYP2C19 *19 is associated with increased catalytic activity of CYP2C19 when exposed to omeprazole as compared to CYP2C19 *1.
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;Associated  with  increased catalytic  activity  of CYP2C19 when exposed to ➔ CLOPIDOGREL;Metabolism/PK;association compared to *1B. Please note the article separated between *1A and *1B. While the Vmax was increased compared to *1B the Vmax for *1A was decreased compared to *1B. For both * alleles no-significant difference was shown for Km values.;CYP2C19 *28 is associated with increased catalytic activity of CYP2C19 when exposed to clopidogrel in cos-7 cells as compared to CYP2C19 *1.
GEMCITABINE;FKBP5;rs73748206;CT;Associated  with  increased  expression of FKBP5 when exposed to ➔ GEMCITABINE;Other;Cell lines are from from pancreatic cancer patients.  The significant difference was seen at 0.1 micromolar gemcitabine, which is close to the IC-50 in these cell lines.;Genotype CT is associated with increased expression of FKBP5 when exposed to gemcitabine as compared to genotype CC.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;Associated  with  decreasedcatalytic  activity  of CYP2C19 when exposed to ➔ MEPHENYTOIN;Metabolism/PK;The association is reported for *1B.;CYP2C19 *10 + *14 + *19 + *25 + *26 are associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in cos-7 cells as compared to CYP2C19 *1.
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*13, CYP2C19*14, CYP2C19*15, CYP2C19*18, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;Associated  with  decreasedcatalytic  activity  of CYP2C19 when exposed to ➔ CLOPIDOGREL;Metabolism/PK;The Km, Vmax and CLint values for clopidogrel 2-oxidation were measured and compared to *1B. Although differences in Vmax compared to *1B are found for *1A, *10, *13, *14, *15, *18, *19, *23, *25, *26, the Km value only differed for *19 and *26. The clearance was affected for *10, *14, *19, *23, *25, *26. Please note the article separated *1A and *1B.;CYP2C19 *10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26 are associated with decreased catalytic activity of CYP2C19 when exposed to clopidogrel in cos-7 cells as compared to CYP2C19 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;Associated  with  decreasedcatalytic  activity  of CYP2C19 when exposed to ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;"Healthy volunteers (113 Vietnamese and 94 Korean) received a single 20 mg dose of omeprazole after overnight fasting. Blood samples were taken 3 hr after administration of omeprazole. Samples from volunteers with 1) 1/*2 or *1/*3 genotypes and 2) a metabolic ratio (MR) of omeprazole/ 5-hydroxyomeprazole that was higher than the average MR for *2/*2 or *3/*3 underwent direct DNA sequencing of CYP2C19 to search for novel variants responsible for the high MR. The corresponding variants were recreated by site-directed mutagenesis of CYP2C19 cDNA which was integrated into plasmids and transfected into DH5 alpha ""E.coli"" cells. CYP2C19 protein variants were eluted and tested for their effect on enzymatic activity. *Note: D256N has been designated CYP2C19*26 in the manuscript.";CYP2C19 *26 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin and omeprazole as compared to CYP2C19 *1.
ACETAMINOPHEN;UGT1A;rs8330;CC;Associated  with  decreased activity  of UGT1A when exposed to ➔ ACETAMINOPHEN;Metabolism/PK;Acetaminophen glucuronidation activity is decreased in human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Analysis was performed at acetaminophen concentrations of 0.1 mM (therapeutic concentration), 2 mM and 40 mM (overdose concentration). Significant results were seen at all concentrations.;Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CG + GG.
ETHANOL;ADH1B;rs1229984;CT + TT;Associated  with  increased enzyme  activity  of ADH1B when exposed to ➔ ETHANOL;Metabolism/PK;"markedly higher hepatic activities with ADH1B*2 variant. The activity ratios of pH 10.5/pH 8.5 were well above 1.0 for ADH1B*1/*1 individuals (i.e. 2.15), but lower than 1.0 for those of ADH1B*1/*2 (0.64) and ADH1B*2/*2 (0.52) individuals. ADH activity was determined at 30›C in 0.1mol/l sodium phosphate (pH 7.5), 0.1mol/l sodium pyrophosphate (pH 8.5), and 0.1mol/l glycine-NaOH (pH 10.5), respectively, containing 33 mmol/l ethanol.PMID 25365528 describes ADH1B*2 [cf., Arg(*1)48His(*2); rs1229984], His represents T on plus chromosomal strand.";Genotypes CT + TT are associated with increased enzyme activity of ADH1B when exposed to ethanol as compared to genotype CC.
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;Associated  with  increased transport of CFTR when exposed to ➔ ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;Other;In vitro, VX-445-tezacaftor-ivacaftor significantly improved Phe508del CFTR protein processing, trafficking, and chloride transport to a greater extent than any two of these agents in dual combination. VX-445 is a synonym for elexacaftor according to PubChem Compound CID: 134587348. Human bronchial epithelial (HBE) cells were isolated from the upper and lower bronchi of Phe508del/minimal function (lack of CFTR protein production - 3905insT, G542X, or E585X, 4 donors) or Phe508del/Phe508del (3 donors) cystic fibrosis donors.;Genotype del/del are associated with increased transport of CFTR when exposed to elexacaftor, ivacaftor and tezacaftor.
ACETAMINOPHEN;UGT1A;rs10929303;CC;Associated  with  decreased activity  of UGT1A when exposed to ➔ ACETAMINOPHEN;Metabolism/PK;Acetaminophen glucuronidation activity is decreased in human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Analysis was performed at acetaminophen concentrations of 0.1 mM (therapeutic concentration), 2 mM and 40 mM (overdose concentration). Significant results were seen for 2 mM and 40 mM only.;Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CT + TT.
XENOBIOTICS;AHR;rs2066853;A;Associated  with  increased  expression of CYP1A1 when exposed to ➔ XENOBIOTICS;Metabolism/PK;(xenobiotic used = 3-methylcholanthrene);Allele A is associated with increased expression of CYP1A1 when exposed to xenobiotics in lymphocytes.
OMEPRAZOLE, XENOBIOTICS;AHR;rs75519181;G;Associated  with  decreased expression of CYP1A1 when exposed to ➔ OMEPRAZOLE, XENOBIOTICS;Metabolism/PK;as measured by luciferase reporter;Allele G is associated with decreased expression of CYP1A1 when exposed to omeprazole and xenobiotics in HeLa cells.
ACETAMINOPHEN;UGT1A;rs1042640;CC;Associated  with  decreased activity  of UGT1A when exposed to ➔ ACETAMINOPHEN;Metabolism/PK;Acetaminophen glucuronidation activity is decreased in human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Analysis was performed at acetaminophen concentrations of 0.1 mM (therapeutic concentration), 2 mM and 40 mM (overdose concentration). Significant results were seen for 2 mM and 40 mM only.;Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CG + GG.
GEMCITABINE;FKBP5;rs73748206;CT;Associated  with  increased  expression of NR3C1 when exposed to ➔ GEMCITABINE;Other;Cell lines are from from pancreatic cancer patients.  The significant difference was seen at 0.1 micromolar gemcitabine, which is close to the IC-50 in these cell lines.;Genotype CT is associated with increased expression of NR3C1 when exposed to gemcitabine as compared to genotype CC.
ESTRADIOL;;rs3802201;GG;Associated  with  increased  expression of MIR2052 when exposed to ➔ ESTRADIOL;Other;;Genotype GG is associated with increased expression of MIR2052 when exposed to estradiol in lymphoblastoid cell lines as compared to genotype CC.
ALDOSTERONE, INSULIN RECOMBINANT;SCNN1B;rs34241435;A;Associated  with  increased transcription of SCNN1B when exposed to ➔ ALDOSTERONE, INSULIN RECOMBINANT;Other;;Allele A is associated with increased transcription of SCNN1B when exposed to aldosterone and insulin recombinant in COS cells.
ESTRADIOL;;rs4476990;CC;Associated  with  increased  expression of MIR2052 when exposed to ➔ ESTRADIOL;Other;;Genotype CC is associated with increased expression of MIR2052 when exposed to estradiol in lymphoblastoid cell lines as compared to genotype GG.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*9;*9;Associated  with  decreased activity  of CYP2C19 when exposed to ➔ MEPHENYTOIN;Metabolism/PK;"Genomic DNA was prepared from 92 different lymphoblastoid cell lines from healthy volunteers (Coriell Genetic Cell Repositories). Each exon, intron-exon junction, and -1.46 kb of the upstream region of CYP2C19 was amplified and products were directly sequenced. ""Novel"" SNPs were then introduced into plasmids with regions of cDNA flanking the mutated nucleotides were excised and subcloned into new pCW 2C191.B plasmid , transfected into E. coli, expressed and purified. Variant proteins were then assayed for catalytic activity on mephenytoin.";CYP2C19 *9 is associated with decreased activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Associated  with  decreased activity  of CYP2C19 when exposed to ➔ MEPHENYTOIN;Metabolism/PK;"Genomic DNA was prepared from 92 different lymphoblastoid cell lines from healthy volunteers (Coriell Genetic Cell Repositories). Each exon, intron-exon junction, and -1.46 kb of the upstream region of CYP2C19 was amplified and products were directly sequenced. ""Novel"" SNPs were then introduced into plasmidswith regions of cDNA flanking the mutated nucleotides were excised and subcloned into new pCW 2C191.B plasmid, transfected into E. coli, expressed and purified. Variant proteins were then assayed for catalytic activity on mephenytoin.";CYP2C19 *10 is associated with decreased activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.
BERBERINE, COPTISINE;CYP2D6;CYP2D6*1;*1/*1;Associated  with  increased inhibition of CYP2D6 when exposed to ➔ BERBERINE, COPTISINE;Metabolism/PK;"The study authors investigated the effects of the ""Zuojin Pill"" (active ingredients are berberine and cotipisine) on CYP2D6 metabolic activity as assayed by dextromethorphan. Zuojin pill was given 3g twice daily for 7 days, and co-administered with dextromethorphan on day 8. As compared to baseline (before administration of the Zuojin Pill), the CYP2D6 *1/*1 genotype was associated with an increase in exposure to dextromethorphan.";CYP2D6 *1/*1 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine.
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*10;*8 + *10;Associated  with  decreasedcatalytic  activity  of CYP2C19 when exposed to ➔ 3-CYANO-7-ETHOXYCOUMARIN;Metabolism/PK;;CYP2C19 *8 + *10 are associated with decreased catalytic activity of CYP2C19 when exposed to 3-cyano-7-ethoxycoumarin as compared to CYP2C19 *1.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;Associated  with  increased catalytic  activity  of CYP2C19 when exposed to ➔ MEPHENYTOIN;Metabolism/PK;The association is reported in comparison to *1B. Please note the study separates *1A and *1B. An increased Vmax was found for *23 compared to *1B (7.53 compared to 4.54). Vmax for *1A was 5.26.;CYP2C19 *23 is associated with increased catalytic activity of CYP2C19 when exposed to mephenytoin in cos-7 cells as compared to CYP2C19 *1.
BERBERINE, COPTISINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;Associated  with  increased inhibition of CYP2D6 when exposed to ➔ BERBERINE, COPTISINE;Metabolism/PK;"The study authors investigated the effects of the ""Zuojin Pill"" (active ingredients are berberine and cotipisine) on CYP2D6 metabolic activity as assayed by dextromethorphan. Zuojin pill was given 3g twice daily for 7 days, and co-administered with dextromethorphan on day 8. As compared to baseline (before administration of the Zuojin Pill), the CYP2D6 *1/*10 genotype was associated with an increase in exposure to dextromethorphan.";CYP2D6 *1/*10 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine.
DISOPYRAMIDE;KCNH2;rs104894021;C;Associated  with  decreasedinhibition of KCNH2 when exposed to ➔ DISOPYRAMIDE;Efficacy;"Although the decrease in KCNH2 inhibition was statistically significant, the authors describe the decrease as ""modest"" and suggest that disopyramidine may be a suitable treatment for idiopathic short QT syndrome associated with the N588K mutation. Please note that alleles have been complemented to the positive strand. Both the C and T alleles cause the N588K amino acid substitution studied in the paper. However, it is unclear whether the authors specifically looked at the C or T allele.";Allele C is associated with decreased inhibition of KCNH2 when exposed to disopyramide as compared to allele G.
IVACAFTOR;CFTR;rs74503330;A;Associated  with  increased  activity  of CFTR when exposed to ➔ IVACAFTOR;Other;Activity measured in a cell assay of intestinal current measurements in rectal biopsies treated with ivacaftor and genistein. Cells from subjects compound heterozygous F508del/S1251N were compared to cells from subjects with the F508del/F508del genotype.;Allele A is associated with increased activity of CFTR when exposed to ivacaftor.
FLUOROURACIL;DPYD;rs372307932;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" I948N maps to rs372307932A>T in table S2.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.
MIDAZOLAM;CYP3A4;rs35599367;AG;Associated  with  decreased activity  of CYP3A4 when assayed  with  ➔ MIDAZOLAM;Metabolism/PK;measuring formation of 1-hydroxy metabolite. There were no AA genotype microsomes. Alleles complemented to plus chromosomal strand.;Genotype AG is associated with decreased activity of CYP3A4 when assayed with midazolam in human liver microsomes as compared to genotype GG.
DEXTROMETHORPHAN;CYP3A4;rs35599367;AG;Associated  with  decreased activity  of CYP3A4 when assayed  with  ➔ DEXTROMETHORPHAN;Metabolism/PK;measuring formation of N-demethyl metabolite but not the O-demethyl metabolite. There were no AA genotype microsomes. Alleles complemented to plus chromosomal strand.;Genotype AG is associated with decreased activity of CYP3A4 when assayed with dextromethorphan in human liver microsomes as compared to genotype GG.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;Metabolism/PK;The S-mephenytoin 4'-hydroxylation  activities of the recombinant enzymes were determined at two concentrations, one near the Km of CYP2C19 (25 ‘M-mephenytoin) and one near the Vmax of the enzyme (200 ‘M-mephenytoin).;CYP2C19 *10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;The S-mephenytoin 4'-hydroxylation and Omeprazole 5'-Hydroxylation activities of the recombinant enzymes were determined at two concentrations, one near the Km of CYP2C19 (25 ‘M-mephenytoin and Omeprazole = 5 ‘M) and one near the Vmax of the enzyme (200 ‘M-mephenytoin and Omeprazole = 100 ‘M).;CYP2C19 *16 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;Metabolism/PK;The S-mephenytoin 4'-hydroxylation activities of the recombinant enzymes were determined at two concentrations, one near the Km of CYP2C19 (25 ‘M-mephenytoin) and one near the Vmax of the enzyme (200 ‘M-mephenytoin). Only significant for the low concentration Km.;CYP2C19 *19 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*18;*18;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;Metabolism/PK;The S-mephenytoin 4'-hydroxylation activities of the recombinant enzymes were determined at two concentrations, one near the Km of CYP2C19 (25 ‘M-mephenytoin) and one near the Vmax of the enzyme (200 ‘M-mephenytoin). Only significant for the low concentration Km.;CYP2C19 *18 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.
FLUOROURACIL;DPYD;rs376073289;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" R208Q maps to rs376073289C>T in table S2.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
FLUOROURACIL;DPYD;rs374527058;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight additional variants had moderate to mild reductions in DPD activity that were 35?70% of wildtype activity (T132S, V586A, G603E, K616Q, S644N, G676E, V714A, and A777D)."" V586A maps to rs374527058A>G in table S2.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.
FLUOROURACIL;DPYD;rs538336580;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight additional variants had moderate to mild reductions in DPD activity that were 35?70% of wildtype activity (T132S, V586A, G603E, K616Q, S644N, G676E, V714A, and A777D)."" T132S maps to rs538336580T>A in table S2.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;The S-mephenytoin 4'-hydroxylation and Omeprazole 5'-Hydroxylation activities of the recombinant enzymes were determined at two concentrations, one near the Km of CYP2C19 (25 ‘M-mephenytoin and Omeprazole = 5 ‘M) and one near the Vmax of the enzyme (200 ‘M-mephenytoin and Omeprazole = 100 ‘M).;CYP2C19 *9 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.
FLUOROURACIL;DPYD;rs568367673;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight variants showed modest reductions that were 15?35% of wildtype activity (M77V, C87F, Q156R, I560N, T573I, R692W, G767V, and S994T)."" G767V maps to rs568367673C>A in table S2.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
FLUOROURACIL;DPYD;rs558354142;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight variants showed modest reductions that were 15?35% of wildtype activity (M77V, C87F, Q156R, I560N, T573I, R692W, G767V, and S994T)."" T573I maps to rs558354142G>A in table S2.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs770829708;A;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced.D341N showed close to 20% relative activity for S-mephenytoin and about 20% for omeprazole (based on graphic). And low expression. Please note, the construct was named *2F but no mention of the presence of the *2 key SNP on the construct was given.;Allele A is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele G.
FLUOROURACIL;DPYD;rs374825099;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight additional variants had moderate to mild reductions in DPD activity that were 35?70% of wildtype activity (T132S, V586A, G603E, K616Q, S644N, G676E, V714A, and A777D)."" A777D maps to rs374825099G>T in table S2.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs199654337;T;Associated  with  decreasedtransport of SLCO2B1 when assayed  with  ➔ ESTRONE SULFATE, ROSUVASTATIN;Metabolism/PK;"""The c.953C>T variant also modestly reduced the uptake of all substrates (uptake 64?86% of reference)."" It was not significant for rosuvastatin but was for estrone sulfate and other probe substrates. ""c.953C>T p.Thr318Ile rs199654337""";Allele T is associated with decreased transport of SLCO2B1 when assayed with estrone sulfate or rosuvastatin HEK293 cells expressing OATP2B1 variants as compared to allele C.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*10, CYP2C19*16;*9 + *10 + *16;Associated  with  decreasedclearance of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;CYP2C19.9, CYP2C19.10, CYP2C19.16 demonstrated a significant decrease in their Clint values. *9 about 40 %, *10 showed 16% for mephenytoin and 34% for omeprazole compared to *1. *16 showed 10 and 26 %, respectively.;CYP2C19 *9 + *10 + *16 are associated with decreased clearance of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Associated  with  decreasedclearance of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Metabolism/PK;CYP2C19.19 demonstrated some significant decrease in Clint values but only for omeprazole (44% of wild type) but not mephenytoin (60% of wildtype being not significantly different).;CYP2C19 *19 are associated with decreased clearance of CYP2C19 when assayed with omeprazole in yeast microsomes as compared to CYP2C19 *1.
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1009122956;C;Associated  with  decreasedtransport of SLCO2B1 when assayed  with  ➔ ESTRONE SULFATE, ROSUVASTATIN;Metabolism/PK;"""Most of the studied variants had comparable or only modest reductions in uptake and expression compared to the OATP2B1 reference. However, the rare c.1559G>C (p.Cys520Ser) variant could not transport any of the four tested substrates DBF, 5-CF, estrone sulfate, or rosuvastatin."" ""In our study, the abolished activity of c.1559G>C could not completely be explained by decreased membrane expression since the abundance of the variant was approximately half of the OATP2B1 reference (Figure 4)."" ""c.1559G>C p.Cys520Ser rs1009122956""";Allele C is associated with decreased transport of SLCO2B1 when assayed with estrone sulfate or rosuvastatin HEK293 cells expressing OATP2B1 variants as compared to allele G.
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1621378;T;Associated  with  decreasedtransport of SLCO2B1 when assayed  with  ➔ ESTRONE SULFATE, ROSUVASTATIN;Metabolism/PK;"""our study suggests moderate impairment of OATP2B1 by c.1175C>T since uptake of substrates was reduced to 48?81% of reference.""""c.1175C>T p.Thr392Ile rs1621378""";Allele T is associated with decreased transport of SLCO2B1 when assayed with estrone sulfate or rosuvastatin HEK293 cells expressing OATP2B1 variants as compared to allele C.
ESTRONE SULFATE;SLCO2B1;rs2306168;T;Associated  with  decreasedtransport of SLCO2B1 when assayed  with  ➔ ESTRONE SULFATE;Metabolism/PK;"""Variant c.1457C>T appeared to reduce especially the uptake of estrone sulfate (uptake 58% of reference). "" ""c.1457C>T p.Ser486Phe rs2306168""";Allele T is associated with decreased transport of SLCO2B1 when assayed with estrone sulfate HEK293 cells expressing OATP2B1 variants as compared to allele C.
FLUOROURACIL;DPYD;rs548783838;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight additional variants had moderate to mild reductions in DPD activity that were 35?70% of wildtype activity (T132S, V586A, G603E, K616Q, S644N, G676E, V714A, and A777D)."" S644N maps to rs548783838C>T in table S2.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;Associated  with  increased  activity  of CYP2B6 when assayed  with  ➔ ;Efficacy;The ratio of hydroxybupropion versus bupropion (AUC_hyd/ AUC_bup) in terms of area under the time-concentration curve (AUC) was used to assay CYP2B6 activity.;CYP2B6 *1/*1 is associated with increased activity of CYP2B6 when assayed with as compared to CYP2B6 *6/*6.
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;Associated  with  increased  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Efficacy;The ratio of hydroxybupropion versus bupropion (AUC_hyd/ AUC_bup) in terms of area under the time-concentration curve (AUC) was used to assay CYP2B6 activity.;CYP2B6 *1/*1 is associated with increased activity of CYP2B6 when assayed with bupropion as compared to CYP2B6 *1/*6.
FLUOROURACIL;DPYD;rs140989814;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight variants showed modest reductions that were 15?35% of wildtype activity (M77V, C87F, Q156R, I560N, T573I, R692W, G767V, and S994T)."" S994T maps to rs140989814C>G in table S2.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;CYP2C19.8 only showed negligible activity (approximately 4% of CYP2C19.1A) at 200 ‘M of mephenytoin or Omeprazole = 100 ‘M.;CYP2C19 *8 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*13;*13;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;Metabolism/PK;The S-mephenytoin 4'-hydroxylation activities of the recombinant enzymes were determined at two concentrations, one near the Km of CYP2C19 (25 ‘M-mephenytoin) and one near the Vmax of the enzyme (200 ‘M-mephenytoin). Only significant for the low concentration Km.;CYP2C19 *13 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*29;*29;Associated  with  increased  activity  of CYP3A4 when assayed  with  ➔ BLONANSERIN;Metabolism/PK;"""Clearance of blonanserin by CYP3A4.4, 5, 7?10, 12?14, 16?18, 23?24, 28, 31, 33, and 34 decreased notably, but increased with CYP3A4.29.""";CYP3A4 *29 is associated with increased activity of CYP3A4 when assayed with blonanserin as compared to CYP3A4 *1.
TESTOSTERONE;CYP3A4;rs35599367;AG;Associated  with  decreased activity  of CYP3A4 when assayed  with  ➔ TESTOSTERONE;Metabolism/PK;measuring formation of 6beta hydroxy metabolite. There were no AA genotype microsomes. Alleles complemented to plus chromosomal strand.;Genotype AG is associated with decreased activity of CYP3A4 when assayed with testosterone in human liver microsomes as compared to genotype GG.
ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*29, CYP3A4*33;*2 + *3 + *11 + *29 + *33;Associated  with  increased catalytic  activity  of CYP3A4 when assayed  with  ➔ ACALABRUTINIB;Metabolism/PK;authors reference the old CYP nomenclature as source of star alleles.;CYP3A4 *2 + *3 + *11 + *29 + *33 is associated with increased catalytic activity of CYP3A4 when assayed with acalabrutinib as compared to CYP3A4 *1.
ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*14, CYP3A4*16, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*32;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;Associated  with  decreasedcatalytic  activity  of CYP3A4 when assayed  with  ➔ ACALABRUTINIB;Metabolism/PK;authors reference the old CYP nomenclature as source of star alleles.;CYP3A4 *9 + *14 + *16 + *19 + *23 + *24 + *28 + *32 is associated with decreased catalytic activity of CYP3A4 when assayed with acalabrutinib as compared to CYP3A4 *1.
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*9, CYP3A4*15, CYP3A4*16, CYP3A4*29, CYP3A4*32, CYP3A4*33;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;Associated  with  increased clearance of CYP3A4 when assayed  with  ➔ VANDETANIB;Metabolism/PK;;CYP3A4 *2 + *3 + *9 + *15 + *16 + *29 + *32 + *33 is associated with increased clearance of CYP3A4 when assayed with vandetanib as compared to CYP3A4 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;"The corresponding variants were recreated by site-directed mutagenesis of CYP2C19 cDNA which was integrated into plasmids and transfected into DH5 alpha ""E.coli"" cells. CYP2C19 protein variants were eluted and tested for their effect on enzymatic activity.";CYP2C19 *10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.
FLUOROURACIL;DPYD;rs1801266;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with DPYD activity at 13% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (R235W) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
DEXTROMETHORPHAN;SEPTIN3, WBP2NL;rs1062753;G;Associated  with  increased enzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Metabolism/PK;"""Following the conditional analysis, five SNPs, including the cis-variants rs1807493 and rs1062753, and the trans-variants rs4073010, rs729559, and rs80274432, emerged as independent variants significantly correlated with hepatic CYP2D6 protein expressions. Notably, four of these SNPs, except for rs80274432, also exhibited a significant association with CYP2D6 activities in human livers, suggesting their potential as novel and independent cis- and trans-variants regulating CYP2D6.""";Allele G is associated with increased enzyme activity of CYP2D6 when assayed with dextromethorphan in human liver s9 fractions as compared to allele A.
BUMETANIDE;SLC17A3;rs34376145;A;Associated  with  decreasedtransport of SLC17A3 when assayed  with  ➔ BUMETANIDE;Metabolism/PK;This variant also displayed reduced uptake of urate.;Allele A is associated with decreased transport of SLC17A3 when assayed with bumetanide in Xenopus oocytes as compared to allele C.
BUMETANIDE;SLC17A3;rs34902660;A;Associated  with  decreasedtransport of SLC17A3 when assayed  with  ➔ BUMETANIDE;Metabolism/PK;This variant did not show reduced uptake of urate.;Allele A is associated with decreased transport of SLC17A3 when assayed with bumetanide in Xenopus oocytes as compared to allele C.
BUMETANIDE;SLC17A3;rs11966370;A;Associated  with  decreasedtransport of SLC17A3 when assayed  with  ➔ BUMETANIDE;Metabolism/PK;This variant was highly defective for uptake of all substrates tested including urate. The authors reported an unpublished observation that this variant was very rare.;Allele A is associated with decreased transport of SLC17A3 when assayed with bumetanide in Xenopus oocytes as compared to allele G.
BUMETANIDE;SLC17A3;rs56027330;T;Associated  with  decreasedtransport of SLC17A3 when assayed  with  ➔ BUMETANIDE;Metabolism/PK;This variant also displayed reduced uptake of urate.;Allele T is associated with decreased transport of SLC17A3 when assayed with bumetanide in Xenopus oocytes as compared to allele C.
OMEPRAZOLE;CYP2C19;rs148247410;G;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Metabolism/PK;"""As shown in Fig. 1A, six of the variants exhibited significantly lower catalytic activity compared to the CYP2C19.1 enzyme. In particular, the H251Q and A297V variants showed the lowest catalytic activity, while the M339T variant appeared to have normal catalytic activity."" Variant H251Q is described as ""rs148247410  Ref.=C Alt.=G MAF % (EstBB) 0.02"" Figure 1 shows *** but does not give p-value";Allele G is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele C.
FLUOROURACIL;DPYD;rs528152707;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight variants showed modest reductions that were 15?35% of wildtype activity (M77V, C87F, Q156R, I560N, T573I, R692W, G767V, and S994T)."" C87F maps to rs528152707C>A in table S2.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
FLUOROURACIL;DPYD;rs570122671;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" T737I maps to rs570122671G>A in table S2.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
FLUOROURACIL;DPYD;rs201268750;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" H978Q maps to rs201268750G>T in table S2.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
FLUOROURACIL;DPYD;rs527580106;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight variants showed modest reductions that were 15?35% of wildtype activity (M77V, C87F, Q156R, I560N, T573I, R692W, G767V, and S994T)."" M77V maps to rs527580106T>C in table S2.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
FLUOROURACIL;DPYD;rs55886062;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight variants showed modest reductions that were 15?35% of wildtype activity (M77V, C87F, Q156R, I560N, T573I, R692W, G767V, and S994T)."" I560N maps to rs55886062A>C in table S2.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs550527959;T;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced. D360V showed close to 20% relative activity for S-mephenytoin and about 20% for omeprazole (based on graphic). And low expression. Please note, the construct was named *2G but no mention of the presence of the *2 key SNP on the construct was given.;Allele T is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele A.
FLUOROURACIL;DPYD;rs538703919;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight variants showed modest reductions that were 15?35% of wildtype activity (M77V, C87F, Q156R, I560N, T573I, R692W, G767V, and S994T)."" R692W maps to rs538703919G>A in table S2.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
IBUPROFEN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*18, CYP3A4*23, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;Associated  with  decreasedclearance of CYP3A4 when assayed  with  ➔ IBUPROFEN;Other;"""six variants (CYP3A4*4, *5, *18, *23, *32, *34) exhibiting 16?48% reduction in CLint value were classified as the mild reduction group and four variants (CYP3A4*28, *29, *31, and *33) exhibiting 53?81% reduction in CLint value were classified as the significantly reduced group.""";CYP3A4 *4 + *5 + *18 + *23 + *32 + *34 + *28 + *29 + *31 + *33 is associated with decreased clearance of CYP3A4 when assayed with ibuprofen as compared to CYP3A4 *1.
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*20;*20;Associated  with  decreased activity  of CYP3A4 when assayed  with  ➔ BLONANSERIN;Metabolism/PK;"""Compared with CYP3A4.1, a vast majority of CYP3A4 variants; were deficient in enzymatic activity (Figure 1G). Specifically, CYP3A4.20 showed no enzymatic; activity""";CYP3A4 *20 is associated with decreased activity of CYP3A4 when assayed with blonanserin as compared to CYP3A4 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs763625282;A;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced. M136K showed close to 5% relative activity for S-mephenytoin and about 45% for omeprazole (based on graphic). Please note, the construct was named *3C but no mention of the presence of the *3 key SNP on the construct was given.;Allele A is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele T.
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*31, CYP3A4*33, CYP3A4*34;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;Associated  with  decreased activity  of CYP3A4 when assayed  with  ➔ BLONANSERIN;Metabolism/PK;"""Clearance of blonanserin by CYP3A4.4, 5, 7?10, 12?14, 16?18, 23?24, 28, 31, 33, and 34 decreased notably, but increased with CYP3A4.29.""";CYP3A4 *4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34 is associated with decreased activity of CYP3A4 when assayed with blonanserin as compared to CYP3A4 *1.
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*20;*20;Associated  with  decreasedcatalytic  activity  of CYP3A4 when assayed  with  ➔ REGORAFENIB;Metabolism/PK;This variant had no activity.;CYP3A4 *20 is associated with decreased catalytic activity of CYP3A4 when assayed with regorafenib as compared to CYP3A4 *1.
FLUOROURACIL;DPYD;rs72549307;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 14% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (Y211C) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
OMEPRAZOLE;CYP2C19;rs1431015009;T;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Metabolism/PK;"""As shown in Fig. 1A, six of the variants exhibited significantly lower catalytic activity compared to the CYP2C19.1 enzyme. In particular, the H251Q and A297V variants showed the lowest catalytic activity, while the M339T variant appeared to have normal catalytic activity."" Variant K275M is described as ""rs1431015009  Ref.=A Alt.=T MAF % (EstBB) 0.02"" Figure 1 shows *** but does not give p-value";Allele T is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele A.
BUFURALOL;CYP2D6;rs1058171;T;Associated  with  decreased activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;"""Two of the variants, R133C and A305T, showed very low activity, while D301N showed almost no catalytic activity. The CYP2D6 variant L314M showed slightly lower activity than CYP2D6.1."" Variant D301N is described as ""rs1058171 Ref.=C Alt.=T MAF % (EstBB) 0.02"" Figure 1 shows *** but does not give p-value";Allele T is associated with decreased activity of CYP2D6 when assayed with bufuralol in HEK293 as compared to allele C.
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*72;*72;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;Metabolism/PK;Relative clearance was 17.90% for tolbutamide, 5.54% for losartan and 24.73% for diclofenac compared to *1 (p< 0.05);CYP2C9 *72 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.
SUMATRIPTAN;HTR1B;rs130060;C;Associated  with  increased concentrations of cAMP when assayed  with  ➔ SUMATRIPTAN;PD;C allele referred to as Cys-124 in the paper and mapped to rs130060 by PharmGKB.;Allele C is associated with increased concentrations of cAMP when assayed with sumatriptan in stably transfected C6 cells as compared to allele G.
BUFURALOL;CYP2D6;rs1230912765;A;Associated  with  decreased activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;"""Two of the variants, R133C and A305T, showed very low activity, while D301N showed almost no catalytic activity. The CYP2D6 variant L314M showed slightly lower activity than CYP2D6.1."" Variant R133C is described as ""rs1230912765 Ref.=G Alt.=A MAF % (EstBB) 0.02"" Figure 1 shows *** but does not give p-value";Allele A is associated with decreased activity of CYP2D6 when assayed with bufuralol in HEK293 as compared to allele G.
PURINE ANALOGUES;PACSIN2;rs2413739;C;Associated  with  increased  activity  of TPMT when assayed  with  ➔ PURINE ANALOGUES;Other, Metabolism/PK;[stat_test:univariate linear regression];Allele C is associated with increased activity of TPMT when assayed with purine analogues erythrocytes as compared to allele T.
L-PHENYLALANINE;PAH;rs76394784;A;Associated  with  decreased activity  of PAH when assayed  with  ➔ L-PHENYLALANINE;Metabolism/PK;Enzyme carrying the A allele showed significantly lower activity after pre-incubation with phenylalanine than the WT protein. Allele referred to in the paper as R68S. Please note that alleles have been complemented to the positive strand.;Allele A is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele T.
CARBOCISTEINE;PAH;rs62516101;T;Associated  with  decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Metabolism/PK;Enzyme carrying the T allele showed significantly lower activity before and after pre-incubation with carbocisteine than the WT protein. Allele referred to in the paper as V388M. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele C.
CARBOCISTEINE;PAH;rs75193786;G;Associated  with  decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Metabolism/PK;Enzyme carrying the G allele showed significantly lower activity before and after pre-incubation with carbocisteine than the WT protein. Allele referred to in the paper as I65T. Please note that alleles have been complemented to the positive strand.;Allele G is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele A.
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;Metabolism/PK;Relative clearance was 8.93% for tolbutamide, 7.61% for losartan and 34.95% for diclofenac compared to *1 (p< 0.05);CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*75;*75;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ LOSARTAN;Metabolism/PK;Relative clearance was 64.85% for tolbutamide and 61.89% for diclofenac (not significant) and 23.64% for losartan compared to *1 (p< 0.05);CYP2C9 *75 is associated with decreased enzyme activity of CYP2C9 when assayed with losartan as compared to CYP2C9 *1.
L-PHENYLALANINE;PAH;rs62516101;T;Associated  with  decreased activity  of PAH when assayed  with  ➔ L-PHENYLALANINE;Metabolism/PK;Enzyme carrying the T allele showed significantly lower activity after pre-incubation with phenylalanine than the WT protein. Allele referred to in the paper as V388M. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele C.
CARBOCISTEINE;PAH;rs5030860;C;Associated  with  decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Metabolism/PK;Enzyme carrying the C allele showed significantly lower activity before and after pre-incubation with carbocisteine than the WT protein. Allele referred to in the paper as Y414C. Please note that alleles have been complemented to the positive strand.;Allele C is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele T.
L-PHENYLALANINE;PAH;rs5030849;T;Associated  with  decreased activity  of PAH when assayed  with  ➔ L-PHENYLALANINE;Metabolism/PK;Enzyme carrying the T allele showed significantly lower activity after pre-incubation with phenylalanine than the WT protein. Allele referred to in the paper as R261Q. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele C.
CARBOCISTEINE;PAH;rs76394784;A;Associated  with  decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Metabolism/PK;Enzyme carrying the A allele showed significantly lower activity before and after pre-incubation with carbocisteine than the WT protein. Allele referred to in the paper as R68S. Please note that alleles have been complemented to the positive strand.;Allele A is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele T.
DICLOFENAC;CYP2C9;CYP2C9*3;*3;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;Approximate metabolic ratio for *1 was 35% whereas for *3 ratio was approximately 13%;CYP2C9 *3 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*60;*60;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ WARFARIN;Metabolism/PK;Km was increased and Vmax was decreased resulting in relative clearance of 11.26% as compared to 100% for CYP2C9*1.;CYP2C9 *60 is associated with decreased enzyme activity of CYP2C9 when assayed with warfarin as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*37;*37;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*37 had significantly lower catalytic capacity than *1 but higher activity than variant *2;CYP2C9 *37 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*46;*46;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*46 had lower catalytic capacity than variants *2 and *3 but higher activity than variant *13;CYP2C9 *46 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
CARBOCISTEINE;PAH;rs5030849;T;Associated  with  decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Metabolism/PK;Enzyme carrying the T allele showed significantly lower activity before and after pre-incubation with carbocisteine than the WT protein. Allele referred to in the paper as R261Q. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele C.
L-PHENYLALANINE;PAH;rs5030860;C;Associated  with  decreased activity  of PAH when assayed  with  ➔ L-PHENYLALANINE;Metabolism/PK;Enzyme carrying the C allele showed significantly lower activity after pre-incubation with phenylalanine than the WT protein. Allele referred to in the paper as Y414C. Please note that alleles have been complemented to the positive strand.;Allele C is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele T.
DICLOFENAC;CYP2C9;CYP2C9*54;*54;Associated  with  increased catalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;;CYP2C9 *54 is associated with increased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*74;*74;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;Metabolism/PK;Relative clearance was 24.55% for tolbutamide, 5.28% for losartan and 55.5% for diclofenac compared to *1 (p< 0.05);CYP2C9 *74 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.
TOLBUTAMIDE;CYP2C9;rs9332239;T;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ TOLBUTAMIDE;Metabolism/PK;p value 0.05;Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with tolbutamide.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*49, CYP2D6*55;*49 + *55;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *49 p<0.05) and *55 (p<0.01) protein was reduced compared to the *1 protein. The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*55 construct compared to the *1 construct (p<0.05). The CLint values of CYP2D6.49 and .55 was lower than that of CYP2D6.1 (7?35% of that of CYP2D6.1).;CYP2D6 *49 + *55 are associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
TOLTERODINE;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;Associated  with  decreased activity  of CYP2D6 when assayed  with  ➔ TOLTERODINE;Metabolism/PK;CYP2D6*92 and CYP2D6*96 were found to be catalytically inactive.;CYP2D6 *92 + *96 are associated with decreased activity of CYP2D6 when assayed with tolterodine.
GEFITINIB;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;Associated  with  decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ GEFITINIB;Metabolism/PK;CYP2D6.92 and CYP2D6.96 showed no enzymatic activity as no concentration of O-desmethyl gefitinib was detected. Recombinant microsomes expressing CYP2D6 variants generated in Spodoptera frugioerda 21 (Sf21) insect cells were used. Gefitinib and its metabolite O-desmethyl gefitinib were analyzed by an ultra-performance liquid chromatography-tandem mass spectrometry system.;CYP2D6 *92 + *96 are associated with decreased catalytic activity of CYP2D6 when assayed with gefitinib.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*18, CYP2D6*36, CYP2D6*47, CYP2D6*49, CYP2D6*50, CYP2D6*51, CYP2D6*54, CYP2D6*55, CYP2D6*114;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Metabolism/PK;cDNA constructs were transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *47, *49, *50, *51, *55 protein (p<0.05) and the *10, *36, *54, *57 (now *36 sub allele), *114 (p<0.005) protein were reduced compared to the *1 protein. The dextromethorphan O-demethylation activity was lower with the CYP2D6*10, *18, *49, *50, *54, *55 (p<0.05) construct compared to the *1 construct. CYP2D6.14A, *36, *47, *51, *57 (now *36 sub allele) had no detectable enzyme activity toward dextromethorphan. Variants in constructs not specified but the in the figure of the article *14A (re-assigned to *114, Nov 2018 through PharmVar) contains 100C>T, 1758G>A, 2850C>T, and 4180G>C.;CYP2D6 *10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114 are associated with decreased enzyme activity of CYP2D6 when assayed with dextromethorphan in COS-7 cells as compared to CYP2D6 *1.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*18;*18;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *18 protein was not reduced compared to the *1 protein. The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*18 construct compared to the *1 construct (p<0.05). The CLint values of CYP2D6.18 was lower than that of CYP2D6.1 (7?35% of that of CYP2D6.1).;CYP2D6 *18 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*4/*5 + *4/*6;Associated  with  increased  activity  of NAT2 when assayed  with  ➔ HYDRALAZINE;Other;"Originally annotated as NAT2 *4/*5B + *4/*6A compared to NAT2 *5B/*5B + *5B/*6A + *6A/*6A + *6A/*7B (assigned as slow acetylator phenotype). Hydralazine NAT activities exhibited a robust and significant acetylator gene dose-response in vitro from human cryopreserved human hepatocytes. At concentrations of hydralazine ranging from 10 to 1000 mM, the hydralazine NAT activities differed significantly between NAT2 acetylator phenotypes at 1000 (P = 0.0319), 100 (P = 0.002), and 10 mM hydralazine (P = 0.0029). NAT2 genotypes and deduced phenotypes were determined as described previously (Doll and Hein, 2001). Cryopreserved human hepatocytes were selected at random with rapid genotypes NAT2*4/*4 [n = 6; (three males and three females); intermediate genotypes NAT2*4/*5 (n = 3) and NAT2*4/*6 (n = 2) (three males and two females); and slow genotypes NAT2*6/*6 (n = 2), NAT2*6/*7 (n = 1), NAT2*5/*5 (n = 1), and NAT2*5/*6 (n = 1) (four males and one unknown).; The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024. The alleles in this annotation are mapped as following: NAT2*5B under the *5 core allele; NAT2*6A under the *6 core allele; NAT2*7B under the *7 core allele.";NAT2 *4/*5 + *4/*6 are associated with increased activity of NAT2 when assayed with hydralazine as compared to NAT2 *5/*5 + *5/*6 + *6/*6 + *6/*7 (assigned as slow acetylator phenotype) .
HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6;*4/*4;Associated  with  increased  activity  of NAT2 when assayed  with  ➔ HYDRALAZINE;Other;"Originally annotated as ""compared to NAT2 *4/*5 + *4/*6 (assigned as intermediate acetylator phenotype)"". Hydralazine NAT activities exhibited a robust and significant acetylator gene dose-response in vitro from human cryopreserved human hepatocytes. At concentrations of hydralazine ranging from 10 to 1000 mM, the hydralazine NAT activities differed significantly between NAT2 acetylator phenotypes at 1000 (P = 0.0319), 100 (P = 0.002), and 10 mM hydralazine (P = 0.0029). NAT2 genotypes and deduced phenotypes were determined as described previously (Doll and Hein, 2001). Cryopreserved human hepatocytes were selected at random with rapid genotypes NAT2*4/*4 [n = 6; (three males and three females); intermediate genotypes NAT2*4/*5 (n = 3) and NAT2*4/*6 (n = 2) (three males and two females); and slow genotypes NAT2*6/*6 (n = 2), NAT2*6/*7B (n = 1), NAT2*5/*5 (n = 1), and NAT2*5/*6 (n = 1) (four males and one unknown).; The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024. The alleles included in this annotation are mapped as following: NAT2*5B under the *5 core allele; NAT2*6A under the *6 core allele.";NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased activity of NAT2 when assayed with hydralazine as compared to NAT2 *4/*5 + *4/*6 (assigned as intermediate acetylator phenotype) .
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;Note, *57 was re-assigned to CYP2D6*36.005 by PharmVar Sep 2023 because *57 has the core variants of the *36 (no function allele) (100C>T and exon 9 conversion). PharmGKB annotates on PharmVar core alleles not sub-alleles. The article describes that CYP2D6.57 (CYP2D6*36.005) showed extremely low activity, and the kinetic parameters could not be determined. cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *57 protein was reduced compared to the *1 protein (p<0.005). The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*57 construct compared to the *1 construct (p<0.05).;CYP2D6 *36 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
DICLOFENAC, LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*73;*73;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC, LOSARTAN;Metabolism/PK;Relative clearance was 60.50% for tolbutamide (not significantly different), 15.53%% for losartan and 48.88% for diclofenac compared to *1 (p< 0.05);CYP2C9 *73 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac or losartan as compared to CYP2C9 *1.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;CYP2D6.36 showed extremely low activity, and the kinetic parameters could not be determined. cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *36 protein was reduced compared to the *1 protein (p<0.005). The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*36 construct compared to the *1 construct (p<0.05).;CYP2D6 *36 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
FLUOXETINE;CYP2D6;CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*92, CYP2D6*93, CYP2D6*96;*10 + *92 + *93 + *96 + *87 + *2;Associated  with  decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ FLUOXETINE;Metabolism/PK;"""it is essential to evaluate the roles of different CYP2D6 variants in the metabolism of fluoxetine and design individualized therapies. For instance, a total of 9 allelic variants exhibited decreased clearance rates compared to the wild-type, as summarized in Table 4, due to an increased in the Km and a decreased in the Vmax. Among these, four allelic isoforms (CYP2D6*10, CYP2D6*92, CYP2D6*93/T249P and CYP2D6*96) retained less than 10% of the metabolic activity of the wild-type. """;CYP2D6 *10 + *92 + *93 + *96 + *87 + *2 is associated with decreased catalytic activity of CYP2D6 when assayed with fluoxetine.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*2 + *10 + *89 + *92 + *93 + *96;Associated  with  decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;"*89, *92, *93, *96 exhibited >90% decreases in catalytic activity compared with the wild-type  CYP2D6.1 in vitro. *10 (100C>T; 4180G>C) exhibited 10% of the catalytic activity compared with the wild-type CYP2D6.1 (cDNA) in vitro. *2 (2850C>T; 4180G>C) exhibited slight decrease in catalytic activity compared with the wild-type CYP2D6.1 (cDNA) in vitro.";CYP2D6 *2 + *10 + *89 + *92 + *93 + *96 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol in 293 FT cells as compared to CYP2D6 *1.
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*60;*60;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ TOLBUTAMIDE;Metabolism/PK;Km was increased and Vmax was decreased resulting in relative clearance of 13.52% as compared to 100% for CYP2C9*1.;CYP2C9 *60 is associated with decreased enzyme activity of CYP2C9 when assayed with tolbutamide as compared to CYP2C9 *1.
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ TOLBUTAMIDE;Metabolism/PK;Km was increased and Vmax was decreased resulting in relative clearance of 8.61% as compared to 100% for CYP2C9*1.;CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with tolbutamide as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;Km was increased resulting in relative clearance of 30.73% as compared to 100% for CYP2C9*1.;CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*60;*60;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;Km was increased and Vmax was decreased resulting in relative clearance of 19.65% as compared to 100% for CYP2C9*1.;CYP2C9 *60 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac as compared to CYP2C9 *1.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Associated  with  decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Metabolism/PK;"*10 (100C>T; 4180G>C) exhibited 10% of the catalytic activity compared with the wild-type CYP2D6.1 (cDNA) in vitro.";CYP2D6 *10 is associated with decreased catalytic activity of CYP2D6 when assayed with dextromethorphan in 293 FT cells as compared to CYP2D6 *1.
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Associated  with  decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ WARFARIN;Metabolism/PK;Km was increased and Vmax was decreased resulting in relative clearance of 9.21% as compared to 100% for CYP2C9*1.;CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with warfarin as compared to CYP2C9 *1.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*50;*50;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *50 protein was reduced compared to the *1 protein (p<0.05). The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*50 construct compared to the *1 construct (p<0.05).;CYP2D6 *50 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
DICLOFENAC;CYP2C9;CYP2C9*44;*44;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*44 had lower catalytic capacity than variant *2 but higher activity than variant *3;CYP2C9 *44 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*42;*42;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;"*42 was described as ""almost null catalytic activity""";CYP2C9 *42 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*40;*40;Associated  with  increased catalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;;CYP2C9 *40 is associated with increased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200346442;A;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced. R124Q   showed close to 0 activity for both substrates.;Allele A is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele G.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200150287;G;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced. R125G   showed close to 0% relative activity for S-mephenytoin and about 20% (based on graphic).;Allele G is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele C.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs150152656;T;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced.  T130M  showed close to 5% relative activity for S-mephenytoin and about 75% for omeprazole (based on graphic).;Allele T is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele C.
BUPROPION;POR;rs2868177;AA;Associated  with  decreasedenzyme  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Other, Metabolism/PK;The ratio of hydroxybupropion versus bupropion (AUC_hyd/ AUC_bup) in terms of area under the time-concentration curve (AUC) was used to assay CYP2B6 activity.;Genotype AA is associated with decreased enzyme activity of CYP2B6 when assayed with bupropion as compared to genotype AG.
BUPROPION;POR;rs2868177;GG;Associated  with  increased  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Other, Metabolism/PK;In study members who are CYP2B6 *1/*1 and CYP2B6 *6 carriers. The ratio of hydroxybupropion versus bupropion (AUC_hyd/ AUC_bup) in terms of area under the time-concentration curve (AUC) was used to assay CYP2B6 activity.;Genotype GG is associated with increased activity of CYP2B6 when assayed with bupropion.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*51;*51;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;CYP2D6.51 showed extremely low activity, and the kinetic parameters could not be determined. cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *51 protein was reduced compared to the *1 protein (p<0.05). The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*51 construct compared to the *1 construct (p<0.005).;CYP2D6 *51 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*32;*32;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;Metabolism/PK;CYP2C19*32(H99R) about 70% of wt p<0.001 based on graphic. Relative S-mephenytoin hydroxylation activity of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of S-mephenytoin was 20‘M. Three independent experiments were done. Student's t-test.;CYP2C19 *32 is associated with decreased activity of CYP2C19 when assayed with mephenytoin as compared to CYP2C19 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*33;*29 + *30 + *31 + *33;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;*29 (K28I) showed decrease for both substrates p<0.05 (about 70% of wt based on graphic).  CYP2C19*30(R73C) about 50% of wt p<0.001, CYP2C19*31(H78Y) about 60% of wt p<0.001, CYP2C19*33(D188N) about 70% of wt p<0.001based on graphic. Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.  Student's t-test.;CYP2C19 *29 + *30 + *31 + *33 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.
;POR;rs2868177;AA;Associated  with  decreased activity  of CYP2B6 when assayed  with  ➔ ;Other, Metabolism/PK;The ratio of hydroxybupropion versus bupropion (AUC_hyd/ AUC_bup) in terms of area under the time-concentration curve (AUC) was used to assay CYP2B6 activity.;Genotype AA is associated with decreased activity of CYP2B6 when assayed with as compared to genotype GG.
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Associated  with  decreasedcatalytic  activity  of CYP2C19 when assayed  with  ➔ CLOPIDOGREL;Metabolism/PK;"This was also true for 2-oxo-clopidogrel.  For *10, rs6413438 was assayed.  CYP2C19.1B was used as the comparison and is described as ""wild-type"".";CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when assayed with clopidogrel in E. coli DH5alpha as compared to CYP2C19 *1.
OMEPRAZOLE;CYP2C19;rs140278421;A;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Metabolism/PK;"""As shown in Fig. 1A, six of the variants exhibited significantly lower catalytic activity compared to the CYP2C19.1 enzyme. In particular, the H251Q and A297V variants showed the lowest catalytic activity, while the M339T variant appeared to have normal catalytic activity.""; Variant R186H described as ""rs140278421 Ref.=G Alt.=A MAF % (EstBB) 0.04"" Figure 1 shows *** but does not give p-value";Genotype A is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele G.
OMEPRAZOLE;CYP2C19;rs1361528097;G;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Metabolism/PK;"""As shown in Fig. 1A, six of the variants exhibited significantly lower catalytic activity compared to the CYP2C19.1 enzyme. In particular, the H251Q and A297V variants showed the lowest catalytic activity, while the M339T variant appeared to have normal catalytic activity."" Variant C164G described as ""rs1361528097 Ref.=T Alt.=G MAF % (EstBB) 0.02 "" Figure 1 shows *** but does not give p-value";Allele G is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele T.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. No activity was detected for *3. Sequence for *1 not referenced. Three independent experiments were done. p<0.001 compared with wild-type CYP2C19.1 by Student's t-test.;CYP2C19 *3 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.
FLUOROURACIL;DPYD;rs536577604;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight variants showed modest reductions that were 15?35% of wildtype activity (M77V, C87F, Q156R, I560N, T573I, R692W, G767V, and S994T)."" Q156R maps to rs536577604T>C in table S2.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Associated  with  decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ DEBRISOQUINE;Metabolism/PK;Vmax and Kcat were significantly lower. *10 defined as presence of P34S and S486T.;CYP2D6 *10 is associated with decreased catalytic activity of CYP2D6 when assayed with debrisoquine in yeast microsomes as compared to CYP2D6 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1267723490;C;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced. I327T showed close to 10% relative activity for S-mephenytoin and about 15% for omeprazole (based on graphic). And low expression.;Allele C is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele T.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*54;*54;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *54 protein was reduced compared to the *1 protein (p<0.005). The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*54 construct compared to the *1 construct (p<0.05). The Vmax values of CYP2D6.54 was 6% of that of CYP2D6.1. The CLint values of CYP2D6.54 was lower than that of CYP2D6.1 (7?35% of that of CYP2D6.1).;CYP2D6 *54 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
BUFURALOL, DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*29;*29;Associated  with  decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL, DEBRISOQUINE;Metabolism/PK;"1'-hydroxybufuralol catalytic activity of the CYP2D6*29 mutant expressed in COS-1 cells was only 26% of the wild-type (P < 0.01; Mann-Whitney U-test) and the debrisoquine hydroxylation activity was 63% of that of CYP2D6.1.";CYP2D6 *29 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or debrisoquine in COS-1 cells as compared to CYP2D6 *1.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*47;*47;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;CYP2D6.47 showed extremely low activity, and the kinetic parameters could not be determined. cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *47 protein was reduced compared to the *1 protein (p<0.05). The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*47 construct compared to the *1 construct (p<0.005).;CYP2D6 *47 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs764137538;T;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced. R261W showed close to 5% relative activity for S-mephenytoin and about 5% for omeprazole (based on graphic). And low expression.;Allele T is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele C.
IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*3, CYP2C19*35;*3 + *35;Associated  with  decreasedcatalytic  activity  of CYP2C19 when assayed  with  ➔ IBUPROFEN;Other;"""compared to the wild-type. CYP2C19*3 and CYP2C19*35FS exhibited no catalytic activity""";CYP2C19 *3 + *35 is associated with decreased catalytic activity of CYP2C19 when assayed with ibuprofen as compared to CYP2C19 *1.
IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*33 + *30 + *31 + *32;Associated  with  decreasedcatalytic  activity  of CYP2C19 when assayed  with  ➔ IBUPROFEN;Other;"""15 variants exhibited substantially reduced CLint (1?71% of that of CYP2C19*1). Among the 15 variants, three (CYP2C19*33, *S303N and *G91R) with a decrease in CLint of approximately 30?35% were classified as the mild reduction group, seven (CYP2C19*2F, *T130M, *R125G, *30-*32 and *2G) with a decrease of 56?88% in CLint were classified as the significantly reduced group; the remaining five were classified as the severely reduced group because their CLint value decreased by >90%."" Several variants are described with non-standard terms and are not mapped.";CYP2C19 *33 + *30 + *31 + *32 is associated with decreased catalytic activity of CYP2C19 when assayed with ibuprofen as compared to CYP2C19 *1.
DEXTROMETHORPHAN;PHETA2, SMDT1;rs1807493;G;Associated  with  increased enzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Metabolism/PK;"""Following the conditional analysis, five SNPs, including the cis-variants rs1807493 and rs1062753, and the trans-variants rs4073010, rs729559, and rs80274432, emerged as independent variants significantly correlated with hepatic CYP2D6 protein expressions. Notably, four of these SNPs, except for rs80274432, also exhibited a significant association with CYP2D6 activities in human livers, suggesting their potential as novel and independent cis- and trans-variants regulating CYP2D6.""";Allele G is associated with increased enzyme activity of CYP2D6 when assayed with dextromethorphan in human liver s9 fractions as compared to allele C.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Associated  with  decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Metabolism/PK;cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The expression of the *10 protein was reduced compared to the *1 protein (P < 0.005). The bufuralol 1'-hydroxylation activity was lower with the CYP2D6*10 construct compared to the *1 construct (p<0.05). The Vmax values of CYP2D6.10 was 20% of that of CYP2D6.1, respectively. The CLint values of CYP2D6.10 was lower than that of CYP2D6.1 (7?35% of that of CYP2D6.1).;CYP2D6 *10 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.
DICLOFENAC;CYP2C9;CYP2C9*52;*52;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;"*52 was described as ""almost null catalytic activity""";CYP2C9 *52 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*43;*43;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;"*43 was described as ""almost null catalytic activity""";CYP2C9 *43 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*45;*45;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;"*45 was described as ""almost null catalytic activity""";CYP2C9 *45 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*36;*36;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*36 had lower catalytic capacity than variants *2 and *3 but higher activity than variant *13;CYP2C9 *36 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*55;*55;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*55 had lower catalytic capacity than variants *2 and *3 but higher activity than variant *13;CYP2C9 *55 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*39;*39;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*39 had lower catalytic capacity than variants *2 and *3 but higher activity than variant *13;CYP2C9 *39 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*50;*50;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*50 had significantly lower catalytic capacity than *1 but higher activity than variant *2;CYP2C9 *50 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*47;*47;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*47 had significantly lower catalytic capacity than *1 but higher activity than variant *2;CYP2C9 *47 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*53;*53;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*53 had significantly lower catalytic capacity than *1 but higher activity than variant *2;CYP2C9 *53 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*38;*38;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*38 had significantly lower catalytic capacity than *1 but higher activity than variant *2;CYP2C9 *38 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*48;*48;Associated  with  decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;Metabolism/PK;*48 had significantly lower catalytic capacity than *1 but higher activity than variant *2;CYP2C9 *48 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1463550071;T;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced.  N403I  showed close to 70% relative activity for S-mephenytoin and about 50% for omeprazole (based on graphic).;Allele T is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele A.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1349931378;A;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced. S303N showed close to 20% relative activity for S-mephenytoin and about 30% for omeprazole (based on graphic). And low expression.;Allele A is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele G.
DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*75;*75;Associated  with  decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ DEBRISOQUINE;Metabolism/PK;Km was significantly higher, Vmax and Kcat were significantly lower. *75 defined as presence of R441H.;CYP2D6 *75 is associated with decreased catalytic activity of CYP2D6 when assayed with debrisoquine in yeast microsomes as compared to CYP2D6 *1.
OMEPRAZOLE;CYP2C19;rs1393133490;T;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Metabolism/PK;"""As shown in Fig. 1A, six of the variants exhibited significantly lower catalytic activity compared to the CYP2C19.1 enzyme. In particular, the H251Q and A297V variants showed the lowest catalytic activity, while the M339T variant appeared to have normal catalytic activity."" Variant A297V is described as ""rs1393133490 Ref.=C Alt.=T MAF % (EstBB) 0.02"" Figure 1 shows *** but does not give p-value";Allele T is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele C.
OMEPRAZOLE;CYP2C19;rs1466428833;G;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Metabolism/PK;"""As shown in Fig. 1A, six of the variants exhibited significantly lower catalytic activity compared to the CYP2C19.1 enzyme. In particular, the H251Q and A297V variants showed the lowest catalytic activity, while the M339T variant appeared to have normal catalytic activity."" Variant described as ""rs1466428833 Chr10:96,535,156 Ref.=T Alt.=G MAF % (EstBB) 0.02 F114C"" Figure 1 shows *** but does not give p-value";Allele G is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele T.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs749678783;C;Associated  with  decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;Relative omeprazole and S-mephenytoin hydroxylation activities of CYP2C19 variant proteins expressed in 293FT cells. Concentrations of omeprazole and S-mephenytoin were 10 and 20‘M, respectively. Three independent experiments were done.   The sequence for *1 cDNA was not referenced. M255T showed close to 15% relative activity for S-mephenytoin and about 10% for omeprazole (based on graphic). And low expression.;Allele C is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele T.
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;Associated  with  decreasedcatalytic  activity  of CYP3A4 when assayed  with  ➔ IBRUTINIB;Metabolism/PK;CYP3A4.17 and CYP3A4.24 showed extremely low activity or no activity.;CYP3A4 *17 + *24 is associated with decreased catalytic activity of CYP3A4 when assayed with ibrutinib as compared to CYP3A4 *1.
EFAVIRENZ;CYP2B6;rs58871670;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as V183I in Fig1B.";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.
FLUOROURACIL;DPYD;rs72547601;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 6% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (H978R) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
BUPROPION;CYP2B6;rs201500445;C;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele C is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele T.
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B;*1/*3A + *1/*3B;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;"Genotypes assayed were *2,*3A,*3B and *3C.  There were six *1/*3A,one *1/*3B,and one *1/*3C.  5/6 *1/*3A showed intermediate TPMT activity (8.60 +/- 0.22  pmol/10(7) RBC/h); 1/6 showed high activity (13.5 +/-0.81 pmol/10(7) RBC/h).  The *1/*3B showed intermediate activity of 7.87 +/- 0.46 pmol/10(7) RBC/h.";TPMT *1/*3A + *1/*3B is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in red blood cells as compared to TPMT *1/*1.
FLUOROURACIL;DPYD;rs188052243;C;Associated  with  decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate.;Allele C is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele T.
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;Genotyping was performed for *2,*3A,and *3C.  There was no overlap in activity range of the *1/*3A subjects as compared to the *1/*1 subjects.  Activity was 17 +/- 3.6  for *1/*3A vs. 32.4 +/- 4.8 nmol 6-mMP/g Hb/h for *1/*1.;TPMT *1/*3A is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in red blood cells as compared to TPMT *1/*1.
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;Kidney Transplant patients treated with azathioprine were genotyped for *2,*3A,*3B and *3C alleles.  Out of 150 patients, seven were *1/*3C, and all of these cases had intermediate TPMT activity (defined here as 13.04-23.70 U). Mean activity for this group was 16.75 +/- 2.09 U, which was significantly lower than that of *1/*1 patients.  17 patients with intermediate activity were typed as *1/*1.;TPMT *1/*3C is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in red blood cells as compared to TPMT *1/*1.
DAUNORUBICIN, DOXORUBICIN;AKR7A2;rs1043657;T;Associated  with  decreasedenzyme  activity  of AKR7A2 when assayed  with  ➔ DAUNORUBICIN, DOXORUBICIN;Metabolism/PK;;Allele T is associated with decreased enzyme activity of AKR7A2 when assayed with daunorubicin or doxorubicin as compared to allele C.
DAUNORUBICIN;AKR1C4;rs17134592;G;Associated  with  decreasedenzyme  activity  of AKR1C4 when assayed  with  ➔ DAUNORUBICIN;Metabolism/PK;;Allele G is associated with decreased enzyme activity of AKR1C4 when assayed with daunorubicin as compared to allele C.
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*1;Associated  with  increased enzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;The mean activity of the TPMT *1/*1 group was higher than that of the *1/*3 group (*3A or *3C not determined) at 13.1(95% CI 12.5-13.7) IU/mL vs 8.3 (95% CI 6.8-9.8 IU/mL). But,  4/61 *1/*1 subjects had TPMT activity in the intermediate range, and 2/7 of the *1/*3 subjects had activity in the normal range.  Patients were also genotyped for *2.;TPMT *1/*1 is associated with increased enzyme activity of TPMT when assayed with mercaptopurine in red blood cell lysates as compared to TPMT *1/*3A + *1/*3C.
MERCAPTOPURINE;TPMT;rs3931660;AT;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;"There were 17 AT subjects out of a total of 253.  Activity for the AT group was 47.20 +/- 11.35 and for the AA group, it was 92.96 +/- 34.97.   p value is uncorrected; however, authors state that the corrected value was significant.";Genotype AT is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocytes as compared to genotype AA.
MERCAPTOPURINE;TPMT;rs1142345;CT;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;"There were 17 T alleles (?) in a cohort of 253 subjects.  Activity for the TT group was 92.71 +/- 34.96 and for the CT subjects, it was 47 +/- 11.11.  p value is uncorrected; however, authors state that the corrected value was significant.";Genotype CT is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocytes as compared to genotype TT.
DAUNORUBICIN;AKR1C3;rs4987102;A;Associated  with  decreasedenzyme  activity  of AKR1C3 when assayed  with  ➔ DAUNORUBICIN;Metabolism/PK;;Allele A is associated with decreased enzyme activity of AKR1C3 when assayed with daunorubicin as compared to allele G.
DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs35575889;T;Associated  with  decreasedenzyme  activity  of AKR1C3 when assayed  with  ➔ DAUNORUBICIN, DOXORUBICIN;Metabolism/PK;The rs number listed in Table 1 is rs35575889 for R170C of AKR1C3. dbSNP lists NP_001240837.1:p.Arg170Cys in HGVS names but does not show it translated on the mapping. Base change was calculated based on codon table.;Allele T is associated with decreased enzyme activity of AKR1C3 when assayed with daunorubicin or doxorubicin as compared to allele C.
DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs34186955;T;Associated  with  decreasedenzyme  activity  of AKR1C3 when assayed  with  ➔ DAUNORUBICIN, DOXORUBICIN;Metabolism/PK;;Allele T is associated with decreased enzyme activity of AKR1C3 when assayed with daunorubicin or doxorubicin as compared to allele C.
;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*5, TPMT*12, TPMT*14, TPMT*18, TPMT*22;*2 + *3A + *5 + *12 + *14 + *18 + *22;Associated  with  decreased expression of TPMT when assayed  with  ➔ ;Metabolism/PK;Three separate transfection experiments were each assayed in triplicate for each allele. Alleles were grouped by PharmGKB.;TPMT *2 + *3A + *5 + *12 + *14 + *18 + *22 is associated with decreased expression of TPMT when assayed with in COS-7 cells as compared to TPMT *1.
FLUOROURACIL;DPYD;rs72549306;A;Associated  with  decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate. Note the variant is translated as V335M in the article however the C>A change results in V335L.;Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*1/*28 + *28/*28 + *1/*37;Associated  with  decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Metabolism/PK;"When (TA)n genotypes were regarded as the sum of; TA repeat number in both chromosomes [i.e. <12 (5/6,; 6/6, 5/7), 13 (6/7) and > 14 (7/7, 6/8, 7/8) genotypes], a; significant trend of reduced UGT1A1 activity (P ,; 0.01) was measured across the three groups (the lowest; being the > 14 genotype group)";UGT1A1 *1/*28 + *28/*28 + *1/*37 are associated with decreased enzyme activity of UGT1A1 when assayed with SN-38 in human livers as compared to UGT1A1 *1/*1.
SN-38;UGT1A1;rs4148323;A;Associated  with  decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Metabolism/PK;Compared to allele G (1* wildtype), in vitro assays with microsomal fractions with UGT1A1 transfected HEK-293 cells. The variant was referred to as G71R in this study.;Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.
FLUOROURACIL;DPYD;rs137999090;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The T allele was associated with DPYD activity at 3% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (G674D) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
FLUOROURACIL;DPYD;rs145773863;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The T allele was associated with DPYD activity at 2% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (G593R) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs200858900;T;Associated  with  decreasedcatalytic  activity  of ABCC4 when assayed  with  ➔ 17BETA-ESTRADIOL GLUCURONIDE;Metabolism/PK;"rs numbers listed in figure 1 legend. Variant described as  ""V458M (rs200858900)"", minor alleles curated from gnomad.  ""V458M, a novel variant not previously studied, showed reduced surface expression with; no change in total protein, thus altered membrane trafficking may in part explain the modified activity"".";Allele T is associated with decreased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele C.
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;Associated  with  decreased activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;Out of 12 heterozygous subjects, 11 were intermediate methylators and one was a high methylator(but on the low end of that range).  Out of 131 *1/*1 subjects, 128 were high methylators and 3 were intermediate methylators.;TPMT *1/*2 + *1/*3A + *1/*3C is associated with decreased activity of TPMT when assayed with mercaptopurine in erythrocyte lysates as compared to TPMT *1/*1.
FLUOROURACIL;DPYD;rs59086055;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with DPYD activity at 9% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (R592W) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B/*3C;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;Genotype assays were performed for *2,*3A,*3B,and *3C.  There was one *3B/*3C subject, whose assay showed very low TPMT activity (1.6 U/gHb). *1/*1 subjects had assay results ranging from 8.3-75.2 U/gHb.  Authors stated that the results were adjusted for multiple hypothesis testing.  They observed a 4-group distribution of TPMT activity phenotypes.;TPMT *3B/*3C is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocyte lysates as compared to TPMT *1/*1.
PURINE ANALOGUES;TPMT;rs1142345;CT;Associated  with  decreased activity  of TPMT when assayed  with  ➔ PURINE ANALOGUES;Other, Metabolism/PK;HapMap CEU cell line trios. [stat_test:Welch test];Genotype CT is associated with decreased activity of TPMT when assayed with purine analogues as compared to genotype TT.
ELEXACAFTOR, TEZACAFTOR;CFTR;rs1792306355;T;Associated  with  increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Efficacy;"""all five variants proved responsive to the clinically used CFTR modulator drugs. The corrector combination VX-661 + Vx-445 improved glycosylation (Fig. 8: ?), and this effect was significant (Fig. 8: ??) for the three mutants that showed the most severe maturation defects (T465I, I336K and D984V). In addition, the potentiator combination VX-770 + VX-445 significantly stimulated the currents for all five variants. This effect can be graded as modest (<5-fold; Fig. 8: ?) for D984V, strong (5?20-fold; Fig. 8: ??) for G126D, I336K and T582I, or excessive (>20-fold; Fig. 8: ???) for T465I. Thus, the data predict that the combined effect of ETI treatment should result in substantial fractional restoration of CFTR-mediated anion transport in CF patients carrying an allele with any of the five mutations."" rs1792306355A>T = D984V";Allele T is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs186089140;CT;Associated  with  increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;PD;"""Nasal epithelia derived from a S737F homozygous subject displayed a total CFTR-mediated current comparable to that observed in epithelia from healthy subjects, without any significant improvements following treatment with CFTR modulators."" ""On the contrary, some degree of CFTR dysfunction was observed when we evaluated chloride secretion in epithelia derived from three subjects compound heterozygous for the S737F variant and a CF-causing variant resembling a null allele, not rescuable by CFTR modulators. Indeed, these individuals represent the ideal system to study the function of the variant S737F protein produced by a single allele in the native cell context. Interestingly, epithelia derived from these three individuals displayed reduced CFTR-mediated current, that was significantly increased by ivacaftor. CFTR activity was also improved by pre-treatment with correctors (ELX/TEZ).""";Genotype CT is associated with increased activity of CFTR when assayed with elexacaftor / tezacaftor / ivacaftor in immortalized bronchial epithelial cells as compared to genotype CC.
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs35516286;A;Associated  with  increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;PD;"""The FIS results obtained here in IOs bearing the p.Ile148Asn variant in heterozygosity with p.Phe508del or p.Gly542Ter, respectively, revealed functional rescue of CFTR by both teza/iva and elexa/teza/iva treatments, with the addition of elexa not causing significantly additive rescue vs the teza/iva combination. However, the rescue is lower (by ?35 %) than the one observed for the reference p.Phe508del/p.Phe508del organoids.""";Allele A is associated with increased activity of CFTR when assayed with elexacaftor / tezacaftor / ivacaftor or ivacaftor / tezacaftor intestinal organoids as compared to allele T.
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs143718310;G;Associated  with  decreasedmetabolism of  when assayed  with  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Metabolism/PK;The SNP caused a 50% in CES1 enzyme activity when assayed with enalapril, clopidogrel, sacubitril.;Allele G is associated with decreased metabolism of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele T.
ENALAPRIL;CES1;rs202121317;C;Associated  with  decreasedenzyme  activity  of  when assayed  with  ➔ ENALAPRIL;Metabolism/PK;The SNP abolished CES1 enzyme activity when assayed with enapiril.;Allele C is associated with decreased enzyme activity of when assayed with enalapril in HEK cells as compared to allele A.
REMIMAZOLAM;CES1;rs2307240;T;Associated  with  increased catalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Metabolism/PK;"""In contrast, S75N significantly increased the remimazolam deactivation rate to nearly 2-fold that of the WT CES1 group (VS75N = 61.03 ¤ 2.84 nmol/min/mg protein; P = .0228)."" ""rs2307240 S75N G332A""";Allele T is associated with increased catalytic activity of CES1 when assayed with remimazolam as compared to allele C.
CLOPIDOGREL;CES1;rs202001817;A;Associated  with  decreasedenzyme  activity  of  when assayed  with  ➔ CLOPIDOGREL;Metabolism/PK;The SNP abolished CES1 enzyme activity when assayed with clopidogrel.;Allele A is associated with decreased enzyme activity of when assayed with clopidogrel in HEK cells as compared to allele G.
REMIMAZOLAM;CES1;rs71647871;T;Associated  with  decreasedcatalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Metabolism/PK;"""Significant impairments were observed in the E220G (VE220G = 9.98 ¤ 0.50 nmol/min/mg protein; P = .0177), Q169P (VQ169P = 7.22 ¤ 0.29 nmol/min/mg protein; P = .0116), and G143E groups (VG143E = 5.96 ¤ 0.05 nmol/min/mg protein; P = .0097). "" ""rs71647871 G143E G428A""";Allele T is associated with decreased catalytic activity of CES1 when assayed with remimazolam as compared to allele C.
REMIMAZOLAM;CES1;rs151291296;C;Associated  with  decreasedcatalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Metabolism/PK;"""Consistent with our previous reports for other CES1 substrates, remimazolam was efficiently hydrolyzed in WT CES1 at a rate of 31.30 ¤ 2.52 nmol/min/mg protein, while no appreciable hydrolysis was detected in the L40Ter or Vector groups."" ""rs151291296 L40Ter T227G""";Allele C is associated with decreased catalytic activity of CES1 when assayed with remimazolam as compared to allele A.
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs151291296;C;Associated  with  decreasedenzyme  activity  of  when assayed  with  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Metabolism/PK;The SNP abolished CES1 enzyme activity when assayed with enalapril, clopidogrel, sacubitril.;Allele C is associated with decreased enzyme activity of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele A.
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs146456965;A;Associated  with  decreasedmetabolism of  when assayed  with  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Metabolism/PK;The SNP abolished CES1 enzyme activity when assayed with enalapril, clopidogrel, sacubitril.;Allele A is associated with decreased metabolism of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele C.
REMIMAZOLAM;CES1;rs143718310;G;Associated  with  decreasedcatalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Metabolism/PK;"""Significant impairments were observed in the E220G (VE220G = 9.98 ¤ 0.50 nmol/min/mg protein; P = .0177), Q169P (VQ169P = 7.22 ¤ 0.29 nmol/min/mg protein; P = .0116), and G143E groups (VG143E = 5.96 ¤ 0.05 nmol/min/mg protein; P = .0097). "" ""rs143718310 Q169P A614C""";Allele G is associated with decreased catalytic activity of CES1 when assayed with remimazolam as compared to allele T.
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs200707504;C;Associated  with  decreasedenzyme  activity  of  when assayed  with  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Metabolism/PK;The SNP caused a decrease in CES1 enzyme activity when assayed with enalapril (- 78.8%), clopidogrel (-82.3%), sacubitril (-80.3%).;Allele C is associated with decreased enzyme activity of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele T.
ENALAPRIL;CES1;rs2307243;T;Associated  with  decreasedenzyme  activity  of  when assayed  with  ➔ ENALAPRIL;Metabolism/PK;The SNP abolished CES1 enzyme activity when assayed with enapiril.;Allele T is associated with decreased enzyme activity of when assayed with enalapril in HEK cells as compared to allele C.
REMIMAZOLAM;CES1;rs200707504;C;Associated  with  decreasedcatalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Metabolism/PK;"""Significant impairments were observed in the E220G (VE220G = 9.98 ¤ 0.50 nmol/min/mg protein; P = .0177), Q169P (VQ169P = 7.22 ¤ 0.29 nmol/min/mg protein; P = .0116), and G143E groups (VG143E = 5.96 ¤ 0.05 nmol/min/mg protein; P = .0097). "" ""rs200707504 E220G A767G""";Allele C is associated with decreased catalytic activity of CES1 when assayed with remimazolam as compared to allele T.
BUPROPION;CYP2B6;rs58871670;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.
FLUOROURACIL;DPYD;rs755692084;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The G allele was associated with DPYD activity at 75% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""possibly damaging"". Please note that this SNP was referred to by its amino acid change (D687A) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*8, TPMT*10, TPMT*11, TPMT*12, TPMT*13;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;Alleles grouped by PharmGKB;TPMT *2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13 are associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in COS-1 cells as compared to TPMT *1.
THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*7, TPMT*9, TPMT*10, TPMT*12, TPMT*14, TPMT*17, TPMT*18, TPMT*19, TPMT*20, TPMT*21, TPMT*22, TPMT*23, TPMT*30;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ THIOGUANINE;Metabolism/PK;Alleles were grouped by PharmGKB.;TPMT *2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30 are associated with decreased enzyme activity of TPMT when assayed with thioguanine in COS-7 cells as compared to TPMT *1.
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;Associated  with  decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Metabolism/PK;"Genotype assays were performed for *2,*3A,*3B,and *3C.  Most of the heterozygotes were *1/*3A.  There was a concordance rate of 71.6% between genotype and phenotype;11/51 heterozygotes had normal activity, and 265/891 ""*1/*1"" subjects had intermediate TPMT activity.  There was one *3B/*3C subject, whose assay showed very low TPMT activity (1.6 U/gHb). *1/*1 subjects had assay results ranging from 8.3-75.2 U/gHb. Heterozygous subjects had activity ranging from 10.6-24.4 U/gHb.   Authors stated that the statistical results were adjusted for multiple hypothesis testing.  They observed a 4-group distribution of TPMT activity phenotypes.  *1/*1 infants (0.08-5 yrs) showed 9% avg. higher TPMT activity than did other *1/*1 groups.";TPMT *1/*3A + *1/*3B + *1/*3C is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocyte lysates as compared to TPMT *1/*1.
ELEXACAFTOR, TEZACAFTOR;CFTR;rs758900656;T;Associated  with  increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Efficacy;"""all five variants proved responsive to the clinically used CFTR modulator drugs. The corrector combination VX-661 + Vx-445 improved glycosylation (Fig. 8: ?), and this effect was significant (Fig. 8: ??) for the three mutants that showed the most severe maturation defects (T465I, I336K and D984V). In addition, the potentiator combination VX-770 + VX-445 significantly stimulated the currents for all five variants. This effect can be graded as modest (<5-fold; Fig. 8: ?) for D984V, strong (5?20-fold; Fig. 8: ??) for G126D, I336K and T582I, or excessive (>20-fold; Fig. 8: ???) for T465I. Thus, the data predict that the combined effect of ETI treatment should result in substantial fractional restoration of CFTR-mediated anion transport in CF patients carrying an allele with any of the five mutations."" rs758900656C>T = T465I";Allele T is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568681;T;Associated  with  increased catalytic  activity  of ABCC4 when assayed  with  ➔ 17BETA-ESTRADIOL GLUCURONIDE;Metabolism/PK;"rs numbers listed in figure 1 legend. Variant described as  ""L18I (rs11568681)"", minor alleles curated from gnomad.  ""Our results suggest moderately increased transport; activity for L18I, K293E, and R531Q without changes in expression suggesting altered intrinsic activity. """;Allele T is associated with increased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele G.
FLUOROURACIL;DPYD;rs183385770;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The T allele was associated with DPYD activity at 17% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (D342N) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
ESLICARBAZEPINE ACETATE;AADAC;rs35084477;A;Associated  with  increased catalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Metabolism/PK;V172I had large increase in activity compared to V172V;Allele A is associated with increased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele G.
ESLICARBAZEPINE ACETATE;AADAC;rs1803155;A;Associated  with  increased catalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Metabolism/PK;V281I had a moderate increase in activity compared to V281V;Allele A is associated with increased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele G.
ESLICARBAZEPINE ACETATE;AADAC;rs61733692;C;Associated  with  decreasedcatalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Metabolism/PK;X400Q had large decrease in activity compared to X400X;Allele C is associated with decreased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele T.
FLUOROURACIL;DPYD;rs114096998;T;Associated  with  increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The T allele was associated with 138% increased enzyme activity of DPYD as compared to wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. However, using PolyPhen-2, this variant was classified as ""benign"". Please note that this SNP was referred to by its amino acid change (P1023T) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele T is associated with increased activity of DPYD when assayed with fluorouracil as compared to allele G.
FLUOROURACIL;DPYD;rs60139309;C;Associated  with  increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with 130% increased enzyme activity of DPYD as compared to wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. However, using PolyPhen-2, this variant was classified as ""benign"". Please note that this SNP was referred to by its amino acid change (K861R) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with increased activity of DPYD when assayed with fluorouracil as compared to allele T.
FLUOROURACIL;DPYD;rs143986398;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 75% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (P92A) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
SN-38;UGT1A9;rs11692021;C;Associated  with  decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Metabolism/PK;Compared to allele T (1* wildtype), in vitro assays with microsomal fractions with UGT1A7 transfected HEK-293 cells. The variant was referred to as W208R in this study.;Allele C is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.
SN-38;UGT1A9;rs72551344;G;Associated  with  decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Metabolism/PK;Compared to allele T (1* wildtype), in vitro assays with microsomal fractions with UGT1A1 transfected HEK-293 cells. This variant was referred to as L233R in this study.;Allele G is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.
SN-38;UGT1A9;rs34993780;G;Associated  with  decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Metabolism/PK;Compared to allele T (*1 wildtype). In in vitro assays with microsomal fractions with UGT1A1 transfected HEK-293 cells. This variant was referred to as Y486D in this study.;Allele G is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.
FLUOROURACIL;DPYD;rs72549308;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The G allele was associated with DPYD activity at 1% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (S201R) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
FLUOROURACIL;DPYD;rs1184321568;del;Associated  with  decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate.;Allele del is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele T.
FLUOROURACIL;DPYD;rs143879757;A;Associated  with  decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate.;Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele G.
FLUOROURACIL;DPYD;rs59086055;A;Associated  with  decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate.;Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele G.
FLUOROURACIL;DPYD;rs148994843;T;Associated  with  decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate.;Allele T is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.
DEXTROMETHORPHAN;;rs729559;GG;Associated  with  increased enzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Metabolism/PK;"""Following the conditional analysis, five SNPs, including the cis-variants rs1807493 and rs1062753, and the trans-variants rs4073010, rs729559, and rs80274432, emerged as independent variants significantly correlated with hepatic CYP2D6 protein expressions. Notably, four of these SNPs, except for rs80274432, also exhibited a significant association with CYP2D6 activities in human livers, suggesting their potential as novel and independent cis- and trans-variants regulating CYP2D6.""";Genotype GG is associated with increased enzyme activity of CYP2D6 when assayed with dextromethorphan in human liver s9 fractions as compared to genotypes AA + AG.
FLUOROURACIL;DPYD;rs748620513;G;Associated  with  decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;One of 21 variants found in 1020 individuals in Japan. Assays were down in triplicate.;Allele G is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.
DEXTROMETHORPHAN;;rs4073010;TT;Associated  with  increased enzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Metabolism/PK;"""Following the conditional analysis, five SNPs, including the cis-variants rs1807493 and rs1062753, and the trans-variants rs4073010, rs729559, and rs80274432, emerged as independent variants significantly correlated with hepatic CYP2D6 protein expressions. Notably, four of these SNPs, except for rs80274432, also exhibited a significant association with CYP2D6 activities in human livers, suggesting their potential as novel and independent cis- and trans-variants regulating CYP2D6.""";Genotype TT is associated with increased enzyme activity of CYP2D6 when assayed with dextromethorphan in human liver s9 fractions as compared to genotypes CC + CT.
FLUOROURACIL;DPYD;rs72549304;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with DPYD activity at 18% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (S492L) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
FLUOROURACIL;DPYD;rs200687447;T;Associated  with  increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The T allele was associated with 116% increased enzyme activity of DPYD as compared to wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""benign"". Please note that this SNP was referred to by its amino acid change (E828K) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele T is associated with increased activity of DPYD when assayed with fluorouracil as compared to allele G.
ESLICARBAZEPINE ACETATE;AADAC;rs144650170;G;Associated  with  increased catalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Metabolism/PK;T74A had small increase in activity compared to T74T;Allele G is associated with increased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele A.
FLUOROURACIL;DPYD;rs146356975;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 45% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. However, using PolyPhen-2, this variant was classified as ""benign"". Please note that this SNP was referred to by its amino acid change (K290E) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
ESLICARBAZEPINE ACETATE;AADAC;rs140197497;G;Associated  with  increased catalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Metabolism/PK;N366K had a moderate increase in activity compared to N366N. Rs number given in Table 2 did not match to correct protein changes, therefore re-mapped on dbSNP.;Allele G is associated with increased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele C.
FLUOROURACIL;DPYD;rs2297595;C;Associated  with  increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with 120% increased enzyme activity of DPYD as compared to wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (M166V) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with increased activity of DPYD when assayed with fluorouracil as compared to allele T.
FLUOROURACIL;DPYD;rs183105782;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The G allele was associated with DPYD activity at 80% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (Y304H) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.
FLUOROURACIL;DPYD;rs190577302;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 77% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. However, using PolyPhen-2, this variant was classified as ""benign"". Please note that this SNP was referred to by its amino acid change (L352V) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568644;A;Associated  with  decreasedcatalytic  activity  of ABCC4 when assayed  with  ➔ 17BETA-ESTRADIOL GLUCURONIDE;Metabolism/PK;"rs numbers listed in figure 1 legend. Variant described as  ""T1142M (rs11568644)"", minor alleles curated from gnomad.  ""While cell surface protein of T1142M was 34% lower than; wildtype, this difference was NS"".";Allele A is associated with decreased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele G.
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs142211148;T;Associated  with  increased catalytic  activity  of ABCC4 when assayed  with  ➔ 17BETA-ESTRADIOL GLUCURONIDE;Metabolism/PK;"rs numbers listed in figure 1 legend. Variant described as  ""R531Q (rs142211148)"", minor alleles curated from gnomad.  ""Our results suggest moderately increased transport; activity for L18I, K293E, and R531Q without changes in expression suggesting altered intrinsic activity. """;Allele T is associated with increased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele C.
FLUOROURACIL;DPYD;rs186169810;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 47% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""possibly damaging"". Please note that this SNP was referred to by its amino acid change (F438L) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.
FLUOROURACIL;DPYD;rs143154602;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with completely absent DPYD activity. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. However, using PolyPhen-2, this variant was classified as ""benign"". Please note that this SNP was referred to by its amino acid change (R353C) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
FLUOROURACIL;DPYD;rs368146607;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight additional variants had moderate to mild reductions in DPD activity that were 35?70% of wildtype activity (T132S, V586A, G603E, K616Q, S644N, G676E, V714A, and A777D)."" K616Q maps to rs368146607T>G in table S2.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
FLUOROURACIL;DPYD;rs371258350;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight additional variants had moderate to mild reductions in DPD activity that were 35?70% of wildtype activity (T132S, V586A, G603E, K616Q, S644N, G676E, V714A, and A777D)."" G603E maps to rs371258350C>T in table S2.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
FLUOROURACIL;DPYD;rs575853463;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight additional variants had moderate to mild reductions in DPD activity that were 35?70% of wildtype activity (T132S, V586A, G603E, K616Q, S644N, G676E, V714A, and A777D)."" G676E maps to rs575853463C>T in table S2.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
FLUOROURACIL;DPYD;rs569661196;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Eight additional variants had moderate to mild reductions in DPD activity that were 35?70% of wildtype activity (T132S, V586A, G603E, K616Q, S644N, G676E, V714A, and A777D)."" V714A maps to rs569661196A>G in table S2.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.
FLUOROURACIL;DPYD;rs138616379;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The T allele was associated with DPYD activity at 16% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (R592Q) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;ABCB1;rs2229109;T;Associated  with  decreasedtransport of ABCB1 when assayed  with  ➔ AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;Metabolism/PK;;Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C.
FLUOROURACIL;DPYD;rs115232898;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 85% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (Y186C) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
CLOZAPINE;UGT1A4;rs2011425;G;Associated  with  increased catalytic  activity  of UGT1A4 when assayed  with  ➔ CLOZAPINE;Metabolism/PK;"The effect is reported for L48V where 48V maps to rs2011425 G using the UGT nomenclature and dbSNP. Authors state  ""In the present study, L48V was twice as efficient as the wild type in glucuronidating the antipsychotic drug clozapine""";Allele G is associated with increased catalytic activity of UGT1A4 when assayed with clozapine as compared to allele T.
FLUOROURACIL;DPYD;rs111858276;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 15% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (D495G) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;Associated  with  increased  activity  of UGT1A6 when assayed  with  ➔ ACETAMINOPHEN;Metabolism/PK;*2 construct had a greater glucuronidation activity compared to *1 using serotonin, acetaminophen, and valporate as substrates. *2 genotype in this article is determined by rs6759892, rs2070959, rs1105879. No subtype for *2 was used in this study.;UGT1A6 *2a is associated with increased activity of UGT1A6 when assayed with acetaminophen in HEK cells as compared to UGT1A6 *1a.
FLUOROURACIL;DPYD;rs140039091;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" A549P maps to rs140039091C>G in table S2.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
FLUOROURACIL;DPYD;rs187713395;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" M680T maps to rs187713395A>G in table S2.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.
SN-38;UGT1A9;rs35350960;A;Associated  with  decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Metabolism/PK;Compared to allele C (1* wildtype), in vitro assays with microsomal fractions with UGT1A1 transfected HEK-293 cells. This variant was referred to as P229Q in this study.;Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.
ESLICARBAZEPINE ACETATE;AADAC;rs186388618;T;Associated  with  decreasedcatalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Metabolism/PK;R248S protein had almost no activity;Allele T is associated with decreased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele A.
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508139;A;Associated  with  increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Efficacy;"""all five variants proved responsive to the clinically used CFTR modulator drugs. The corrector combination VX-661 + Vx-445 improved glycosylation (Fig. 8: ?), and this effect was significant (Fig. 8: ??) for the three mutants that showed the most severe maturation defects (T465I, I336K and D984V). In addition, the potentiator combination VX-770 + VX-445 significantly stimulated the currents for all five variants. This effect can be graded as modest (<5-fold; Fig. 8: ?) for D984V, strong (5?20-fold; Fig. 8: ??) for G126D, I336K and T582I, or excessive (>20-fold; Fig. 8: ???) for T465I. Thus, the data predict that the combined effect of ETI treatment should result in substantial fractional restoration of CFTR-mediated anion transport in CF patients carrying an allele with any of the five mutations."" rs397508139T>A = I336K";Allele A is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.
FLUOROURACIL;MIR27A;rs895819;C;Associated  with  decreasedenzyme  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;Activity was correct for age, sex and DPYD SNP p.C29R (rs1801265).;Allele C is associated with decreased enzyme activity of DPYD when assayed with fluorouracil in peripheral blood mononuclear cells as compared to allele T.
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508609;A;Associated  with  increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Efficacy;"""all five variants proved responsive to the clinically used CFTR modulator drugs. The corrector combination VX-661 + Vx-445 improved glycosylation (Fig. 8: ?), and this effect was significant (Fig. 8: ??) for the three mutants that showed the most severe maturation defects (T465I, I336K and D984V). In addition, the potentiator combination VX-770 + VX-445 significantly stimulated the currents for all five variants. This effect can be graded as modest (<5-fold; Fig. 8: ?) for D984V, strong (5?20-fold; Fig. 8: ??) for G126D, I336K and T582I, or excessive (>20-fold; Fig. 8: ???) for T465I. Thus, the data predict that the combined effect of ETI treatment should result in substantial fractional restoration of CFTR-mediated anion transport in CF patients carrying an allele with any of the five mutations."" rs397508609G>A = G126D";Allele A is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.
FLUOROURACIL;DPYD;rs141044036;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with absent DPYD activity. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (K958E) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
ARACHIDONIC ACID;CYP4F2;rs753169154;G;Associated  with  decreasedcatalytic  activity  of CYP4F2 when assayed  with  ➔ ARACHIDONIC ACID;PD;"""Notably, Vmax values were significantly lower in three variants (Arg108Trp, Val433Met, and; Ile459Thr) than in the wild type"". Alleles complemented.";Allele G is associated with decreased catalytic activity of CYP4F2 when assayed with arachidonic acid as compared to allele A.
EFAVIRENZ;CYP2B6;rs201500445;C;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as Y380H in Fig1B.";Allele C is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele T.
BUPROPION;CYP2B6;rs535039125;T;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele T is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele C.
EFAVIRENZ;CYP2B6;rs117872433;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as A464T in Fig1B.";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.
BUPROPION;CYP2B6;rs200238771;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele T.
ARACHIDONIC ACID;CYP4F2;rs114396708;A;Associated  with  decreasedcatalytic  activity  of CYP4F2 when assayed  with  ➔ ARACHIDONIC ACID;PD;"""Notably, Vmax values were significantly lower in three variants (Arg108Trp, Val433Met, and; Ile459Thr) than in the wild type"". Alleles complemented.";Allele A is associated with decreased catalytic activity of CYP4F2 when assayed with arachidonic acid as compared to allele G.
COUMARIN, NICOTINE, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*7, CYP2A6*19;*7 + *19;Associated  with  decreasedcatalytic  activity  of CYP2A6 when assayed  with  ➔ COUMARIN, NICOTINE, TEGAFUR;Metabolism/PK;Kinetic assays in vitro using CYP2A6 transformed E. coli membrane preparations (n=3). The CYP2A6*7 allele was defined as containing SNP T1412C (I471T amino acid change, rs5031016), and a gene conversion with the CYP2A7 gene in the 3'-UTR. *19 allele was defined as rs1809810, T6354C, rs5031016, 3' UTR gene conversion with CYP2A7.;CYP2A6 *7 + *19 are associated with decreased catalytic activity of CYP2A6 when assayed with coumarin, nicotine or tegafur as compared to CYP2A6 *1.
BUPROPION;CYP2B6;CYP2B6*47;*47;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects."" Shown as Y354R in Fig1B with bupriopion but as Y354H with efavirenz. *47 has two adjacent variants that together result in Y354R but separately could generate Y354H or Y354C.";CYP2B6 *47 is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells.
NICOTINE;CYP2A6;rs4803381;CC + CT;Associated  with  increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;Novel SNP were significantly associated with higher in-vitro CYP2A6 activity in liver microsomes measured as rate of cotinine formation from nicotine (nmol/min/ mg) among 327 White liver donors.;Genotypes CC + CT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT.
EFAVIRENZ;CYP2B6;CYP2B6*47;*47;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1"" Shown as Y354R in Fig1B with bupriopion but as Y354H with efavirenz. *47 has two adjacent variants that together result in Y354R but separately could generate Y354H or Y354C.";CYP2B6 *47 is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells.
NICOTINE;CYP2A6;rs57837628;AG + GG;Associated  with  increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;Novel SNP were significantly associated with higher in-vitro CYP2A6 activity in liver microsomes measured as rate of cotinine formation from nicotine (nmol/min/ mg) among 327 White liver donors.;Genotypes AG + GG are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype AA.
COUMARIN, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*18;*18;Associated  with  decreasedcatalytic  activity  of CYP2A6 when assayed  with  ➔ COUMARIN, TEGAFUR;Metabolism/PK;Compared to *1 wild type. Kinetic assays in vitro using CYP2A6 transformed E. coli membrane preparations (n=3). CYP2A6 *18 is defined by the SNP rs1809810.;CYP2A6 *18 is associated with decreased catalytic activity of CYP2A6 when assayed with coumarin or tegafur as compared to CYP2A6 *1.
FLUOROURACIL;DPYD;rs67376798;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with DPYD activity at 59% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (D949V) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
EFAVIRENZ;CYP2B6;CYP2B6*46;*46;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" The H247P variant does not yet have an rs number but has been classified by PharmVar as *46.";CYP2B6 *46 is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells.
NICOTINE;CYP2A6;rs72549435;C;Associated  with  decreasedcatalytic  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;Variant described as V110L in the paper and mapped to rs72549435 by PharmGKB.;Allele C is associated with decreased catalytic activity of CYP2A6 when assayed with nicotine as compared to allele G.
EFAVIRENZ;CYP2B6;rs535039125;T;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as R140W in Fig 1B";Allele T is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele C.
PREGNENOLONE;SULT2B1;rs746398875;T;Associated  with  decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Metabolism/PK;"""Seven allozymes exhibited barely detectable sulfating activity at across all three concentrations: P54A, G57V, T58M, R132H, R259Q, G261V, and G261W.""";Allele T is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele G.
PREGNENOLONE;SULT2B1;rs762765702;A;Associated  with  decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Metabolism/PK;"""Seven allozymes exhibited barely detectable sulfating activity at across all three concentrations: P54A, G57V, T58M, R132H, R259Q, G261V, and G261W.""";Allele A is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele G.
COUMARIN;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;Associated  with  decreasedenzyme  activity  of CYP2A6 when assayed  with  ➔ COUMARIN;Metabolism/PK;Paper originally identified the *4B allele which has been reassigned as *4 following CYP2A6's release in PharmVar;CYP2A6 *4/*9 is associated with decreased enzyme activity of CYP2A6 when assayed with coumarin.
BUPROPION;CYP2B6;rs374099483;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.
BUPROPION;CYP2B6;rs764288403;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.
BUPROPION;CYP2B6;CYP2B6*46;*46;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects."" The H247P variant does not yet have an rs number but has been classified by PharmVar as *46.";CYP2B6 *46 is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells.
EFAVIRENZ;CYP2B6;rs374099483;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as R443H in Fig1B.";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.
BUPROPION;CYP2B6;rs117872433;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.
FLUOROURACIL;DPYD;rs112766203;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with DPYD activity at 45% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""possibly damaging"". Please note that this SNP was referred to by its amino acid change (T760I) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
FLUOROURACIL;DPYD;rs1801158;TT;Associated  with  increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Other;DPYD*4 or S534N. Study looked at the conversion of [6-C14]-fluorouracil to [6-C14]-5-dihydrofluorouracil. DPD enzyme activity was assessed relative to wild-type and the catalytically inactive *2A variant. S534N was 36% more active than wild-type. Additionally, it was more protective against 5-FU toxicity when expressed in cells.;Genotype TT is associated with increased activity of DPYD when assayed with fluorouracil as compared to genotype CC.
FLUOROURACIL;DPYD;rs188052243;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The C allele was associated with DPYD activity at 80% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. However, using PolyPhen-2, this variant was classified as ""benign"". Please note that this SNP was referred to by its amino acid change (N893S) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
PREGNENOLONE;SULT2B1;rs527454384;T;Associated  with  decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Metabolism/PK;"""Seven allozymes exhibited barely detectable sulfating activity at across all three concentrations: P54A, G57V, T58M, R132H, R259Q, G261V, and G261W.""";Allele T is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele C.
FLUOROURACIL;DPYD;rs61757362;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with DPYD activity at 73% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. However, using PolyPhen-2, this variant was classified as ""benign"". Please note that this SNP was referred to by its amino acid change (T983I) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.
ARACHIDONIC ACID;CYP4F2;rs2108622;T;Associated  with  decreasedcatalytic  activity  of CYP4F2 when assayed  with  ➔ ARACHIDONIC ACID;PD;"""Notably, Vmax values were significantly lower in three variants (Arg108Trp, Val433Met, and; Ile459Thr) than in the wild type"". Alleles complemented.";Allele T is associated with decreased catalytic activity of CYP4F2 when assayed with arachidonic acid as compared to allele C.
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*17, CYP2A6*35;*17 + *35;Associated  with  decreasedcatalytic  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;;CYP2A6 *17 + *35 are associated with decreased catalytic activity of CYP2A6 when assayed with nicotine as compared to CYP2A6 *1.
BUPROPION;CYP2B6;rs148009906;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508293;T;Associated  with  increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Efficacy;"""all five variants proved responsive to the clinically used CFTR modulator drugs. The corrector combination VX-661 + Vx-445 improved glycosylation (Fig. 8: ?), and this effect was significant (Fig. 8: ??) for the three mutants that showed the most severe maturation defects (T465I, I336K and D984V). In addition, the potentiator combination VX-770 + VX-445 significantly stimulated the currents for all five variants. This effect can be graded as modest (<5-fold; Fig. 8: ?) for D984V, strong (5?20-fold; Fig. 8: ??) for G126D, I336K and T582I, or excessive (>20-fold; Fig. 8: ???) for T465I. Thus, the data predict that the combined effect of ETI treatment should result in substantial fractional restoration of CFTR-mediated anion transport in CF patients carrying an allele with any of the five mutations."" rs397508293C>T = T582I";Allele T is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.
FLUOROURACIL;DPYD;rs1801268;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with DPYD activity at 1% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (V995F) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
BUPROPION;CYP2B6;rs200458614;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C). As a result, patients with these variants may require a lower oral dose of bupropion to achieve the desired concentration in the bloodstream and therapeutic effects.""";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.
EFAVIRENZ;CYP2B6;rs764288403;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as R434Q in Fig1B.";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.
EFAVIRENZ;CYP2B6;rs200238771;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as I382N in Fig1B.";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele T.
FLUOROURACIL;DPYD;rs367619008;C;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" K63E maps to rs367619008T>C in table S2.";Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.
EFAVIRENZ;CYP2B6;rs200458614;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as R378Q in Fig1B.";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.
NICOTINE;CYP2A6;rs56113850;CC + CT;Associated  with  increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;Novel SNP were significantly associated with higher in-vitro CYP2A6 activity in liver microsomes measured as rate of cotinine formation from nicotine (nmol/min/ mg) among 327 White liver donors.;Genotypes CC + CT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT.
FLUOROURACIL;DPYD;rs758649719;T;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" G795R maps to rs758649719C>T in table S2.";Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
NICOTINE;CYP2A6;rs7259706;TT;Associated  with  increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;Novel SNP were significantly associated with higher in-vitro CYP2A6 activity in liver microsomes measured as rate of cotinine formation from nicotine (nmol/min/ mg) among 327 White liver donors. CT vs CC is not associated with increased activity P=0.23.;Genotype TT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype CC.
FLUOROURACIL;DPYD;rs369103276;G;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"""Of the 25 deleterious variants, 9 exhibited DPD activities that were less than 15% of wildtype activity (K63E, R208Q, I281T, A549P, M680T, G795R, T737I, I948N, and H978Q)."" I281T maps to rs369103276A>G in table S2.";Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*30;*6 + *30;Associated  with  decreasedcatalytic  activity  of CYP3A4 when assayed  with  ➔ VANDETANIB;Metabolism/PK;"these are considered no function by the authors although this is written poorly in the abstract it is better described in the discussion :  ""CYP3A4.6 and CYP3A4.30 were non-functional mutants""";CYP3A4 *6 + *30 is associated with decreased catalytic activity of CYP3A4 when assayed with vandetanib as compared to CYP3A4 *1.
NICOTINE;CYP2A6;rs28399453;AA + AG;Associated  with  increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;Novel SNP were significantly associated with higher in-vitro CYP2A6 activity in liver microsomes measured as rate of cotinine formation from nicotine (nmol/min/ mg) among 327 White liver donors.;Genotypes AA + AG are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype GG.
NICOTINE;CYP2A6;rs8192733;CC + CG;Associated  with  increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;Novel SNP were significantly associated with higher in-vitro CYP2A6 activity in liver microsomes measured as rate of cotinine formation from nicotine (nmol/min/ mg) among 327 White liver donors.;Genotypes CC + CG are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype GG.
EFAVIRENZ;CYP2B6;rs148009906;A;Associated  with  decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Metabolism/PK;"""The results showed that all the novel variants (p.A102T in *44, p.R140W in *39, p.V183I in *45, p.H247P in *46, p.Y354R in *47, p.R378Q in *40, p.Y380H in *41, p.I382 N in *48, p.R434Q in *49, p.R443H in *42, and p.A464T in *43) exhibited significant lower activities than the reference CYP2B6*1 (Fig. 1. A, B and C)."" Shown as A102T in Fig1B.";Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.
PREGNENOLONE;SULT2B1;rs777924668;G;Associated  with  decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Metabolism/PK;"""Seven allozymes exhibited barely detectable sulfating activity at across all three concentrations: P54A, G57V, T58M, R132H, R259Q, G261V, and G261W.""";Allele G is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele C.
FLUOROURACIL;DPYD;rs55674432;A;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Metabolism/PK;"Functional study. The A allele was associated with DPYD activity at 3% of wild-type. Activity measured by conversion of 5-fluorouracil to 5-dihydrofluorouracil, the product of DPYD catabolism. Using PolyPhen-2, this variant was classified as ""probably damaging"". Please note that this SNP was referred to by its amino acid change (G880V) within the paper. Alleles have been complemented to the plus chromosomal strand.";Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.
FLUOROURACIL;DPYD;rs55886062;CC;Associated  with  decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Other;DPYD*13 or I560S. Study looked at the conversion of [6-C14]-fluorouracil to [6-C14]-5-dihydrofluorouracil. DPD enzyme activity was assessed relative to wild-type and the catalytically inactive *2A variant. DPD enzyme function showed a 75% reduction relative to wild-type.;Genotype CC is associated with decreased activity of DPYD when assayed with fluorouracil as compared to genotype AA.
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *4/*4 + *4/*9;Associated  with  decreasedenzyme  activity  of CYP2A6 when assayed  with  ➔ LETROZOLE;Metabolism/PK;;CYP2A6 *1/*4 + *1/*7 + *4/*4 + *4/*9 are associated with decreased enzyme activity of CYP2A6 when assayed with letrozole in human liver microsome samples as compared to CYP2A6 *1/*1.
NICOTINE;CYP2A6;rs7260629;GG;Associated  with  increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Metabolism/PK;Novel SNP were significantly associated with higher in-vitro CYP2A6 activity in liver microsomes measured as rate of cotinine formation from nicotine (nmol/min/ mg) among 327 White liver donors. GT vs TT is not associated with increased activity P=0.23.;Genotype GG are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT.
FLUOROURACIL;DPYD;rs1801265;GG;Associated  with  increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Other;DPYD*9A or C29R. Study looked at the conversion of [6-C14]-fluorouracil to [6-C14]-5-dihydrofluorouracil. DPD enzyme activity was assessed relative to wild-type and the catalytically inactive *2A variant. C29R was 13% more active than wild-type.;Genotype GG is associated with increased activity of DPYD when assayed with fluorouracil as compared to genotype AA.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*89 + *92 + *93 + *96;Associated  with  decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Metabolism/PK;*96, *93, *92, *89 exhibited >90% decreases in catalytic activity compared with the wild-type  CYP2D6.1 in vitro.;CYP2D6 *89 + *92 + *93 + *96 are associated with decreased catalytic activity of CYP2D6 when assayed with dextromethorphan in 293 FT cells as compared to CYP2D6 *1.
PREGNENOLONE;SULT2B1;rs777140014;A;Associated  with  decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Metabolism/PK;"""Seven allozymes exhibited barely detectable sulfating activity at across all three concentrations: P54A, G57V, T58M, R132H, R259Q, G261V, and G261W.""";Allele A is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele G.
TESTOSTERONE;CYP3A5;rs55817950;A;Associated  with  decreasedenzyme  activity  of CYP3A5 when assayed  with  ➔ TESTOSTERONE;Metabolism/PK;"Authors state ""The CYP3A5 R28C allele exhibited significantly lower; catalytic activity compared to CYP3A51 for testosterone 6- and 2-hydroxylation. CYP3A5 R28C exhibited; 68 and 43% decreases in the maximal clearances of 6-; hydroxytestosterone."" Mapped using PharmVar.";Allele A is associated with decreased enzyme activity of CYP3A5 when assayed with testosterone as compared to allele G.
NIFEDIPINE;CYP3A5;rs72552791;C;Associated  with  decreasedenzyme  activity  of CYP3A5 when assayed  with  ➔ NIFEDIPINE;Metabolism/PK;effect is described for CYP3A5.11 protein (mapped to suballele CYP3A5*3.008 on PharmVar), where protein studied has just the Tyr53Cys change on the CYP3A5*1 background. Variant has decreased Vmax, increased Km and decreased intrinsic clearance.;Allele C is associated with decreased enzyme activity of CYP3A5 when assayed with nifedipine as compared to allele T.
PREGNENOLONE;SULT2B1;rs774212320;T;Associated  with  decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Metabolism/PK;"""Seven allozymes exhibited barely detectable sulfating activity at across all three concentrations: P54A, G57V, T58M, R132H, R259Q, G261V, and G261W.""";Allele T is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele G.
;CYP2C9;rs762081829;T;Associated  with  decreased expression of CYP2C9protein ➔ ;Other;Western blot analysis showed that expression of CYP2C9 protein containing the T allele was significantly reduced compared to WT protein. Variant referred to as 218C>T in the paper. Note that there are discrepancies between the text in the Results section of this manuscript and the data presented in Figure 1 regarding protein expression of variants studied in this paper. After thorough reading of the paper, we have decided to annotate based on the data presented in Figure 1 and have contacted the corresponding author to notify them of this discrepancy.;Allele T is associated with decreased expression of CYP2C9 protein as compared to allele C.
;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;Associated  with  increased  expression of SLCO1B1protein ➔ ;Other;This variant was also significantly associated with decreased AUC for atorvastatin (P=0.0126).;SLCO1B1 *14 is associated with increased expression of SLCO1B1 protein as compared to SLCO1B1 *1.
;VDR;rs11568820;T;Associated  with  increased steady-state level of CYP3A4protein ➔ ;Other;Jejunal CYP3A4 protein levels. TT>CT>CC.;Allele T is associated with increased steady-state level of CYP3A4 protein as compared to allele C.
;A2M;rs669;T;Associated  with  increased steady-state level of A2Mprotein ➔ ;Metabolism/PK;Increased plasma levels of A2M were seen both at baseline and at the end of tissue plasminogen activator (t-PA) infusion. Please note alleles have been complemented to the plus chromosomal strand.;Allele T is associated with increased steady-state level of A2M protein as compared to allele C.
;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37;Associated  with  increased  expression of SLCO1B1protein ➔ ;Other;This variant was also significantly associated with decreased AUC for atorvastatin (P=0.00066, recessive model). Please note *1B was mentioned in the article. SLCO1B1*1B was consolidated into  SLCO1B1*37  by PharmVar in 2021.;SLCO1B1 *37 is associated with increased expression of SLCO1B1 protein as compared to SLCO1B1 *1.
;NAMPT;rs1319501;CC + CT;Associated  with  decreasedsteady-state level of NAMPTprotein ➔ ;Other;In patients with pre-eclampsia who are non-responsive to antihypertensive treatment.;Genotypes CC + CT is associated with decreased steady-state level of NAMPT protein as compared to genotype TT.
;DPYD;rs1801160;T;Associated  with  increased  expression of DPYDprotein ➔ ;Other;;Allele T is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.
;NAMPT;rs3801266;CC + CT;Associated  with  increased steady-state level of NAMPTprotein ➔ ;Other;In patients with pre-eclampsia who are non-responsive to antihypertensive treatment. Please note that alleles have been complemented to the plus chromosomal strand.;Genotypes CC + CT is associated with increased steady-state level of NAMPT protein as compared to genotype TT.
;SLCO1B1;SLCO1B1*1, SLCO1B1*20;*20;Associated  with  increased  expression of SLCO1B1protein ➔ ;Other;;SLCO1B1 *20 is associated with increased expression of SLCO1B1 protein as compared to SLCO1B1 *1/*1.
;ABCC11;rs17822471;AA + AG;Associated  with  decreased expression of ABCC11protein ➔ ;Other;;Genotypes AA + AG are associated with decreased expression of ABCC11 protein in liver samples as compared to genotype GG.
;CYP2C9;rs771237265;C;Associated  with  decreased expression of CYP2C9protein ➔ ;Other;Western blot analysis showed that expression of CYP2C9 protein containing the C allele was significantly reduced compared to WT protein. Variant referred to as 343A>C in the paper. Note that there are discrepancies between the text in the Results section of this manuscript and the data presented in Figure 1 regarding protein expression of variants studied in this paper. After thorough reading of the paper, we have decided to annotate based on the data presented in Figure 1 and have contacted the corresponding author to notify them of this discrepancy.;Allele C is associated with decreased expression of CYP2C9 protein as compared to allele A.
;CYP2C9;rs761895497;C;Associated  with  decreased expression of CYP2C9protein ➔ ;Other;Western blot analysis showed that expression of CYP2C9 protein containing the C allele was significantly reduced compared to WT protein. Variant referred to as 791T>C in the paper. Note that there are discrepancies between the text in the Results section of this manuscript and the data presented in Figure 1 regarding protein expression of variants studied in this paper. After thorough reading of the paper, we have decided to annotate based on the data presented in Figure 1 and have contacted the corresponding author to notify them of this discrepancy.;Allele C is associated with decreased expression of CYP2C9 protein as compared to allele T.
;CYP2C19;rs183701923;T;Associated  with  decreased expression of CYP2C19protein ➔ ;Other;Western blot analysis showed expression of CYP2C19 protein containing the T allele was significantly reduced compared to WT protein. Variant referred to as 556C>T in the paper. Note that there are discrepancies between the text in the Results section of this manuscript and the data presented in Figure 1 regarding protein expression of variants studied in this paper. After thorough reading of the paper, we have decided to annotate based on the data presented in Figure 1 and have contacted the corresponding author to notify them of this discrepancy.;Allele T is associated with decreased expression of CYP2C19 protein as compared to allele C.
;DPYD;rs748620513;G;Associated  with  increased  expression of DPYDprotein ➔ ;Other;;Allele G is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.
;CYP2C19;rs61311738;T;Associated  with  decreased expression of CYP2C19protein ➔ ;Other;Western blot analysis showed expression of CYP2C19 protein containing the T allele was significantly reduced compared to WT protein. Variant referred to as 518C>T in the paper. Note that there are discrepancies between the text in the Results section of this manuscript and the data presented in Figure 1 regarding protein expression of variants studied in this paper. After thorough reading of the paper, we have decided to annotate based on the data presented in Figure 1 and have contacted the corresponding author to notify them of this discrepancy.;Allele T is associated with decreased expression of CYP2C19 protein as compared to allele C.
;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;Associated  with  decreasedenzyme  activity  of TPMTprotein ➔ ;;Children with the *1/*2, *1/*3A or *1/*3C genotype receiving either thioguanine (n=37) or mercaptopurine (n=67) had a decreased median TPMT activity level, increased levels of thioguanine nucleotides, and decreased levels of methylmercaptopurine nucleotides, as compared to those with the *1/*1 genotype (n=381 and 613, respectively).;TPMT *1/*2 + *1/*3A + *1/*3C is associated with decreased enzyme activity of TPMT protein as compared to TPMT *1/*1.
;DPYD;rs143879757;A;Associated  with  increased  expression of DPYDprotein ➔ ;Other;;Allele A is associated with increased expression of DPYD protein in 293FT cells as compared to allele G.
;DPYD;rs1212037891;T;Associated  with  increased  expression of DPYDprotein ➔ ;Other;;Allele T is associated with increased expression of DPYD protein in 293FT cells as compared to allele A.
;DPYD;rs72549306;A;Associated  with  increased  expression of DPYDprotein ➔ ;Other;;Allele A is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.
;CYP2C19;rs140278421;A;Associated  with  decreased expression of CYP2C19protein ➔ ;Other;Western blot analysis showed expression of CYP2C19 protein containing the A allele was significantly reduced compared to WT protein. Variant referred to as 557G>A in the paper. Note that there are discrepancies between the text in the Results section of this manuscript and the data presented in Figure 1 regarding protein expression of variants studied in this paper. After thorough reading of the paper, we have decided to annotate based on the data presented in Figure 1 and have contacted the corresponding author to notify them of this discrepancy.;Allele A is associated with decreased expression of CYP2C19 protein as compared to allele G.
DOXORUBICIN;CBR1;rs9024;GG;Associated  with  increased catalytic  activity  of CBR1of  ➔ DOXORUBICIN;Metabolism/PK;GG cell lines synthesized twice as much doxorubinicol as did AA cell lines (44.2 +/- 25.4 nmol doxol/min-mg vs 22.0 +/- 24.0 nmol doxol/min-mg);Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.
DOXORUBICIN;CBR1;rs9024;GG;Associated  with  increased catalytic  activity  of CBR1of  ➔ DOXORUBICIN;Metabolism/PK;(in cytosols from liver samples).  The finding was that GG liver cytosols showed higher maximal rates of doxorubicinol synthesis (1.5-fold) compared with GA: 4.4 +/- 2.2 nmol doxol/min-mg vs. 2.9 +/- 1.4 nmol doxol/min-mg.;Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.
;ADRB2;rs1042713;G;Associated  with  decreased activity  of ADRB2of  ➔ ;Other;A number of in vitro assays measuring the activity of ADRB2 Arg16Gly variants suggested that the rs1042713 G variant is a loss of function allele.;Allele G is associated with decreased activity of ADRB2 of peripheral lymphocytes as compared to allele A.
;NOS3;rs1799983;GT + TT;Associated  with  decreased expression of NOS3mRNA ➔ ;;Patients with the GT and TT genotypes had significantly lower NOS3 mRNA (normalized to GADPH) compared to patients with the GG genotype.;Genotypes GT + TT is associated with decreased expression of NOS3 mRNA as compared to genotype GG.
;IL18;rs5744247;CC + CG;Associated  with  increased  expression of IL18mRNA ➔ ;Other;The IL-18 mRNA expression was CC>CG>GG. Liver tissues. Please note that alleles have been complemented to the plus chromosomal strand.;Genotypes CC + CG is associated with increased expression of IL18 mRNA as compared to genotype GG.
;IL18;rs1946518;GG + GT;Associated  with  increased  expression of IL18mRNA ➔ ;Other;The IL-18 mRNA expression was GG>GT>TT. Liver tissues. Please note that alleles have been complemented to the plus chromosomal strand.;Genotypes GG + GT is associated with increased expression of IL18 mRNA as compared to genotype TT.
;CYP3A5;rs776746;CC;Associated  with  decreased expression of CYP3A5mRNA ➔ ;Other;Donor liver biopsy specimens were analyzed for the expression level of CYP3A5 mRNA. The mean mRNA (amol/ug total RNA) for TT, CT and CC were 4.85, 2.99 and 0.41 respectively. Please note alleles have been complemented to the plus chromosomal strand.;Genotype CC is associated with decreased expression of CYP3A5 mRNA as compared to genotypes CT + TT.
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Associated  with  decreased expression of HDAC2mRNA ➔ ;PD;"""The mRNA expression levels of FKBP5, GLCCI1, HDAC2, and NR3C1 in PBMCs were significantly lower in patients carrying the CYP3A5*1 allele than in those carrying the *3/*3 allele (Figure E2). """;CYP3A5 *1/*1 + *1/*3 is associated with decreased expression of HDAC2 mRNA as compared to CYP3A5 *3/*3.
;CYP3A5;rs776746;TT;Associated  with  increased  expression of CYP3A5mRNA ➔ ;Other;Only significant when collected in liver transplant patients when liver samples were collected AFTER transplantation through biopsy. Please note that alleles have been complemented to the plus chromosomal strand.;Genotype TT is associated with increased expression of CYP3A5 mRNA in liver samples as compared to genotypes CC + CT.
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Associated  with  decreased expression of FKBP5mRNA ➔ ;PD;"""The mRNA expression levels of FKBP5, GLCCI1, HDAC2, and NR3C1 in PBMCs were significantly lower in patients carrying the CYP3A5*1 allele than in those carrying the *3/*3 allele (Figure E2). """;CYP3A5 *1/*1 + *1/*3 is associated with decreased expression of FKBP5 mRNA as compared to CYP3A5 *3/*3.
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Associated  with  decreased expression of NR3C1mRNA ➔ ;PD;"""The mRNA expression levels of FKBP5, GLCCI1, HDAC2, and NR3C1 in PBMCs were significantly lower in patients carrying the CYP3A5*1 allele than in those carrying the *3/*3 allele (Figure E2). """;CYP3A5 *1/*1 + *1/*3 is associated with decreased expression of NR3C1 mRNA as compared to CYP3A5 *3/*3.
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Associated  with  decreased expression of GLCCI1mRNA ➔ ;PD;"""The mRNA expression levels of FKBP5, GLCCI1, HDAC2, and NR3C1 in PBMCs were significantly lower in patients carrying the CYP3A5*1 allele than in those carrying the *3/*3 allele (Figure E2). """;CYP3A5 *1/*1 + *1/*3 is associated with decreased expression of GLCCI1 mRNA as compared to CYP3A5 *3/*3.
;ERCC1;rs2298881;A;Associated  with  decreased expression of ERCC1mRNA ➔ ;Other;;Allele A is associated with decreased expression of ERCC1 mRNA in whole blood and gastric cells as compared to allele C.
;HSPA5;rs430397;TT;Associated  with  increased  expression of HSPA5mRNA ➔ ;Other;Please note alleles have been complemented to the positive chromosomal strand.;Genotype TT is associated with increased expression of HSPA5 mRNA in NSCLC tissue samples as compared to genotype CC.
;CCND1;rs9344;AA + AG;Associated  with  increased transcription of CCND1mRNA ➔ ;Other;specifically the CCND1beta transcript. There was no difference between genotypes in the transcription of the CCND1alpha transcript.;Genotypes AA + AG is associated with increased transcription of CCND1 mRNA as compared to genotype GG.
;ABCC2;rs113646094;CG;Associated  with  increased  expression of ABCC2mRNA ➔ ;Other;;Genotype CG is associated with increased expression of ABCC2 mRNA in human liver samples as compared to genotype CC.
;ABCB1;rs1128503;GG;Associated  with  increased  expression of ABCB1mRNA ➔ ;;mRNA expression level was greater for those with the GG genotype as compared to those with the AA genotype. No significant difference was seen when comparing GG vs AG (p=0.33) or AA vs AG (p=0.837). Please note alleles have been complemented to the plus chromosomal strand.;Genotype GG is associated with increased expression of ABCB1 mRNA as compared to genotype AA.
;XRCC4;rs2075685;T;Associated  with  increased  expression of XRCC4mRNA ➔ ;Other;;Allele T is associated with increased expression of XRCC4 mRNA in gastric cells as compared to allele G.
;XRCC4;rs10040363;G;Associated  with  increased  expression of ERCC1mRNA ➔ ;Other;;Allele G is associated with increased expression of ERCC1 mRNA in whole blood but not gastric cells as compared to allele A.
;GCLC;rs761142;CC;Associated  with  decreased expression of GCLCmRNA ➔ ;Other;Please note alleles have been complemented to the plus chromosomal strand.;Genotype CC is associated with decreased expression of GCLC mRNA in liver tissue and B-lymphocytes as compared to genotype AA.
;BCL2L11;rs724710;T;Associated  with  decreased expression of BCL2L11mRNA ➔ ;Other;in healthy controls.;Allele T is associated with decreased expression of BCL2L11 mRNA as compared to allele C.
;EPO;rs1617640;AA;Associated  with  increased  expression of EPOmRNA ➔ ;Other;In a genome-wide association study, each copy of the A allele at rs1617640 was associated with increased endogenous circulating EPO levels. EPO expression levels were compared in two isogenic HEK-293 cell lines, one homozygous for the A allele, one heterozygous with an A and a C allele of rs1617640.;Genotype AA is associated with increased expression of EPO mRNA as compared to genotype AC.
;KDR;rs34231037;G;Associated  with  decreasedsteady-state level of KDR ➔ ;Other;in the serum. Serum soluble vascular endothelial growth factor receptor-2 concentrations [sVEGFR2] is a pharmacodynamic biomarker for VEGFR2 inhibitors. The minor G allele lowered [sVEGFR2] approximately 1.80 ng/mL per allele.;Allele G is associated with decreased steady-state level of KDR as compared to allele A.
METHOTREXATE;GGH;rs11545078;A;Associated  with  decreasedclearance of  ➔ METHOTREXATE;Metabolism/PK;;Allele A is associated with decreased clearance of methotrexate.
;DPYD;rs1801265;G;Associated  with  increased  activity  of DPYD ➔ ;Metabolism/PK;Study evaluated the baseline plasma 5,6-dihydrouracil/uracil ratio (UH2/U) as a marker of DPD activity in the context of DPYD genotypes in healthy individuals. When the joint effect of this variant and rs2297595 were analyzed a significant association was observed between the two variants and the UH2/U ratio, with carriers of the G allele showing a positive correlation with the ratio. HOWEVER, the authors state that baseline UH2/U ratio is a poor predictor of decreased DPD activity (though they note that it may be predictive during fluorouracil administration, such during cancer treatment). Please note that alleles have been complemented to the plus chromosomal strand.;Allele G is associated with increased activity of DPYD.
;FCER2;rs28364072;GG;Associated  with  decreased expression of FCER2 ➔ ;;compared with the AG and AA genotypic groups combined.;Genotype GG is associated with decreased expression of FCER2.
;DPYD;rs114096998;T;Associated  with  decreasedcatalytic  activity  of DPYD ➔ ;Other;This variant is also called p.P1023S and is found in East African population. It is associated with significantly reduced DPYD activity (0.79 of normal activity) and may contribute to 5-Fluorouracil sensitivity in East African population.;Allele T is associated with decreased catalytic activity of DPYD as compared to allele G.
;DPYD;rs55886062;AC;Associated  with  decreased activity  of DPYD ➔ ;Other;DPYD activity was reduced by 68% in heterozygous carriers as compared to non-carriers. In allelic association tests, this variant did not achieve single marker significance (p=0.21), and in a full linear model, adjusted for covariates, the p-value was also non-significant (p=0.12).;Genotype AC is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype AA.
;MGMT;rs4751104;G;Associated  with  increased transcription of MGMT ➔ ;Metabolism/PK;;Allele G is associated with increased transcription of MGMT in human liver samples as compared to allele A.
;ERCC2;rs1799793;TT;Associated  with  increased  expression of ERCC2 ➔ ;;"""patients harboring mutant homozygous variants of the ERCC1 rs11615 and of the two SNPs of ERCC2 (rs13181 and rs1799793) had significantly higher expression of the corresponding gene (Fig. 2A).""";Genotype TT is associated with increased expression of ERCC2 in diagnostic FFPE tumor samples as compared to genotypes CC + CT.
CISPLATIN;ERCC2;rs13181;GG;Associated  with  decreasedsensitivity to ➔ CISPLATIN;Toxicity;"""For ERCC2 rs13181, the genotype of the detected polymorphism was heterozygous variant GT in the sensitive and the two Saos-2 resistant variants with lower resistance levels, while in the Saos-2/CDDP6‘g variant the genotype changed to homozygous variant GG """;Genotype GG is associated with decreased sensitivity to cisplatin High-grade osteosarcoma cells as compared to genotype TT.
;ERCC2;rs13181;GG;Associated  with  increased  expression of ERCC2 ➔ ;;"""patients harboring mutant homozygous variants of the ERCC1 rs11615 and of the two SNPs of ERCC2 (rs13181 and rs1799793) had significantly higher expression of the corresponding gene (Fig. 2A).""";Genotype GG is associated with increased expression of ERCC2 in diagnostic FFPE tumor samples as compared to genotypes GT + TT.
;GSTT1;rs1007888;T;Associated  with  increased transcription of GSTT1 ➔ ;Metabolism/PK;;Allele T is associated with increased transcription of GSTT1 in human liver samples as compared to allele C.
;KCNQ3;rs7818112;AA;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AC + CC.
;GSK3B;rs334558;A;Associated  with  increased transcription of GSK3B ➔ ;;;Allele A is associated with increased transcription of GSK3B.
CISPLATIN;GSTP1;rs1695;AG;Associated  with  decreasedsensitivity to ➔ CISPLATIN;Toxicity;"""Ile105Val caused by the GSTP1 rs1695 variant allele was identified by the CLC GWB in all three CDDP-resistant U-2OS variants """;Genotype AG is associated with decreased sensitivity to cisplatin High-grade osteosarcoma cells as compared to genotype AA.
BUSULFAN;GSTM1;rs3754446;C;Associated  with  increased clearance of  ➔ BUSULFAN;Metabolism/PK;Acute myeloid leukemia patients from the overall cohort were studied, and an association was found between the C allele and reduced busulfan area-under-the-curve after first dose.;Allele C is associated with increased clearance of busulfan as compared to allele A.
;DPYD;rs780025995;A;Associated  with  decreasedcatalytic  activity  of DPYD ➔ ;Other;This variant is also called p.P237L and is found in East African population. It is associated with significantly reduced DPYD activity (0.85 of normal activity) and may contribute to 5-Fluorouracil sensitivity in East African population.;Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.
;F12;rs1801020;G;Associated  with  increased enzyme  activity  of F12 ➔ ;Metabolism/PK;Increased enzyme activity was seen both at baseline and at the end of tissue plasminogen activator (t-PA) infusion. Activity was measured as a percentage of an external calibrator plasma pool for F12. Please note alleles have been complemented to the plus chromosomal strand.;Allele G is associated with increased enzyme activity of F12 as compared to allele A.
;ERCC1;rs11615;GG;Associated  with  increased  expression of ERCC1 ➔ ;;"""patients harboring mutant homozygous variants of the ERCC1 rs11615 and of the two SNPs of ERCC2 (rs13181 and rs1799793) had significantly higher expression of the corresponding gene (Fig. 2A).""";Genotype GG is associated with increased expression of ERCC1 in diagnostic FFPE tumor samples as compared to genotypes AA + AG.
;IL7;rs16906115;AA + AG;Associated  with  increased  expression of IL7 ➔ ;Other;"""Patients carrying the risk allele demonstrate increased pre-treatment B cell IL7 expression, which independently associates with irAE risk, divergent immunoglobulin expression and more B cell receptor mutations.""""Crucially, we found that patient risk allele carriers at rs16906115 demonstrated increased B cell IL7 induction versus non-carriers both pre-treatment and over the course of treatment, but genetic effects were not observed across other cell types in patients (Fig.2b and Extended Data Fig. ?Fig.2c).";Genotypes AA + AG is associated with increased expression of IL7 in B-cells from Melanoma patient as compared to genotype GG.
;F3;rs841698;T;Associated  with  increased  expression of ABCD3 ➔ ;;;Allele T is associated with increased expression of ABCD3 in HapMap cells.
;DPYD;rs56038477;CT + TT;Associated  with  decreased activity  of DPYD ➔ ;Metabolism/PK;"""Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2)."" NOTE: the HapB has two variants, and c.1129-5923C>G rs75017182 is the causative variant, a recent study has shown they are not in perfect LD in all populations [PMID: 38129972].";Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.
;DPYD;rs2297595;C;Associated  with  decreased activity  of DPYD ➔ ;Other;"The DPYD rs2297595 (M166V) C allele was expressed in mammalian cells (HEK293 Flp-In) and protein expression and activity as compared to wild-type DPYD was analyzed. Cells with the C allele had significantly lower activity as compared to wild-type. However, when DPYD activity was assessed within a healthy cohort of 100 individuals (allele frequency = 0.09), there was only a tendency toward lower activity (p=0.1647). Text from the discussion section:""the analysis of recombinantly-expressed DPYD mutants showed that only a mildly-reduced DPD activity, ranging from 68% to 84% of that of the wild-type DPD enzyme, was observed for the DPD mutants carrying the p.C29R, p.M166V, p.G401R, p.S534N and p.V732I mutations.To date, weak or conflicting data exists as to whether the p.C29R, p.M166V, p.S534N and p.V732I mutations confer an increased risk to patients to develop severe 5FU-associated toxicity.""";Allele C is associated with decreased activity of DPYD.
;DPYD;rs1801160;CT + TT;Associated  with  decreased activity  of DPYD ➔ ;Metabolism/PK;"""The association between common DPYD genetic variants (MAF???1%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).";Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.
;DPYD;rs2297595;CC + CT;Associated  with  decreased activity  of DPYD ➔ ;Metabolism/PK;"""The association between common DPYD genetic variants (MAF???1%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).";Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.
;HPR;rs2000999;G;Associated  with  increased  expression of HP ➔ ;Other;"independent of HP CNV status. ""rs2000999 [G] was also associated with higher HP expression (median RNA count G/G, 95.4; G/A, 63.8; and A/A, 25.7; P = 0.008).""";Allele G is associated with increased expression of HP as compared to allele A.
FLUOROURACIL;DPYD;rs4294451;A;Associated  with  increased sensitivity to ➔ FLUOROURACIL;Toxicity;"""Consistent with lower expression of DPYD, knock-in cells homozygous for the rs4294451 A allele were significantly more sensitive to 5-FU than cells homozygous for the T allele (IC50 concentrations were 9.1 and 95.0 ?M 5-FU, respectively; p<0.0001; Figure 4E). Heterozygous T/A cells showed an intermediate IC50 value of 29.9 ‘M 5-FU (Figure 4E).""";Allele A is associated with increased sensitivity to fluorouracil as compared to allele A.
;DPYD;rs115232898;CT;Associated  with  decreased activity  of DPYD ➔ ;Other;Decreased activity by 29%. Using an in vitro system of recombinant expression in HEK293T/c17 cells.;Genotype CT is associated with decreased activity of DPYD as compared to genotype TT.
;DPYD;rs4294451;T;Associated  with  increased  expression of DPYD ➔ ;Other;"""Consistent with the results from the reporter assay (Figure 3B), cells homozygous for the A allele had significantly lower DPYD expression compared to cells that were homozygous for the T allele (P=0.0011, Figure 3C). Heterozygous rs4294451 A/T cells displayed intermediate expression compared to cells with homozygous A/A and T/T genotypes (p=0.00013 and p=0.028, respectively""";Allele T is associated with increased expression of DPYD as compared to allele A.
TAMOXIFEN;E2F7;rs310786;CC;Associated  with  increased sensitivity to ➔ TAMOXIFEN;Other;Cell lines with the CC genotype had a smaller percentage of viable cells remaining after a 10 uM endoxifen treatment, as compared to cell lines with the CT or TT genotype. This indicates higher cellular sensitivity. Endoxifen is a metabolite of tamoxifen.;Genotype CC is associated with increased sensitivity to tamoxifen in lymphoblastoid cell lines as compared to genotypes CT + TT.
;ECHDC1;rs6569487;AA;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance. NB for this gene in replication cohort they saw decreased expression of ABCC2";Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG.
;EGFR;rs712829;TT;Associated  with  increased  expression of EGFR ➔ ;;Data were extracted from the NCI60 database (MT1147).;Genotype TT is associated with increased expression of EGFR NCI60 cell lines.
;HLA-G;rs1063320;C;Associated  with  increased  expression of HLA-G ➔ ;Other;Decreased expression levels of mir-148a and 152 were correlated with higher HLA-G transcript levels in LCLs that were rs1063320 GG homozygotes (P<0.05, n=11). No correlation was seen in LCLs from CC or CG rs1063220 donors (n=15). Gene expression was compared between the CC, CG and GG genotypes.;Allele C is associated with increased expression of HLA-G in lymphoblastoid cell lines as compared to allele G.
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Associated  with  increased sensitivity to ➔ CARBAMAZEPINE;Other;"""The CBZ-mediated response was restricted to HLA-DRB1*07:01+ antigen-presenting cells (APCs). (D) The stimulation index (SI = cpm with drug/ cpm without drug) in the presence of HLA-DRB1*07:01+ APC was compared to the SI in the presence of HLA-DRB1*07:01? APC using a t test. """;HLA-DRB1 *07:01 is associated with increased sensitivity to carbamazepine.
;DPYD;rs3918290;CT;Associated  with  decreased activity  of DPYD ➔ ;Other;When DPYD activity was assessed within a healthy cohort of 100 individuals (only two heterozygotes were present in the population), those with *1/*2A (CT) had significantly lower DPYD activity (nmol/mg/h).;Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.
;IFNL3;rs4803217;C;Associated  with  increased  expression of IFNL3 ➔ ;Other;"in Raji cells and also in peripheral blood mononuclear cells (PBMCs) of eight uninfected donors. This study found a two-fold increased expression of; IFNL3.rs4803217 C specific transcript in Raji cells in four independent experiments (fold-change 2.09 (95% CI = 0.94-1.07) versus 1.01 (95% CI = 1.50-; 2.70), p = 0.029). This SNP is in strong linkage disequilibrium (LD) with the predictive marker rs12979860.";Allele C is associated with increased expression of IFNL3 as compared to allele A.
;DPYD;rs3918290;CT;Associated  with  decreased activity  of DPYD ➔ ;Other;DPYD activity was reduced by 50% in heterozygous carriers as compared to non-carriers. In allelic association tests, this variant remained significant (p=0.016). Additionally, in secondary analysis in a linear model, after adjusting for covariates, this variant was more strongly associated with DPYD activity (p=0.0019).;Genotype CT is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype CC.
CISPLATIN;ERCC1;rs11615;GG;Associated  with  decreasedsensitivity to ➔ CISPLATIN;Toxicity;"""ERCC1 rs11615, which was heterozygous variant GA in the sensitive cell line and the two resistant variants with lower resistance levels, whereas homozygous variant GG in Saos-2/CDDP6‘g""";Genotype GG is associated with decreased sensitivity to cisplatin High-grade osteosarcoma cells as compared to genotype AA.
;DPYD;rs748639205;G;Associated  with  decreasedcatalytic  activity  of DPYD ➔ ;Other;This variant is also called p.V941A and is found in East African population. It is associated with significantly reduced DPYD activity (0.65 of normal activity) and may contribute to 5-Fluorouracil sensitivity in East African population.;Allele G is associated with decreased catalytic activity of DPYD as compared to allele A.
;DPYD;rs75017182;CG;Associated  with  decreased activity  of DPYD ➔ ;Other;DPYD activity was reduced by 35% in heterozygous carriers as compared to non-carriers. In allelic association tests, this variant remained significantly associated (p=0.011). Additionally, in secondary analysis in a linear model, after adjusting for covariates, this variant was more strongly associated with DPYD activity (p=0.0007). The study also shows that levels of correctly spliced DPYD were reduced by 30% in carriers of the C allele (p=2.8E-6), which provides functional support for its association with fluorouracil toxicity.;Genotype CG is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype GG.
FLUOROURACIL;DPYD;rs3918290;CT;Associated  with  decreasedclearance of  ➔ FLUOROURACIL;Other;PBMCs came from patients with a variety of different cancers. Patient cells with the CT genotype (also known as DPYD *1/*2A) had a decreased 5-fluorouracil degradation rate (5-FUDR) as compared to those with the CC genotype (*1/*1). Please note that alleles have been complemented to the plus chromosomal strand.;Genotype CT is associated with decreased clearance of fluorouracil in peripheral blood mononuclear cells as compared to genotype CC.
;IFNL4;rs11322783;TT/TT;Associated  with  increased  expression of IFNAR1 ➔ ;Other;"""Median levels of IFNAR-1 mRNA in PBMC from patients carrying IFNL4; TT/TT were 1,82 fold higher than those from patients carrying the delG allele (either TT/delG or delG/delG) [median: 1.026 (IQR: 0.57?1.42) vs 0.5640 (0.46?0.91) p = 0.0053].""";Genotype TT/TT is associated with increased expression of IFNAR1 as compared to genotypes G/TT + GG.
;DPYD;rs75017182;C;Associated  with  decreased activity  of DPYD ➔ ;Metabolism/PK;Study evaluated the baseline plasma 5,6-dihydrouracil/uracil ratio (UH2/U) as a marker of DPD activity in the context of DPYD genotypes in healthy individuals. They found that carriers of the C allele had lower UH2/U ratios (R2=0.013). HOWEVER, the authors state that baseline UH2/U ratio is a poor predictor of decreased DPD activity (though they note that it may be predictive during fluorouracil administration, such during cancer treatment). Please note that alleles have been complemented to the plus chromosomal strand.;Allele C is associated with decreased activity of DPYD.
;IMPDH2;rs121434586;A;Associated  with  decreasedenzyme  activity  of IMPDH2 ➔ ;Other;;Allele A is associated with decreased enzyme activity of IMPDH2 as compared to allele G.
;DPYD;rs67376798;A;Associated  with  decreased activity  of DPYD ➔ ;Other;The DPYD rs67376798 A allele was expressed in mammalian cells (HEK293 Flp-In) and protein expression and activity as compared to wild-type DPYD was analyzed. Cells with the A allele had significantly lower activity as compared to wild-type. Residual activity was 35%. However, when DPYD activity was assessed within a healthy cohort of 100 individuals (only one heterozygote was present in the population), there was only a tendency toward lower activity (p=0.6176). Please note alleles have been complemented to the plus chromosomal strand.;Allele A is associated with decreased activity of DPYD.
CALCIUM;RYR1;rs118192167;AG;Associated  with  increased steady-state level of  ➔ CALCIUM;Other;Resting calcium concentrations in HEK-293 cells transfected with WT or mutant RYR1 cDNA without the mutation was 81.0 ¤ 2.0 nM whereas with the mutation it was 129.4 ¤ 4.3 nM calcium.;Genotype AG is associated with increased steady-state level of calcium as compared to genotype AA.
;MIR6076;rs1463411;G;Associated  with  decreased expression of P2RY12 ➔ ;Other;"""The mRNA and protein levels of P2RY12 in cells transfected with pre-miR-6076-G were significantly lower than those in cells transfected with miR-6076-T (Fig. 3c; P?<?0.05).""";Allele G is associated with decreased expression of P2RY12 as compared to allele T.
DESMETHYLNAPROXEN;SULT1A1;rs28374453;G;Associated  with  increased sulfation of  ➔ DESMETHYLNAPROXEN;Metabolism/PK;Enzyme carrying the G allele showed a significant increase in sulfation of O-desmethylnaproxen compared to the WT protein. Variant referred to in the paper as F247L. Please note that alleles have been complemented to the positive strand.;Allele G is associated with increased sulfation of desmethylnaproxen as compared to allele A.
ACETAMINOPHEN;SULT1A1;rs28374453;G;Associated  with  increased sulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the G allele showed a significant increase in sulfation of 40uM and 400uM of acetaminophen compared to the WT protein. However, this increase lost significance at a concentration of 1000uM acetaminophen. Variant referred to in the paper as F247L. Please note that alleles have been complemented to the positive strand.;Allele G is associated with increased sulfation of acetaminophen as compared to allele A.
DESMETHYLNAPROXEN;SULT1A1;rs1042008;A;Associated  with  decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Metabolism/PK;Enzyme carrying the A allele showed an approximately 60% decrease in O-desmethylnaproxen sulfation compared to the WT protein. Variant referred to in the paper as H149Y.;Allele A is associated with decreased sulfation of desmethylnaproxen as compared to allele G.
ACETAMINOPHEN;SULT1A1;rs1042008;A;Associated  with  decreasedsulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the A allele showed a more than 77% decrease in acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as H149Y.;Allele A is associated with decreased sulfation of acetaminophen as compared to allele G.
DESMETHYLNAPROXEN;SULT1A1;rs758145522;T;Associated  with  decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Metabolism/PK;Enzyme carrying the G allele showed an approximately 60% decrease in O-desmethylnaproxen sulfation compared to the WT protein. Variant referred to in the paper as V243D. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele A.
DESMETHYLNAPROXEN;SULT1A1;rs767487725;C;Associated  with  decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Metabolism/PK;Enzyme carrying the C allele showed a 80% decrease in O-desmethylnaproxen sulfation compared to the WT protein. Variant referred to in the paper as Y169D.;Allele C is associated with decreased sulfation of desmethylnaproxen as compared to allele A.
ACETAMINOPHEN;SULT1A1;rs72547527;T;Associated  with  decreasedsulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the T allele showed a more than 13% decrease in acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as R37Q. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.
TAPENTADOL;SULT1A1;rs1042008;A;Associated  with  decreasedsulfation of  ➔ TAPENTADOL;Metabolism/PK;Enzyme carrying the A allele showed an approximately 12% decrease in acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as H149Y.;Allele A is associated with decreased sulfation of tapentadol as compared to allele G.
ACETAMINOPHEN;SULT1A1;rs767487725;C;Associated  with  decreasedsulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the C allele showed a more than 77% decrease in acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as Y169D.;Allele C is associated with decreased sulfation of acetaminophen as compared to allele A.
DESMETHYLNAPROXEN;SULT1A1;rs1042028;T;Associated  with  decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Metabolism/PK;Enzyme carrying the T allele showed an approximately 20% decrease in O-desmethylnaproxen sulfation compared to the WT protein. Variant referred to in the paper as R213H and given the rsID rs9282861. rs9282861 was merged into rs1042028 in October 2018.;Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele C.
ACETAMINOPHEN;SULT1A1;rs544820732;A;Associated  with  decreasedsulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the A allele showed a more than 77% decrease in acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as P47S.;Allele A is associated with decreased sulfation of acetaminophen as compared to allele G.
;TBXAS1;rs6962291;AA;Associated  with  decreasedsteady-state level of TBX2 ➔ ;Other;compared to genotype AT or TT.;Genotype AA is associated with decreased steady-state level of TBX2 in plasma.
;TBXAS1;rs6962291;AA;Associated  with  decreased expression of TBXAS1 ➔ ;Other;compared to genotype TT.;Genotype AA is associated with decreased expression of TBXAS1 in PBMCs.
;TMPRSS11E;rs2168047;T;Associated  with  increased  expression of UGT2B4 ➔ ;;;Allele T is associated with increased expression of UGT2B4 in normal breast tissue.
;TNF;rs1800629;AA + AG;Associated  with  increased  activity  of TNF ➔ ;Metabolism/PK;The level of circulating TNFalpha bioactivity was higher in patients with the AA or AG genotype as compared to those with the GG genotype. The authors also note that TNFalpha bioactivity was higher in patients who had good American College of Rheumatology (ACR) response to infliximab (>= 50% improvement), as compared to those with a poor response (<=20% improvement).;Genotypes AA + AG is associated with increased activity of TNF as compared to genotype GG.
;TPH2;rs7305115;AA;Associated  with  increased  expression of TPH2 ➔ ;Other;;Genotype AA is associated with increased expression of TPH2 in human brain samples as compared to genotypes AG + GG.
;TPH2;rs4290270;T;Associated  with  increased  expression of TPH2 ➔ ;Other;;Allele T is associated with increased expression of TPH2 in human brain samples as compared to allele A.
THIOGUANINE;TPMT;TPMT*1, TPMT*7, TPMT*10, TPMT*12, TPMT*13;*7 + *10 + *12 + *13;Associated  with  decreasedclearance of  ➔ THIOGUANINE;Metabolism/PK;Alleles were grouped by PharmGKB;TPMT *7 + *10 + *12 + *13 are associated with decreased clearance of thioguanine in yeast cells as compared to TPMT *1.
;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;Associated  with  decreased activity  of TPMT ➔ ;Other;;TPMT *3A + *3C are associated with decreased activity of TPMT as compared to TPMT *1/*1.
ACETAMINOPHEN;SULT1A1;rs765399160;T;Associated  with  increased sulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the G allele showed a significant increase in acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as M77I.;Allele T is associated with increased sulfation of acetaminophen as compared to allele C.
;TPMT;TPMT*1, TPMT*3A, TPMT*3C, TPMT*24;*3A + *3C + *24;Associated  with  decreased expression of TPMT ➔ ;Other;"""When combining TPMT*3A, TPMT*3C, and TPMT*24 donors into one group (n?=?22), the mean expression was 0.052?¤?0.014 pmol/mg total protein. The mean expression in the wildtype group was 2.07-fold higher than the mean expression in the TPMT variant group (P?=?2.2???10?16, Welch two-sample t-test)""";TPMT *3A + *3C + *24 is associated with decreased expression of TPMT as compared to TPMT *1/*1.
ACETAMINOPHEN;SULT1A1;rs552524124;G;Associated  with  decreasedsulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the G allele showed barely detectable levels of acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as T227P.;Allele G is associated with decreased sulfation of acetaminophen as compared to allele T.
TAPENTADOL;SULT1A1;rs1042028;T;Associated  with  decreasedsulfation of  ➔ TAPENTADOL;Metabolism/PK;Enzyme carrying the T allele showed a significant decrease of approximately 12% in tapentadol sulfation compared to the WT protein at 100uM and 500uM tapentadol. However, this decrease was not significant at 5uM tapentadol. Variant referred to in the paper as R213H and given the rsID rs9282861. rs9282861 was merged into rs1042028 in October 2018.;Allele T is associated with decreased sulfation of tapentadol as compared to allele C.
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;Associated  with  decreaseduptake of  ➔ ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;Metabolism/PK;"in in vitro transporting assay measuring the uptake of statins into HEK293 cells transiently expressing SLCO1B1 allelic variants. The most prominent decrease; in the transport activities of cells expressing SLCO1B1*5 or *15 was found for pravastatin followed by atorvastatin and cerivastatin, but no apparent decrease was found for simvastatin.";SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.
PACLITAXEL;SLCO1B3;rs7311358;A;Associated  with  decreasedtransport of  ➔ PACLITAXEL;Other;;Allele A is associated with decreased transport of paclitaxel in oocytes as compared to allele G.
ROSUVASTATIN;SLCO2B1;rs2306168;T;Associated  with  decreaseduptake of  ➔ ROSUVASTATIN;Metabolism/PK;this variant also had significantly lower protein expression. Described as rs2306168, c.1457C>T, p.Ser486Phe in table 1.;Allele T is associated with decreased uptake of rosuvastatin in transfected HEK293T cells as compared to allele C.
ROSUVASTATIN;SLCO2B1;rs142693902;A;Associated  with  decreaseduptake of  ➔ ROSUVASTATIN;Metabolism/PK;this variant also had significantly lower protein expression. Described as rs142693902, c.332G>A, p.Arg111Gln in table 1.;Allele A is associated with decreased uptake of rosuvastatin in transfected HEK293T cells as compared to allele G.
ROSUVASTATIN;SLCO2B1;rs35199625;A;Associated  with  decreaseduptake of  ➔ ROSUVASTATIN;Metabolism/PK;this variant also had significantly lower protein expression. Described as rs35199625, c.601G>A, p.Val201Met in table 1.;Allele A is associated with decreased uptake of rosuvastatin in transfected HEK293T cells as compared to allele G.
METHOTREXATE;SOD2;rs4880;G;Associated  with  decreasedsensitivity to ➔ METHOTREXATE;Toxicity;PBMCs were obtained from healthy volunteers and response to methotrexate (MTX) was assessed by genotype. The G allele was associated with a decreased sensitivity to the cytotoxic effects of MTX (little change in cell proliferation or cell viability upon exposure to MTX). At increasing MTX concentration the GG genotype was also associated with decreased SOD2 protein activity and increased SOD2 gene expression.  The ratio of anti-apoptotic/pro-apoptotic gene expression (BAX/Bcl2) was lowest in cells with the AG and GG genotype and highest in the AA genotype cells, indicating that the  AA genotype had an increased sensitivity to the cytotoxic effects of MTX. Markers of oxidative stress (gene expression of genes involved in oxidative stress, protein carbonylation, lipid peroxidation and ROS levels) were also observed. DNA damage did not differ significantly between groups. The GG genotype showed evidence of decreased oxidative stress upon exposure to MTX. Note: the authors refer to this polymorphism (rs4880) as Ala16Val and each allele as A for alanine or V for valine. The correct AA change is Val16Ala and A>G. Therefore the genotypes in this annotation were determined by the amino acid change that was stated in the study (e.g. in the study the V allele is listed here as the A allele and the A allele is listed here as the G allele).;Allele G is associated with decreased sensitivity to methotrexate in peripheral blood mononuclear cells as compared to allele A.
;SPAG16;rs35945601;CC;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype CC is associated with increased transcription of ABCB1 as compared to genotypes CT + TT.
;SQSTM1;rs10277;C;Associated  with  increased transcription of SQSTM1 ➔ ;Metabolism/PK;;Allele C is associated with increased transcription of SQSTM1 in human liver samples as compared to allele T.
;STXBP4;rs9303363;AA;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG.
DESMETHYLNAPROXEN;SULT1A1;rs552524124;G;Associated  with  decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Metabolism/PK;Enzyme carrying the G allele showed a greater than 97% decrease in O-desmethylnaproxen sulfation compared to the WT protein. Variant referred to in the paper as T227P.;Allele G is associated with decreased sulfation of desmethylnaproxen as compared to allele T.
TAPENTADOL;SULT1A1;rs758145522;T;Associated  with  decreasedsulfation of  ➔ TAPENTADOL;Metabolism/PK;Enzyme carrying the G allele showed a level of tapentadol sulfation of approximately 28% of that of the WT protein. Variant referred to in the paper as V243D. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased sulfation of tapentadol as compared to allele A.
TAPENTADOL;SULT1A1;rs72547527;T;Associated  with  decreasedsulfation of  ➔ TAPENTADOL;Metabolism/PK;Enzyme carrying the T allele showed an approximately 12% decrease in tapentadol sulfation compared to the WT protein. However, this was only significant at 100uM and 500uM of tapentadol and not at 5uM tapentadol. Variant referred to in the paper as R37Q. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased sulfation of tapentadol as compared to allele C.
TAPENTADOL;SULT1A1;rs544820732;A;Associated  with  decreasedsulfation of  ➔ TAPENTADOL;Metabolism/PK;Enzyme carrying the A allele showed a level of tapentadol sulfation of approximately 24% of that of the WT protein. Variant referred to in the paper as P47S.;Allele A is associated with decreased sulfation of tapentadol as compared to allele G.
TAPENTADOL;SULT1A1;rs767487725;C;Associated  with  decreasedsulfation of  ➔ TAPENTADOL;Metabolism/PK;Enzyme carrying the C allele showed a level of tapentadol sulfation of approximately 28% of that of the WT protein. Variant referred to in the paper as Y169D.;Allele C is associated with decreased sulfation of tapentadol as compared to allele A.
DESMETHYLNAPROXEN;SULT1A1;rs544820732;A;Associated  with  decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Metabolism/PK;Enzyme carrying the A allele showed an approximately 80% decrease in O-desmethylnaproxen sulfation compared to the WT protein. Variant referred to in the paper as P47S.;Allele A is associated with decreased sulfation of desmethylnaproxen as compared to allele G.
ACETAMINOPHEN;SULT1A1;rs1042028;T;Associated  with  decreasedsulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the T allele showed a more than 13% decrease in acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as R213H and given the rsID rs9282861. rs9282861 was merged into rs1042028 in October 2018.;Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.
DESMETHYLNAPROXEN;SULT1A1;rs72547527;T;Associated  with  decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Metabolism/PK;Enzyme carrying the T allele showed an approximately 20% decrease in O-desmethylnaproxen sulfation compared to the WT protein. Variant referred to in the paper as R37Q. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele C.
TAPENTADOL;SULT1A1;rs552524124;G;Associated  with  decreasedsulfation of  ➔ TAPENTADOL;Metabolism/PK;Enzyme carrying the G allele a level of tapentadol sulfation of approximately 13% that of the WT protein. Variant referred to in the paper as T227P.;Allele G is associated with decreased sulfation of tapentadol as compared to allele T.
TAPENTADOL;SULT1A1;rs28374453;G;Associated  with  increased sulfation of  ➔ TAPENTADOL;Metabolism/PK;Enzyme carrying the G allele showed an approximate 27% increase in tapentadol sulfation at 100uM and 500uM tapentadol compared to the WT enzyme. However, there was no significant increase at 5uM tapentadol. Variant referred to in the paper as F247L. Please note that alleles have been complemented to the positive strand.;Allele G is associated with increased sulfation of tapentadol as compared to allele A.
ACETAMINOPHEN;SULT1A1;rs758145522;T;Associated  with  decreasedsulfation of  ➔ ACETAMINOPHEN;Metabolism/PK;Enzyme carrying the G allele showed a more than 77% decrease in acetaminophen sulfation compared to the WT protein. Variant referred to in the paper as V243D. Please note that alleles have been complemented to the positive strand.;Allele T is associated with decreased sulfation of acetaminophen as compared to allele A.
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;Associated  with  decreaseduptake of  ➔ ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;Metabolism/PK;"in in vitro transporting assay measuring the uptake of statins into HEK293 cells transiently expressing SLCO1B1 allelic variants. The most prominent decrease; in the transport activities of cells expressing SLCO1B1*5 or *15 was found for pravastatin followed by atorvastatin and cerivastatin, but no apparent decrease was found for simvastatin.";SLCO1B1 *5 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.
MERCAPTOPURINE;TPMT;TPMT deficiency;;Associated  with  increased concentrations of  ➔ MERCAPTOPURINE;Toxicity, Metabolism/PK;"Bone marrow concentrations in mice; thioguanine nucleotides were significantly higher in mice deficient for TPMT (KO) mice versus WT. Double KO mice (ABCC4 and TPMT KO) also had significantly higher concentrations of mercaptopurine and metabolites in bone marrow. Concentrations of mercaptopurine or 6-Methylmercaptopurine Nucleotides, MMPN) were not significantly different in TPMT KO vs WT.";TPMT deficiency is associated with increased concentrations of mercaptopurine in mice.
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;Associated  with  increased sensitivity to ➔ CISPLATIN;Toxicity;;TPMT *3A is associated with increased sensitivity to cisplatin in UB/OC1 cells as compared to TPMT *1.
SN-38;UGT1A9;rs2741049;CT + TT;Associated  with  increased clearance of  ➔ SN-38;Metabolism/PK;Human liver microsomes with the CT and TT genotypes had 2.43-fold and 1.66-fold higher median formation of the SN-38 glucuronide metabolite (SN-38G), as compared to those with the CC genotype. SN-38 is the active metabolite of irinotecan, and is metabolized via glucuronidation by members of the UGT1A family.;Genotypes CT + TT is associated with increased clearance of SN-38 in human liver microsomes as compared to genotype CC.
;UGT1A9;rs3832043;T/del + TT;Associated  with  increased formation of UGT1A9 ➔ ;Metabolism/PK;Human liver microsomes with the *1b/*1b or *1a/*1b genotype had increased relative UGT1A9 protein levels, as compared to those with the *1a/*1a genotype. *1B is described as g.-118T9>10 with 10 T being the variant allele and rs3832043 with an allele frequency of 55.7% in the studied cohort. UGT1A9*1b and I399C>T, the two common variants in high LD, were associated with increased SN-38G formation rates and UGT1A protein levels, but further analysis demonstrated that their increased effect was probably attributed to their close linkage with UGT1A1 variant alleles.;Genotypes T/del + TT is associated with increased formation of UGT1A9 in human liver microsomes as compared to genotype del/del.
;UGT1A9;rs2741049;TT;Associated  with  increased formation of UGT1A1 ➔ ;Metabolism/PK;Human liver microsomes with the TT genotype had increased relative UGT1A1 protein levels, as compared to those with the CC genotype.;Genotype TT is associated with increased formation of UGT1A1 in human liver microsomes as compared to genotype CC.
SN-38;UGT1A9;rs3806598;AA;Associated  with  increased clearance of  ➔ SN-38;Metabolism/PK;Human liver microsomes with the AA genotype had a higher median formation of the SN-38 glucuronide metabolite (SN-38G), as compared to those with the AC or CC genotype. SN-38 is the active metabolite of irinotecan, and is metabolized via glucuronidation by members of the UGT1A family.;Genotype AA is associated with increased clearance of SN-38 in human liver microsomes as compared to genotypes AC + CC.
;UGT1A9;rs3832043;T/del + TT;Associated  with  increased formation of UGT1A1 ➔ ;Metabolism/PK;Human liver microsomes with the *1b/*1b or *1a/*1b genotype had increased relative UGT1A1 protein levels, as compared to those with the *1a/*1a genotype. *1B is described as g.-118T9>10 with 10 T being the variant allele and rs3832043 with an allele frequency of 55.7% in the studied cohort. UGT1A9*1b and I399C>T, the two common variants in high LD, were associated with increased SN-38G formation rates and UGT1A protein levels, but further analysis demonstrated that their increased effect was probably attributed to their close linkage with UGT1A1 variant alleles.;Genotypes T/del + TT is associated with increased formation of UGT1A1 in human liver microsomes as compared to genotype del/del.
SN-38;UGT1A9;rs3832043;T/del + TT;Associated  with  increased clearance of  ➔ SN-38;Metabolism/PK;Human liver microsomes with the *1b/*1b or *1a/*1b genotype had a higher median formation of the SN-38 glucuronide metabolite (SN-38G), as compared to those with the *1a/*1a genotype. SN-38 is the active metabolite of irinotecan, and is metabolized via glucuronidation by members of the UGT1A family. *1B is described as g.-118T9>10 with 10 T being the variant allele and rs3832043 with an allele frequency of 55.7% in the studied cohort. UGT1A9*1b and I399C>T, the two common variants in high LD, were associated with increased SN-38G formation rates and UGT1A protein levels, but further analysis demonstrated that their increased effect was probably attributed to their close linkage with UGT1A1 variant alleles.;Genotypes T/del + TT is associated with increased clearance of SN-38 in human liver microsomes as compared to genotype del/del.
;UGT1A9;rs2741049;CT + TT;Associated  with  increased formation of UGT1A9 ➔ ;Metabolism/PK;Human liver microsomes with the CT and TT genotypes had increased relative UGT1A9 protein levels, as compared to those with the CC genotype.;Genotypes CT + TT is associated with increased formation of UGT1A9 in human liver microsomes as compared to genotype CC.
OLANZAPINE;UGT2B10;rs61750900;GT + TT;Associated  with  decreasedglucuronidation of  ➔ OLANZAPINE;Metabolism/PK;this increase was for both olanzapine 10-n-glucuronide and olanzapine 4-n-glucuronide.;Genotypes GT + TT is associated with decreased glucuronidation of olanzapine in experiments with expressed proteins and HLMs as compared to genotype GG.
LORAZEPAM;UGT2B15;rs1902023;AA;Associated  with  decreasedclearance of  ➔ LORAZEPAM;Metabolism/PK;The association was with 0.58-fold lower systemic clearance during the basal metabolic state. [stat_test:wilcoxon rank sum test];Genotype AA is associated with decreased clearance of lorazepam.
OXAZEPAM;UGT2B15;rs1902023;A;Associated  with  decreasedglucuronidation of  ➔ OXAZEPAM;Other;"Significantly lower glucoronidation of oxazepam, but not protein abundance in human liver microsomes from individuals with the variant allele rs1902023 (D85Y; c.253G>T).";Allele A is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele C.
;UGT2B17;rs6817882;C;Associated  with  increased  expression of UGT2B17 ➔ ;Other;"This was true for liver samples bearing either one or two copies of UGT2B17.  Expression was measured compared to that of TBP (a house-keeping gene with the lowest internal variability).  For samples with two copies, mean CT expression appears to be higher than mean CC expression; both are higher than mean TT expression.";Allele C is associated with increased expression of UGT2B17 in human livers as compared to allele T.
;UGT2B4;rs4557343;T;Associated  with  increased  expression of UGT2B15 ➔ ;;;Allele T is associated with increased expression of UGT2B15 in normal breast tissue.
BUPRENORPHINE;UGT2B7;rs7438135;A;Associated  with  increased glucuronidation of  ➔ BUPRENORPHINE;Metabolism/PK;Significant increase in glucuronidation was only observed in the absence of the UGT1A1*28 allele.;Allele A is associated with increased glucuronidation of buprenorphine as compared to allele G.
;UMPS;rs1801019;C;Associated  with  increased  expression of UMPS ➔ ;Metabolism/PK;(mRNA expression). UMPS activity was also significantly higher in cells with the C allele compared to the GG genotype.;Allele C is associated with increased expression of UMPS in normal colon mucosa cells.
;VKORC1;rs56314408;C;Associated  with  increased transcription of VKORC1 ➔ ;Other;In the European population, this SNPs is in high LD with rs9923231 but not other populations. This SNP disrupts a binding motif for transcription factor TFAP2A/C.;Allele C is associated with increased transcription of VKORC1 in HepG2 cells as compared to allele T.
;VKORC1;rs9923231;T;Associated  with  decreased expression of VKORC1 ➔ ;;;Allele T is associated with decreased expression of VKORC1.
;WBP2NL;rs5758550;AG + GG;Associated  with  increased  expression of CYP2D6 ➔ ;Other;Enhancer SNPs (rs5758550/rs133333 - in LD) were associated with a 2-fold increase in CYP2D6 mRNA levels (P = 0.036) in a multiple linear regression analyses adjusted for s16947 genotype.;Genotypes AG + GG are associated with increased expression of CYP2D6 in human liver cells as compared to genotype AA.
;YAP1;rs1820453;C;Associated  with  decreasedtranscription of YAP1 ➔ ;;rs1820453 was in complete linkage with rs10895256.;Allele C is associated with decreased transcription of YAP1 H446 cells.
;YEATS4;rs7297610;CC;Associated  with  increased  expression of YEATS4 ➔ ;Metabolism/PK;as compared to whole blood RNA from TT or CT individuals at baseline.;Genotype CC is associated with increased expression of YEATS4 in whole blood RNA.
RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2;*2/*2;Associated  with  increased clearance of  ➔ RALOXIFENE;Metabolism/PK;Human jejunum homogenates with the *2/*2 genotype had an increased rate of total raloxifene-6-glucuronide formation (pmol/min/mg) as compared to those with the *1/*1 or *1/*2 genotype.;UGT1A8 *2/*2 is associated with increased clearance of raloxifene in human jejunum homogenates as compared to UGT1A8 *1a/*1a + *1a/*2.
THIOGUANINE;TPMT;TPMT*1, TPMT*16;*16;Associated  with  decreasedclearance of  ➔ THIOGUANINE;Metabolism/PK;"The intrinsic clearance value (Vmax/Km) was 0.40 +/- 0.05 ml/min/mg prot for *16 vs. 1.25 +/- 0.09 for *1.  The TPMT *16 cDNA was derived from site-directed mutagenesis of ""wild-type"" TPMT cDNA.";TPMT *16 is associated with decreased clearance of thioguanine in artificial constructs expressed in yeast cells as compared to TPMT *1.
VALPROIC ACID;UGT1A6;rs1105879;C;Associated  with  increased glucuronidation of  ➔ VALPROIC ACID;Metabolism/PK;in vitro in HEK293 cells. Significance only as part of UGT1A6*2.;Allele C is associated with increased glucuronidation of valproic acid in HEK 293 cells..
CLOZAPINE 5-N-GLUCURONIDE, DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;rs2011425;G;Associated  with  increased formation of  ➔ CLOZAPINE 5-N-GLUCURONIDE, DESMETHYLCLOZAPINE GLUCURONIDE;Metabolism/PK;UGT1A4*3 allele was a significant (P < 0.0001) predictor of CLZ-5-N-glucuronide and dmCLZ-glucuronide formation.;Allele G is associated with increased formation of clozapine 5-N-glucuronide and desmethylclozapine glucuronide in human liver microsomes as compared to allele T.
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;Associated  with  increased sensitivity to ➔ CISPLATIN;Toxicity;;TPMT *3A is associated with increased sensitivity to cisplatin in HEI-OC1 cells as compared to TPMT *1.
;TXLNB;rs9495425;CC;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype CC is associated with increased transcription of ABCB1 as compared to genotypes CT + TT.
;UGT1A1;rs4124874;GG + GT;Associated  with  decreasedformation of UGT1A1 ➔ ;Metabolism/PK;Human liver microsomes with the *1/*60 and *60/*60 genotypes had decreased relative UGT1A1 protein levels, as compared to those with the *1/*1 genotype. *60 is described as rs4124874 in the article.;Genotypes GG + GT is associated with decreased formation of UGT1A1 in human liver microsomes as compared to genotype TT.
SN-38;UGT1A1;rs4124874;GG + GT;Associated  with  decreasedclearance of  ➔ SN-38;Metabolism/PK;Human liver microsomes with the *1/*60 and *60/*60 genotypes had 1.5-fold and 2.12-fold lower median formation of the SN-38 glucuronide metabolite (SN-38G), as compared to those with the *1/*1 genotype. SN-38 is the active metabolite of irinotecan, and is metabolized via glucuronidation by members of the UGT1A family. *60 is described as rs4124874 in the article.;Genotypes GG + GT is associated with decreased clearance of SN-38 in human liver microsomes as compared to genotype TT.
OXAZEPAM;UGT1A1;rs10929302;A;Associated  with  decreasedglucuronidation of  ➔ OXAZEPAM;Other;"Significantly lower glucoronidation of oxazepam, but not protein abundance in human liver microsomes from individuals with the variant allele rs10929302 (*93; c.3156G>A). The association between age and protein abundance diminished in human liver microsome samples in cells carrying hetero- or homozygous variant alleles.";Allele A is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele G.
;UGT1A1;rs10929302;A;Associated  with  decreasedconcentrations of UGT1A1 ➔ ;Other;"Significantly lower abundance of UGT1A1 protein was observed in human liver microsomes from individuals with the variant allele rs10929302 (*93; c.3156G>A). The association between age and protein abundance diminished in human liver microsome samples in cells carrying hetero- or homozygous variant alleles.";Allele A is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele G.
;UGT1A1;rs28967009;A;Associated  with  increased  expression of UGT1A1 ➔ ;Other;"""The prediction of this SNP as a cis-eQTL is significant with a FDR of 0.006, a p-value of 5.73E-07 and a beta value of 1328. A beta value of 1328 indicates that the variant allele (allele A), is predicted to increase the expression of UGT1A1 by 1328-times on average.""";Allele A is associated with increased expression of UGT1A1 as compared to allele T.
SN-38;UGT1A1;rs4148323;AG;Associated  with  decreasedclearance of  ➔ SN-38;Metabolism/PK;Human liver microsomes with the *6/*60 and *60/*60 genotypes had significantly decreased formation of the SN-38 glucuronide metabolite (SN-38G), as compared to those with the *1/*1 genotype. SN-38 is the active metabolite of irinotecan, and is metabolized via glucuronidation by members of the UGT1A family.*6 is described as rs4148323.;Genotype AG is associated with decreased clearance of SN-38 in human liver microsomes as compared to genotype GG.
;UGT1A1;rs4148323;AG;Associated  with  decreasedformation of UGT1A1 ➔ ;Metabolism/PK;Human liver microsomes with the *6/*60 or *60/*60 genotype had decreased relative UGT1A1 protein levels, as compared to those with the *1/*1 genotype. *6 is described as rs4148323.;Genotype AG is associated with decreased formation of UGT1A1 in human liver microsomes as compared to genotype GG.
OXAZEPAM;UGT1A1;rs887829;T;Associated  with  decreasedglucuronidation of  ➔ OXAZEPAM;Other;;Allele T is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele C.
OXAZEPAM;UGT1A1;rs4124874;G;Associated  with glucuronidation of  ➔ OXAZEPAM;Other;;Allele G is associated with glucuronidation of oxazepam in human liver microsomes as compared to allele T.
;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Associated  with  decreasedconcentrations of UGT1A1 ➔ ;Other;"Significantly lower abundance of UGT1A1 protein was observed in human liver microsomes from individuals with the variant allele rs8175347 (*28; NM_000463.2:c.-53_-52TA[7]). The association between age and protein abundance diminished in human liver microsome samples in cells carrying hetero- or homozygous variant alleles.";UGT1A1 *28 is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to UGT1A1 *1.
CLOZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Associated  with  decreasedmetabolism of  ➔ CLOZAPINE;Metabolism/PK;as measured by formation of clozapine N+ glucuronide.;UGT1A1 *28/*28 is associated with decreased metabolism of clozapine in human liver microsomes as compared to UGT1A1 *1/*1 + *1/*28.
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Associated  with  decreasedmetabolism of  ➔ BELINOSTAT;Metabolism/PK;"Human Liver Microsomes with UGT1A1*28 have lower glucuronidation activity for belinostat when compared to those with *1.  30 min post-incubation glucuronidated-belinostat concentrations: UGT1A1*1/*1:15.39 +/- 6.00; *1/*28: 11.35 +/- 4.11; *28/*28: 7.14 +/- 3.28.";UGT1A1 *28 is associated with decreased metabolism of belinostat in human liver microsomes as compared to UGT1A1 *1.
;UGT1A1;rs887829;T;Associated  with  decreasedconcentrations of UGT1A1 ➔ ;Other;"Significantly lower abundance of UGT1A1 protein was observed in human liver microsomes from individuals with the variant allele rs887829 (*80; c.364C>T). The association between age and protein abundance diminished in human liver microsome samples in cells carrying hetero- or homozygous variant alleles.";Allele T is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele C.
;UGT1A1;rs4124874;G;Associated  with  decreasedconcentrations of UGT1A1 ➔ ;Other;"Significantly lower abundance of UGT1A1 protein was observed in human liver microsomes from individuals with the variant allele rs4124874 (*60; c.3279T>G). The association between age and protein abundance diminished in human liver microsome samples in cells carrying hetero- or homozygous variant alleles.";Allele G is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele T.
RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Associated  with  decreasedformation of  ➔ RALOXIFENE 6-GLUCURONIDE;Metabolism/PK;;UGT1A1 *28 is associated with decreased formation of raloxifene 6-glucuronide in human liver microsomes as compared to UGT1A1 *1.
;UGT1A1;rs11568319;CG;Associated  with  decreasedformation of UGT1A1 ➔ ;Metabolism/PK;Human liver microsomes with the *1/*91 genotype (reported as rs11568319) had decreased relative UGT1A1 protein levels, as compared to those with the *1/*1 genotype. Information from the supplement.;Genotype CG is associated with decreased formation of UGT1A1 in human liver microsomes as compared to genotype CC.
;UGT1A3;rs7604115;T;Associated  with  increased  expression of UGT1A3 ➔ ;Other;in liver samples from patients undergoing laparoscopic gastric bypass operation.;Allele T is associated with increased expression of UGT1A3 as compared to allele C.
OLANZAPINE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;Associated  with  increased glucuronidation of  ➔ OLANZAPINE;Metabolism/PK;this increase was for both olanzapine 10-n-glucuronide and olanzapine 4-n-glucuronide.;UGT1A4 *3a is associated with increased glucuronidation of olanzapine in experiments with expressed proteins and HLMs as compared to UGT1A4 *1a.
;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;Associated  with  decreased expression of SLCO1B1 ➔ ;Other;in liver samples from patients undergoing laparoscopic gastric bypass operation (15% lower per copy).;SLCO1B1 *15 is associated with decreased expression of SLCO1B1 as compared to SLCO1B1 *1/*1.
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;Associated  with  decreasedtransport of  ➔ ATRASENTAN;Metabolism/PK;in vitro. Note that *18 was listed in the original publication. *18 was merged with *14 due to PharmVar 2021 update. Please note *1B was mentioned in the article. SLCO1B1*1B was consolidated into SLCO1B1*37 by PharmVar in 2021.;SLCO1B1 *14 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*9, SLCO1B1*37;*9;Associated  with  decreasedtransport of  ➔ ATRASENTAN;Metabolism/PK;in vitro. Please note *1B was mentioned in the article. SLCO1B1*1B was consolidated into  SLCO1B1*37  by PharmVar in 2021.;SLCO1B1 *9 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.
;PACSIN2;rs2413739;CT + TT;Associated  with  decreased activity  of TPMT ➔ ;Metabolism/PK;In patients with the TPMT *1/*3A or *1/*3C diplotypes ONLY. This association was not found in patients with the TPMT *1/*1 diplotype.;Genotypes CT + TT are associated with decreased activity of TPMT as compared to genotype CC.
;PHETA2, SMDT1;rs1807493;G;Associated  with  increased  expression of CYP2D6 ➔ ;Metabolism/PK;"""Following the conditional analysis, five SNPs, including the cis-variants rs1807493 and rs1062753, and the trans-variants rs4073010, rs729559, and rs80274432, emerged as independent variants significantly correlated with hepatic CYP2D6 protein expressions. Notably, four of these SNPs, except for rs80274432, also exhibited a significant association with CYP2D6 activities in human livers, suggesting their potential as novel and independent cis- and trans-variants regulating CYP2D6.""";Allele G is associated with increased expression of CYP2D6 in human liver s9 fractions as compared to allele C.
;PITPNM2;rs12425009;C;Associated  with  decreased expression of ABCB9 ➔ ;;;Allele C is associated with decreased expression of ABCB9 in HapMap cells.
;PKNOX1;rs2839629;A;Associated  with  increased  expression of PKNOX1 ➔ ;Other;;Allele A is associated with increased expression of PKNOX1 as compared to allele G.
;PKNOX1;rs2839629;A;Associated  with  increased  expression of CBS ➔ ;Other;;Allele A is associated with increased expression of CBS as compared to allele G.
;PLG;rs783145;G;Associated  with  decreasedtranscription of PRSS55 ➔ ;Metabolism/PK;;Allele G is associated with decreased transcription of PRSS55 in human liver samples as compared to allele A.
;PLG;rs783145;G;Associated  with  increased transcription of PLG ➔ ;Metabolism/PK;;Allele G is associated with increased transcription of PLG in human liver samples as compared to allele A.
;PLXNB3;rs4898439;A;Associated  with  increased  expression of ABCD1 ➔ ;;;Allele A is associated with increased expression of ABCD1 in HapMap cells.
;POR;rs2868177;AG;Associated  with  increased enzyme  activity  of CYP2B6 ➔ ;Efficacy;In study members who are CYP2B6 *1/*1 and CYP2B6 *6 carriers. The ratio of hydroxybupropion versus bupropion (AUC_hyd/ AUC_bup) in terms of area under the time-concentration curve (AUC) was used to assay CYP2B6 activity.;Genotype AG is associated with increased enzyme activity of CYP2B6 as compared to genotype AA.
;PPARA;rs4253728;AA;Associated  with  decreasedconcentrations of CYP3A4 ➔ ;Metabolism/PK;;Genotype AA is associated with decreased concentrations of CYP3A4 protein in human liver microsomes as compared to genotypes AG + GG.
;PROM1;rs2286455;CC;Associated  with  decreased expression of PROM1 ➔ ;;;Genotype CC is associated with decreased expression of PROM1 primary tumor tissue.
;PSMB8, TAP1, TAP2;rs2071543;T;Associated  with  increased  expression of TAP2 ➔ ;;;Allele T is associated with increased expression of TAP2 in HapMap cells.
;PSMB8, TAP2;rs9357155;A;Associated  with  increased  expression of TAP2 ➔ ;;;Allele A is associated with increased expression of TAP2 in HapMap cells.
;RALGAPA2;rs3827963;GG;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes AA + AG.
DOXORUBICIN;RARG;rs2229774;A;Associated  with  increased sensitivity to ➔ DOXORUBICIN;Toxicity;"Allele A on plus chromosomal strand, corresponds to 427L and allele G on plus chromosomal strand corresponds to 427S protein. Authors describe ""Genetic correction of RARG-S427L to wild type resulted in reduced doxorubicin-induced double stranded DNA breaks, reactive oxygen species production, and cell death. Conversely, introduction of RARG-S427L increased susceptibility to doxorubicin. """;Allele A is associated with increased sensitivity to doxorubicin in induced pluripotent stem cell derived cardiomyocytes as compared to allele G.
;RARG;rs2229774;A;Associated  with  decreasedprotein stability of RARG ➔ ;Other;"""RARG-S427L leads to greater cell death as a result of an impaired ability to mediate in DNA repair.""";Allele A is associated with decreased protein stability of RARG as compared to allele G.
;REDIC1;rs10783969;T;Associated  with  increased  expression of ABCD2 ➔ ;;;Allele T is associated with increased expression of ABCD2 in HapMap cells.
;RGMA;rs7165938;GG;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes AA + AG.
CAFFEINE;RYR1;rs193922753;T;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;In-vitro analysis for the R163L variant as compared to wild type. Nucleotide change was introduced into rabbit RYR1 cDNA. The constructs expressed in HEK-293 cells and caffeine-induced calcium release was measured.;Allele T is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele G.
;ORMDL3;rs2872507;AG + GG;Associated  with  increased  expression of ORMDL3 ➔ ;Metabolism/PK;This was significant in whole cohort and atopic asthmatic subset, but only significant comparing GG vs AA in non-atopic asthmatics. After ICS therapy (fluticasone), expression was significantly increased in atopic asthmatics but not non-atopic asthmatics.;Genotypes AG + GG are associated with increased expression of ORMDL3 in before-treatment blood samples from pediatric asthma patients as compared to genotype AA.
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs118204423;C;Associated  with  increased sensitivity to ➔ CAFFEINE, CHLOROCRESOL, HALOTHANE;Other;The C allele was found to segregate with malignant hyperthermia susceptibility (MHS) in a pedigree analysis. The authors of the study tested whether this variant confers MHS characteristics using differentiated skeletal muscle from MHS and MH negative (MHN) family members by assaying cells with chlorocrasol, halothane, and caffeine. Maximum calcium release in MHS cells was significantly higher for halothane as compared to MHN cells (168¤23 nM vs. 114¤12 nM, respectively p<0.05).;Allele C is associated with increased sensitivity to caffeine, chlorocresol or halothane in differentiated muscle cells as compared to allele G.
ETHANOL;OPRM1;rs1799971;GG;Associated  with  decreasedsensitivity to ➔ ETHANOL;Efficacy;Acute application of ethanol caused a notable increase in excitability and synaptic release in neurons with the AA genotype, while no increase was seen in GG neurons.;Genotype GG is associated with decreased sensitivity to ethanol in iPS-derived neurons as compared to genotype AA.
;NT5C2;rs11191612;GG;Associated  with  increased transcription of NT5C2 ➔ ;Metabolism/PK;;Genotype GG is associated with increased transcription of NT5C2 as compared to genotypes AA + AG.
PAROMOMYCIN;MT-RNR1;rs267606619;T;Associated  with  increased sensitivity to ➔ PAROMOMYCIN;PD;In vitro study of LCLs and cybrid cell lines derived from patients carrying the C1494T mutation. Cybrids in the presence of paromomycin showed a reduced growth rate, with a similar DT ratio to cells with A1555G.;Allele T is associated with increased sensitivity to paromomycin in cybrid lines.
GEMCITABINE;MTHFR;rs1801131;GG + GT;Associated  with  increased sensitivity to ➔ GEMCITABINE;Toxicity;Non-small-cell lung cancer cell lines (n=17). Cell lines with the TT had higher IC50 values for gemcitabine than those with the GG or GT genotype. Cell lines with higher IC50 values for gemcitabine are more resistant to the drug. Note that this SNP significantly deviated from Hardy-Weinberg equilibrium (p=0.0007). Also note alleles have been complemented to the plus chromosomal strand.;Genotypes GG + GT is associated with increased sensitivity to gemcitabine as compared to genotype TT.
;NAF1;rs17571991;AA;Associated  with  increased transcription of ABCC1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype AA is associated with increased transcription of ABCC1 as compared to genotypes AG + GG.
SOLITHROMYCIN;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*4;Associated  with  increased metabolism of  ➔ SOLITHROMYCIN;Metabolism/PK;"Originally annotated as NAT2 *4 compared to NAT2 *5B + *6A + *7B + *14B. Vmax was significantly decreased for *5+*6+*7+*14 but KM was only decreased for *6+*7; The arylamine N-acetyltransferases (NATs) database was transitioned into the PharmVar database in March 2024. The alleles in this annotation are mapped as following:  NAT2*14B under the *14 core allele; NAT2*5B under the *5 core allele; NAT2*6A under the *6 core allele; NAT2*7B under the *7 core allele.";NAT2 *4 is associated with increased metabolism of solithromycin in yeast expressed recombinant proteins and human hepatocytes as compared to NAT2 *5 + *6 + *7 + *14.
;NAT2;rs4646244;A;Associated  with  decreasedtranscription of NAT2 ➔ ;Other;;Allele A is associated with decreased transcription of NAT2 (as determined in luciferase reporter assays) as compared to allele T.
;NCOA1;rs1804645;T;Associated  with  increased half-life of NCOA1 ➔ ;;t 1/2 = 359 min vs. t 1/2 = 72 min.;Allele T is associated with increased half-life of NCOA1.
;NFATC2;rs6021191;T;Associated  with  increased  expression of NFATC2 ➔ ;Other;"This SNP is located in an intronic region of ""NFATC2"". The region has weak enhancer activity in HUVEC and K562 cell lines. In ALL tumor samples and YRI HapMap lymphoblastoid cell lines the T allele was associated with increased expression of ""NFATC2"".";Allele T is associated with increased expression of NFATC2 as compared to allele A.
;NHLH1;rs11265375;T;Associated  with  increased luciferase  activity  ➔ ;Other;;Allele T is associated with increased luciferase activity in H446 lung cancer cells.
;NQO1;rs1800566;AA;Associated  with  decreasedenzyme  activity  of NQO1 ➔ ;;Tissues from individuals homozygous for the C609T change have no detectable or, only trace amounts of NQO1 protein and are devoid of NQO1 activity.;Genotype AA is associated with decreased enzyme activity of NQO1.
;NQO1;rs1800566;A;Associated  with  decreased expression of NQO1 ➔ ;;"This variant is NQO1*2 and leads to greatly diminished levels of protein due to rapid degradation of the NQO1*2 protein; by the ubiquitin proteasomal pathway.";Allele A is associated with decreased expression of NQO1.
MIDAZOLAM;NR1I2;rs1464602;G;Associated  with  increased clearance of  ➔ MIDAZOLAM;Metabolism/PK;"Study of 54 livers demonstrated that part of haplotype g.252A>G (rs1464603), g.275A>G (rs1464602), and g.4760G>A; AF364606 is significantly (P < .05) associated with oral midazolam clearance in the African American subpopulation (n = 14) but not in European Americans (n = 9).";Allele G is associated with increased clearance of midazolam.
MIDAZOLAM;NR1I2;rs1464603;G;Associated  with  increased clearance of  ➔ MIDAZOLAM;Metabolism/PK;"Study of 54 livers demonstrated that part of haplotype g.252A>G (rs1464603), g.275A>G (rs1464602), and g.4760G>A; AF364606 is significantly (P < .05) associated with oral midazolam clearance in the African American subpopulation (n = 14) but not in European Americans (n = 9).";Allele G is associated with increased clearance of midazolam liver.
;NRP2;rs10932125;C;Associated  with  increased  expression of CYP1B1 ➔ ;;;Allele C is associated with increased expression of CYP1B1 in CEU and YRI cell lines.
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs201045130;G;Associated  with  decreasedsensitivity to ➔ CLADRIBINE, FLUOROURACIL, GEMCITABINE;Other;A cytotoxicity assays after exposure to chemotherapeutic nucleoside analogs (cladribine, gemcitabine, 5-fluorouracil) was used to determine sensitivity.;Allele G is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele A.
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs370457585;T;Associated  with  decreasedsensitivity to ➔ CLADRIBINE, FLUOROURACIL, GEMCITABINE;Other;A cytotoxicity assays after exposure to chemotherapeutic nucleoside analogs (cladribine, gemcitabine, 5-fluorouracil) was used to determine sensitivity.;Allele T is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele C.
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs374150125;A;Associated  with  decreasedsensitivity to ➔ CLADRIBINE, FLUOROURACIL, GEMCITABINE;Other;A cytotoxicity assays after exposure to chemotherapeutic nucleoside analogs (cladribine, gemcitabine, 5-fluorouracil) was used to determine sensitivity.;Allele A is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele G.
CYTARABINE;NT5C2;rs1163075;G;Associated  with  decreasedsensitivity to ➔ CYTARABINE;Efficacy;(ie. increased resistance to cytarabine);Allele G is associated with decreased sensitivity to cytarabine as compared to allele A.
;NT5C2;rs1163075;G;Associated  with  increased transcription of NT5C2 ➔ ;Metabolism/PK;;Allele G is associated with increased transcription of NT5C2 as compared to allele A.
CYTARABINE;NT5C2;rs11191612;GG;Associated  with  decreasedsensitivity to ➔ CYTARABINE;Efficacy;(ie. increased resistance to cytarabine);Genotype GG is associated with decreased sensitivity to cytarabine as compared to genotypes AA + AG.
;NT5E;rs9450278;A;Associated  with  decreased expression of NT5E ➔ ;;Basal expression was measured.;Allele A is associated with decreased expression of NT5E.
CHLOROCRESOL;RYR1;rs121918596;del;Associated  with  increased sensitivity to ➔ CHLOROCRESOL;Other;EC50 for the del allele was 261 micrograms of chlorocresol (4-CmC) vs. 481 micrograms for WT.;Allele del is associated with increased sensitivity to chlorocresol in HEK293T cells transfected with RYR1 as compared to allele GAG.
CAFFEINE;RYR1;rs193922843;T;Associated  with  increased sensitivity to ➔ CAFFEINE;Dosage;EC50 for caffeine-induced calcium release was assessed in HEK293 cells that were transiently transfected with RYR1 constructs containing the T allele (mean EC50 = 1.71 mM 95% CI: 1.3 - 2.21) vs. the A allele (mean EC50 = 4.1 mM 95% CI: 1.64 -5.95).;Allele T is associated with increased sensitivity to caffeine as compared to allele G.
CAFFEINE;RYR1;rs193922816;T;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;In-vitro analysis for the variant as compared to wild type. Nucleotide change was introduced into rabbit RYR1 cDNA. The constructs expressed in HEK-293 cells and caffeine-induced calcium release was measured.;Allele T is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele C.
CAFFEINE;RYR1;rs118192176;A;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;In-vitro analysis for the variant as compared to wild type. Nucleotide change was introduced into rabbit RYR1 cDNA. The constructs expressed in HEK-293 cells and caffeine-induced calcium release was measured.;Allele A is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele G.
;SEMA6A;rs3806915;A;Associated  with  increased luciferase  activity  ➔ ;Other;;Allele A is associated with increased luciferase activity in H446 lung cancer cells as compared to allele C.
;SEPTIN3, WBP2NL;rs1062753;G;Associated  with  increased  expression of CYP2D6 ➔ ;Metabolism/PK;"""Following the conditional analysis, five SNPs, including the cis-variants rs1807493 and rs1062753, and the trans-variants rs4073010, rs729559, and rs80274432, emerged as independent variants significantly correlated with hepatic CYP2D6 protein expressions. Notably, four of these SNPs, except for rs80274432, also exhibited a significant association with CYP2D6 activities in human livers, suggesting their potential as novel and independent cis- and trans-variants regulating CYP2D6.""";Allele G is associated with increased expression of CYP2D6 in human liver s9 fractions as compared to allele A.
RANITIDINE;SLC22A1;rs12208357;T;Associated  with  decreasedtransport of  ➔ RANITIDINE;Metabolism/PK;"reported for *3. Impact of haplotypes on ranitidine transport was measured as changes in Vmax of SLC22A1-mediated uptake of ranitidine.; The authors suggest that this haplotype could reduce hepatic uptake of ranitidine.";Allele T is associated with decreased transport of ranitidine as compared to allele C.
RANITIDINE;SLC22A1;rs72552763;del;Associated  with  decreasedtransport of  ➔ RANITIDINE;Metabolism/PK;"as reported for OCT1*2, with Vmax decreased by more than 50%. This shows substrate-specific effect of haplotypes as *2 is considered active for other substrates.; The authors suggest that this haplotype could reduce hepatic uptake of ranitidine.";Allele del is associated with decreased transport of ranitidine as compared to allele GAT.
RANITIDINE;SLC22A1;rs34130495;A;Associated  with  decreasedtransport of  ➔ RANITIDINE;Metabolism/PK;"reported for *4. Impact of haplotypes on ranitidine transport was measured as changes in Vmax of SLC22A1-mediated uptake of ranitidine.; The authors suggest that this haplotype could reduce hepatic uptake of ranitidine.";Allele A is associated with decreased transport of ranitidine as compared to allele G.
;SLC22A3;rs2076828;G;Associated  with  decreased expression of SLC22A3 ➔ ;Other;The 3' UTR of SLC22A3 was cloned into an expression vector and 11 SNPs were introduced into the 3' UTR. The vector was introduced into various cell lines (HCT-116, HepG2, DU145, A549) and their effect on gene expression was measured by luciferase assay. Data represent mean ¤ S.D., n = 3 replicates per cell line;Allele G is associated with decreased expression of SLC22A3 as compared to allele C.
;SLC22A3;rs884742;C;Associated  with  increased transcription of SLC22A3 ➔ ;Metabolism/PK;;Allele C is associated with increased transcription of SLC22A3 in human liver samples as compared to allele A.
;SLC22A3;rs555754;AA;Associated  with  increased  expression of SLC22A3 ➔ ;;;Genotype AA is associated with increased expression of SLC22A3 human liver tissue.
ADEFOVIR DIPIVOXIL;SLC22A6;rs11568634;T;Associated  with  decreaseduptake of  ➔ ADEFOVIR DIPIVOXIL;Other;in X. laevis oocytes. This variant is also called R454Q.;Allele T is associated with decreased uptake of adefovir dipivoxil as compared to allele C.
CEFOTAXIME;SLC22A8;rs11568482;A;Associated  with  decreasedtransport of  ➔ CEFOTAXIME;Metabolism/PK;"Paper gives results for  Ile and Phe alleles rather than for genotypes.  Ile = A; Phe = T.  Gene is on the negative chromosomal strand, so I entered Ile = T and Phe = A on the positive chromosomal strand.  Transfected cells with allele A had a lower maximum cefotaxime transport activity, Vmax , [159 ¤ 3 nmol*(mg protein)(-1) /min (mean ¤ SD)] compared with such cells with allele T [305 ¤ 28 nmol*(mg protein)(-1) /min, (mean ¤ SD), whereas the Michaelis-Menten constant values (Km ) did not differ.";Allele A is associated with decreased transport of cefotaxime as compared to allele T.
GEMCITABINE TRIPHOSPHATE;SLC28A3;rs7867504;CC;Associated  with  increased formation of  ➔ GEMCITABINE TRIPHOSPHATE;Metabolism/PK;Gemcitabine, gemcitabine triphosphate (dFdCTP), and de-aminated gemcitabine (dFdU) plasma concentrations were measured before (5, 15, 30, 45 min) and after gemcitabine infusion (1, 1.25, 1.5, 2, 6, 24, 48, 72 hrs). Population pharmacokinetic analysis of gemcitabine and metabolites (dFdU, dFdCTP) were performed by non-linear mixed effects modeling. Pharmacokinetics of dFdCTP were described by a three-compartment model. SLC28A3 rs7867504 genotype was associated with formation of dFdCTP, a pharmacologically active metabolite of gemcitabine. The CC genotype was associated with a 1.77 fold increase in formation of dFdCTP (gemcitabine triphosphate).;Genotype CC is associated with increased formation of gemcitabine triphosphate.
DOXORUBICIN;SLC28A3;rs11140490;AA;Associated  with  increased sensitivity to ➔ DOXORUBICIN;Toxicity;"Alleles complemented. ""After we prioritized rs11140490 to be the top candidate causal variant within the DIC?associated SLC28A3?SLC28A3-AS1 locus, we went on to confirm the causality of this variant. Using a base?editor mediated approach, we edited the SNP rs11140490 in hiPSCs from two SLCvar patients that harbor the heterozygous genotype CT back to the reference genotype TT."" ""SLCrs11140490(CT>TT) cardiomyocytes were more sensitive to DOX (LD50 = 1.37 ?M, P = 0.005) as compared to SLCrs11140490(CT) LD50 = 1.9 ?M) (Fig. 3e). Moreover, DOX uptake was significantly higher in SLCrs11140490(CT>TT) when compared to SLC rs11140490(CT) at 3 h post DOX treatment (P = 0.006) (Fig. 3f). This finding confirms that the SNP rs11140490 is the causal cardioprotective SNP affecting DIC.""";Genotype AA is associated with increased sensitivity to doxorubicin in Peripheral blood mononuclear cells from pediatric patients reprogramed to hiPSCs (cardiomyocytes) as compared to genotype AG.
;SLC29A1;rs731780;G;Associated  with  increased  expression of SLC29A1 ➔ ;Other;"This effect of this SNP on expression of SLC29A1 (hENT1) was tested alone, or as part of a haplotype using a luciferase expression assay in Cos-1 cells transfected with the individual SNP.; Alpha was adjusted by the Bonferroni correction to be 0.0125. Any p-value above this alpha was not considered to be statistically significant.";Allele G is associated with increased expression of SLC29A1 as compared to allele C.
;SLC29A1;rs70914;A;Associated  with  increased  expression of SLC29A1 ➔ ;;This effect of this SNP on expression of SLC29A1 (hENT1) was tested alone, or as part of a haplotype using a luciferase expression assay in Cos-1 cells transfected with the individual SNP. Alpha was adjusted by the Bonferroni correction to be 0.0125. Any p-value above this alpha was not considered to be statistically significant.;Allele A is associated with increased expression of SLC29A1 as compared to allele G.
;SLCO1A2;rs4148981;T;Associated  with  decreased expression of SLCO1A2 ➔ ;;;Allele T is associated with decreased expression of SLCO1A2.
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;Associated  with  decreasedtransport of  ➔ ATRASENTAN;Metabolism/PK;in vitro. Please note *1B was mentioned in the article. SLCO1B1*1B was consolidated into  SLCO1B1*37  by PharmVar in 2021.;SLCO1B1 *15 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.
;SLCO1B1;rs4149056;C;Associated  with  decreased expression of SLCO1B1 ➔ ;Other;in liver samples from patients undergoing laparoscopic gastric bypass operation.;Allele C is associated with decreased expression of SLCO1B1 as compared to allele T.
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;Associated  with  decreasedtransport of  ➔ ATRASENTAN;Metabolism/PK;in vitro. Please note *1B was mentioned in the article. SLCO1B1*1B was consolidated into  SLCO1B1*37  by PharmVar in 2021.;SLCO1B1 *5 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.
CAFFEINE, HALOTHANE;RYR1;rs28933397;CT;Associated  with sensitivity to ➔ CAFFEINE, HALOTHANE;Other;The authors used muscle strips from patient biopsies (from in vitro contracture tests) to compare the threshold concentration of caffeine and halothane needed to generate 0.2 g force in muscle strips. They also compared the tension generated in the same muscle a the same concentrations of caffeine and halothane (2 mM). In all cases, muscles carrying the malignant hyperthermia susceptibility (MHS)-causative variant demonstrated greater sensitivity to halothane than caffeine. Homozygous MHS individuals were excluded from analyses.;Genotype CT is associated with sensitivity to caffeine or halothane in muscle.
CAFFEINE, CHLOROCRESOL;RYR1;rs186983396;T;Associated  with  increased sensitivity to ➔ CAFFEINE, CHLOROCRESOL;Metabolism/PK;This variant was discovered in a 9 y.o with symptoms indicating a congenital myopathy. Calcium induced calcium release was performed to test for malignant hyperthermia susceptibility and patient tested positive so no malignant hyperthermia triggering anesthetics were used in anesthesia for surgery for patellar dislocation. Calcium release assays were done in HEK 293 cells transfected with WT and mut. RYR1 as well as patient derived myotubes. Variant shifted dose response curve to the left.;Allele T is associated with increased sensitivity to caffeine and chlorocresol in HEK 293 cells and myotubes as compared to allele C.
CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;T;Associated  with  increased sensitivity to ➔ CAFFEINE, CHLOROCRESOL;Other;Standart assay system was used (introduced by MacLennan), which meets EMHG criteria for functional characterization. Variant was introduced into rabbit skeletal muscle RYR1 cDNA and transfected into HEK-293 cells. Dose-response curve for caffeine and chorocresol as trigger agents were measured with calcium fluorescence measurements. The EC50 values were lower for the construct containing the variant compared to wild-type.;Allele T is associated with increased sensitivity to caffeine and chlorocresol in HEK-293 cells as compared to allele C.
CHLOROCRESOL;RYR1;rs118192124;T;Associated  with  increased sensitivity to ➔ CHLOROCRESOL;Other;HEK 293 cells were transiently transfected with wild-type and mutant RYR1 (rs118192124 C>T referred to as R2452W in this paper). There were no significant differences in protein expression between WT and R2452 expressing cells (confirmed using immunofluorescence as well as western blotting). Calcium release was induced with the RYR1 agonist, chlorocrasol and assayed by fluorescence. The assays show that EC50 values for the  R2452W RYR1 variant were lower than for the WT.;Allele T is associated with increased sensitivity to chlorocresol as compared to allele C.
CAFFEINE;RYR1;rs118192167;G;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;In-vitro analysis for the variant as compared to wild type. Nucleotide change was introduced into rabbit RYR1 cDNA. The constructs expressed in HEK-293 cells and caffeine-induced calcium release was measured.;Allele G is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele A.
CAFFEINE;RYR1;rs193922803;T;Associated  with  increased sensitivity to ➔ CAFFEINE;Dosage;EC50 for caffeine-induced calcium release was assessed in HEK293 cells that were transiently transfected with inducible RYR1 constructs containing the T allele (mean EC50 = 1.38 mM 95% CI: 0.02 - 2.3) vs. the C allele (mean EC50 = 3.8 mM 95% CI: 2.52 -5.4).;Allele T is associated with increased sensitivity to caffeine as compared to allele C.
CAFFEINE;RYR1;rs118192122;A;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;In-vitro analysis for the variant as compared to wild type. Nucleotide change was introduced into rabbit RYR1 cDNA. The constructs expressed in HEK-293 cells and caffeine-induced calcium release was measured.;Allele A is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele G.
CAFFEINE;RYR1;rs193922809;A;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;In-vitro analysis for the variant as compared to wild type. Nucleotide change was introduced into rabbit RYR1 cDNA. The constructs expressed in HEK-293 cells and caffeine-induced calcium release was measured.;Allele A is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele G.
CAFFEINE;RYR1;rs118192168;A;Associated  with  increased sensitivity to ➔ CAFFEINE;Dosage;EC50 for caffeine-induced calcium release was assessed in HEK293 cells that were transiently transfected with RYR1 constructs containing the A allele (mean EC50 = 1.25 mM 95% CI: 0.76 - 1.62) vs. the G allele (mean EC50 = 4.1 mM 95% CI: 1.64 - 5.95).;Allele A is associated with increased sensitivity to caffeine as compared to allele G.
CAFFEINE;RYR1;rs193922832;A;Associated  with  increased sensitivity to ➔ CAFFEINE;Dosage;EC50 for caffeine-induced calcium release was assessed in HEK293 cells that were transiently transfected with RYR1 constructs containing the A allele (mean EC50 = 1.74 mM 95% CI: 1.2 - 2.62) vs. the G allele (mean EC50 = 4.1 mM 95% CI: 1.64 - 5.95).;Allele A is associated with increased sensitivity to caffeine as compared to allele G.
CAFFEINE;RYR1;rs112563513;A;Associated  with  increased sensitivity to ➔ CAFFEINE;Dosage;EC50 for caffeine-induced calcium release was assessed in HEK293 cells that were stably transfected with RYR1 constructs containing the A allele (mean EC50 = 0.91 mM 95% CI: 0.080 - 1.27) vs. the G allele (mean EC50 = 3.21 mM 95% CI: 2.44 -3.77).;Allele A is associated with increased sensitivity to caffeine as compared to allele G.
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs121918594;A;Associated  with  increased sensitivity to ➔ CAFFEINE, CHLOROCRESOL, HALOTHANE;Other;The A allele is designated as MHS causative by the European Malignant Hyperthermia Group. The authors of the study tested whether this variant confers MHS characteristics using differentiated skeletal muscle cells from MHS and MH negative (MHN) controls by assaying cells with chlorocresol, halothane, and caffeine.;Allele A is associated with increased sensitivity to caffeine, chlorocresol or halothane in differentiated muscle cells as compared to allele G.
CAFFEINE;RYR1;rs193922878;G;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;In-vitro caffeine induced calcium release was measured in cells transacted with wild type or variant RYR1 constructs (variation introduced into rabbit RYR1 gene). The L4838V carrying cells showed an increased calcium release compared to wild type.;Allele G is associated with increased sensitivity to caffeine in CHO cells as compared to allele C.
;MIR27A;rs895819;CC;Associated  with  increased  expression of MIR27A ➔ ;Other;"Cells homozygous for the C allele had approximately 50% higher miR-27a expression as compared to those with the TT genotype (p=0.029). Intermediate expression was seen for heterozygotes. This was also tested in HEK293T/c17 cells, and miR-27a expression was 57% higher in cells expression the variant construct encoding the G allele (corresponds to C genotype) as compared to those expression the A allele (T genotype; p=0.0011).";Genotype CC is associated with increased expression of MIR27A in lymphoblastoid cell lines as compared to genotype TT.
CAFFEINE;RYR1;rs118192161;T;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;Primary myotubes were derived from mouse models of malignant hyperthermia susceptibility (MHS). Myotubes derived from homozygous mice (embryonic lethal) were the most sensitive to caffeine induced calcium release, followed by myotubes derived from heterozygote mice, and then wild-type mice.;Allele T is associated with increased sensitivity to caffeine in myotubes as compared to allele C.
CAFFEINE;RYR1;rs118192177;T;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;In-vitro analysis for the variant as compared to wild type. Nucleotide change was introduced into rabbit RYR1 cDNA. The constructs expressed in HEK-293 cells and caffeine-induced calcium release was measured. The G allele was also associated with increased calcium release as compared to the C allele.;Allele T is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele C.
CAFFEINE;RYR1;rs118192167;AG;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;Caffeine EC50 for the calcium induced calcium release in HEK-293 cells transfected with WT or mutant RYR1 cDNA without the mutation was 1.56 ¤ 0.08 mM whereas with the mutation it was 0.98 ¤0.15 mM caffeine.;Genotype AG is associated with increased sensitivity to caffeine as compared to genotype AA.
CAFFEINE, HALOTHANE;RYR1;rs118192172;CT;Associated  with sensitivity to ➔ CAFFEINE, HALOTHANE;Other;The authors used muscle strips from patient biopsies (from in vitro contracture tests) to compare the threshold concentration of caffeine and halothane needed to generate 0.2 g force in muscle strips. They also compared the tension generated in the same muscle a the same concentrations of caffeine and halothane (2 mM). In all cases, muscles carrying the malignant hyperthermia susceptibility (MHS)-causative variant demonstrated greater sensitivity to halothane than caffeine. Homozygous MHS individuals were excluded from analyses.;Genotype CT is associated with sensitivity to caffeine or halothane in muscle.
CAFFEINE, HALOTHANE;RYR1;rs193922772;GT;Associated  with sensitivity to ➔ CAFFEINE, HALOTHANE;Other;The authors used muscle strips from patient biopsies (from in vitro contracture tests) to compare the threshold concentration of caffeine and halothane needed to generate 0.2 g force in muscle strips. They also compared the tension generated in the same muscle a the same concentrations of caffeine and halothane (2 mM). In all cases, muscles carrying the malignant hyperthermia susceptibility (MHS)-causative variant demonstrated greater sensitivity to halothane than caffeine. Homozygous MHS individuals were excluded from analyses.;Genotype GT is associated with sensitivity to caffeine or halothane in muscle.
CAFFEINE, HALOTHANE;RYR1;rs118192175;CT;Associated  with sensitivity to ➔ CAFFEINE, HALOTHANE;Other;The authors used muscle strips from patient biopsies (from in vitro contracture tests) to compare the threshold concentration of caffeine and halothane needed to generate 0.2 g force in muscle strips. They also compared the tension generated in the same muscle a the same concentrations of caffeine and halothane (2 mM). In all cases, muscles carrying the malignant hyperthermia susceptibility (MHS)-causative variant demonstrated greater sensitivity to halothane than caffeine. Homozygous MHS individuals were excluded from analyses.;Genotype CT is associated with sensitivity to caffeine or halothane in muscle.
CAFFEINE, HALOTHANE;RYR1;rs193922747;CT;Associated  with sensitivity to ➔ CAFFEINE, HALOTHANE;Other;The authors used muscle strips from patient biopsies (from in vitro contracture tests) to compare the threshold concentration of caffeine and halothane needed to generate 0.2 g force in muscle strips. They also compared the tension generated in the same muscle a the same concentrations of caffeine and halothane (2 mM). In all cases, muscles carrying the malignant hyperthermia susceptibility (MHS)-causative variant demonstrated greater sensitivity to halothane than caffeine. Homozygous MHS individuals were excluded from analyses.;Genotype CT is associated with sensitivity to caffeine or halothane in muscle.
CAFFEINE, HALOTHANE;RYR1;rs118192176;AG;Associated  with sensitivity to ➔ CAFFEINE, HALOTHANE;Other;The authors used muscle strips from patient biopsies (from in vitro contracture tests) to compare the threshold concentration of caffeine and halothane needed to generate 0.2 g force in muscle strips. They also compared the tension generated in the same muscle a the same concentrations of caffeine and halothane (2 mM). In all cases, muscles carrying the malignant hyperthermia susceptibility (MHS)-causative variant demonstrated greater sensitivity to halothane than caffeine. Homozygous MHS individuals were excluded from analyses.;Genotype AG is associated with sensitivity to caffeine or halothane in muscle.
CHLOROCRESOL;RYR1;rs118192124;T;Associated  with  increased sensitivity to ➔ CHLOROCRESOL;Other;B-lymphoblastoid cell lines and myotubes were derived from patients who were tested for malignant hyperthermia susceptibility by in vitro contracture test (IVCT). B-lymphoblastoid cell lines were immortalized with Epstein-Barr virus. Calcium release was assayed by a fluorometer after addition of the RYR1 agonist chlorocrasol. The R2452W variant (rs118192124 C>T) was present in 2 families and segregated with the malignant hyperthermia sensitive phenotype as assayed by IVCT.;Allele T is associated with increased sensitivity to chlorocresol as compared to allele C.
CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;G;Associated  with  increased sensitivity to ➔ CAFFEINE, CHLOROCRESOL;Other;Standard assay system was used (introduced by MacLennan), which meets EMHG criteria for functional characterization. Variant was introduced into rabbit skeletal muscle RYR1 cDNA  and transfected into HEK-293 cells. Dose-response curve for caffeine and chlorocresol as trigger agents were measured with calcium fluorescence measurements. The EC50 values were lower for the construct containing the variant compared to wild-type.;Allele G is associated with increased sensitivity to caffeine and chlorocresol in HEK-293 cells as compared to allele C.
CAFFEINE, CHLOROCRESOL;RYR1;rs193922818;A;Associated  with  increased sensitivity to ➔ CAFFEINE, CHLOROCRESOL;Other;Standart assay system was used (introduced by MacLennan), which meets EMHG criteria for functional characterization. Variant was introduced into rabbit skeletal muscle RYR1 cDNA  and transfected into HEK-293 cells. Dose-response curve for caffeine and chorocresol as trigger agents were measured with calcium fluorescence measurements. The EC50 values were lower for the construct containing the variant compared to wild-type.;Allele A is associated with increased sensitivity to caffeine and chlorocresol in HEK-293 cells as compared to allele G.
;;rs2000068;G;Associated  with  increased  expression of ABCA1 ➔ ;;;Allele G is associated with increased expression of ABCA1 in HapMap cells.
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*17, CYP2D6*18, CYP2D6*35, CYP2D6*39, CYP2D6*53;*17 + *18 + *35 + *39 + *53;Associated  with  decreasedclearance of  ➔ PRIMAQUINE;Metabolism/PK;"*17 = 1023C>T;2850C>G;4180G>C; *18 (no function allele) = 4125_4133dupGTGCCCACT; *35 (normal function allele) = 31G>A;2850C>G;4180G>C; *39 = 4180G > C; *53 = 1611T>A;1617G>T (normal function allele, in some in vitro assay highly increased clearance of other substrates). Intrinsic clearance of *1: *17 = 42%, *18 = 7.4%, *35 = 27%, *39 = 6.3%, *53 = 12%";CYP2D6 *17 + *18 + *35 + *39 + *53 is associated with decreased clearance of primaquine in 293FT cells as compared to CYP2D6 *1.
;DPYD;rs1801158;T;Associated  with  decreased activity  of DPYD ➔ ;Other;"The DPYD*4 allele (c.1601G>A) was expressed in mammalian cells (HEK293 Flp-In) and protein expression and activity as compared to wild-type DPYD was analyzed. Cells with the DPYD*4 allele (T) had significantly lower activity as compared to wild-type. However, when DPYD activity was assessed within a healthy cohort of 100 individuals (allele frequency = 0.035), there was only a tendency toward lower activity (p=0.3201). Text from the discussion section:""the analysis of recombinantly-expressed DPYD mutants showed that only a mildly-reduced DPD activity, ranging from 68% to 84% of that of the wild-type DPD enzyme, was observed for the DPD mutants carrying the p.C29R, p.M166V, p.G401R, p.S534N and p.V732I mutations.To date, weak or conflicting data exists as to whether the p.C29R, p.M166V, p.S534N and p.V732I mutations confer an increased risk to patients to develop severe 5FU-associated toxicity.""";Allele T is associated with decreased activity of DPYD as compared to allele C.
EFAVIRENZ;CYP2B6;rs142421637;T;Associated  with  decreasedclearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (Ile84Leu, Arg109Trp, Arg120Cys, Arg120Leu, Arg126Gln, Asp266Ala, and Ile486Phe) showed significantly lower CLint values (P<0.05)."" Table 1 shows rs142421637 is 325C>T, R109W";Allele T is associated with decreased clearance of efavirenz as compared to allele C.
EFAVIRENZ;CYP2B6;rs373442191;A;Associated  with  increased clearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (K53R, R158Q, M165V, A260V, H280Y, I435V, and V463M) showed significantly higher intrinsic clearance (CLint; Vmax/Km) values than the wild-type proteins (P<0.05)"" Table 1 shows rs373442191 is 1387G>A, V463M";Allele A is associated with increased clearance of efavirenz as compared to allele G.
PROPOFOL;CYP2B6;rs752695347;T;Associated  with  decreasedclearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs752695347 is 358C>T, R120C";Allele T is associated with decreased clearance of propofol as compared to allele C.
PROPOFOL;CYP2B6;rs142421637;T;Associated  with  decreasedclearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs142421637 is 325C>T, R109W";Allele T is associated with decreased clearance of propofol as compared to allele C.
PROPOFOL;CYP2B6;rs1282926098;T;Associated  with  increased clearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs1282926098 is 779C>T, A260V";Allele T is associated with increased clearance of propofol as compared to allele C.
PROPOFOL;CYP2B6;rs1969136524;C;Associated  with  decreasedclearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs1969136524 is 250A>C, I84L";Allele C is associated with decreased clearance of propofol as compared to allele A.
EFAVIRENZ;CYP2B6;rs773494867;C;Associated  with  decreasedclearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (Ile84Leu, Arg109Trp, Arg120Cys, Arg120Leu, Arg126Gln, Asp266Ala, and Ile486Phe) showed significantly lower CLint values (P<0.05)."" Table 1 shows rs773494867 is 797A>C, D266A";Allele C is associated with decreased clearance of efavirenz as compared to allele A.
EFAVIRENZ;CYP2B6;rs1969376664;T;Associated  with  decreasedclearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (Ile84Leu, Arg109Trp, Arg120Cys, Arg120Leu, Arg126Gln, Asp266Ala, and Ile486Phe) showed significantly lower CLint values (P<0.05)."" Table 1 shows rs1969376664 is 1456A>T, I486F";Allele T is associated with decreased clearance of efavirenz as compared to allele A.
PROPOFOL;CYP2B6;rs138264188;T;Associated  with  decreasedclearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs138264188 is 200C>T, T67M";Allele T is associated with decreased clearance of propofol as compared to allele C.
PROPOFOL;CYP2B6;rs373442191;A;Associated  with  increased clearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs373442191 is 1387G>A, V463M";Allele A is associated with increased clearance of propofol as compared to allele G.
EFAVIRENZ;CYP2B6;rs1969255598;T;Associated  with  increased clearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (K53R, R158Q, M165V, A260V, H280Y, I435V, and V463M) showed significantly higher intrinsic clearance (CLint; Vmax/Km) values than the wild-type proteins (P<0.05)"" Table 1 shows rs1969255598 is 838C>T, H280Y";Allele T is associated with increased clearance of efavirenz as compared to allele C.
EFAVIRENZ;CYP2B6;rs1248477767;G;Associated  with  increased clearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (K53R, R158Q, M165V, A260V, H280Y, I435V, and V463M) showed significantly higher intrinsic clearance (CLint; Vmax/Km) values than the wild-type proteins (P<0.05)"" Table 1 shows rs1248477767 is 1303A>G, I435V";Allele G is associated with increased clearance of efavirenz as compared to allele A.
EFAVIRENZ;CYP2B6;rs750671397;G;Associated  with  increased clearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (K53R, R158Q, M165V, A260V, H280Y, I435V, and V463M) showed significantly higher intrinsic clearance (CLint; Vmax/Km) values than the wild-type proteins (P<0.05)"" Table 1 shows rs750671397 is 493A>G, M165V";Allele G is associated with increased clearance of efavirenz as compared to allele A.
EFAVIRENZ;CYP2B6;rs141666881;A;Associated  with  increased clearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (K53R, R158Q, M165V, A260V, H280Y, I435V, and V463M) showed significantly higher intrinsic clearance (CLint; Vmax/Km) values than the wild-type proteins (P<0.05)"" Table 1 shows rs141666881 is 473G>A, R158Q";Allele A is associated with increased clearance of efavirenz as compared to allele G.
EFAVIRENZ;CYP2B6;rs1968919352;G;Associated  with  increased clearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (K53R, R158Q, M165V, A260V, H280Y, I435V, and V463M) showed significantly higher intrinsic clearance (CLint; Vmax/Km) values than the wild-type proteins (P<0.05)"" Table 1 shows rs1968919352 is 158A>G, K53R";Allele G is associated with increased clearance of efavirenz as compared to allele A.
EFAVIRENZ;CYP2B6;rs1282926098;T;Associated  with  increased clearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (K53R, R158Q, M165V, A260V, H280Y, I435V, and V463M) showed significantly higher intrinsic clearance (CLint; Vmax/Km) values than the wild-type proteins (P<0.05)"" Table 1 shows rs1282926098 is 779C>T, A260V";Allele T is associated with increased clearance of efavirenz as compared to allele C.
R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*4;*4;Associated  with  increased formation of  ➔ R-EDDP, S-EDDP;Metabolism/PK;"""CYP2B6.4>CYP2B6.1"" "" CYP2B6.4 showed the highest activity, which was; 2-fold greater than wild-type CYP2B6.1""";CYP2B6 *4 is associated with increased formation of R-EDDP and S-EDDP as compared to CYP2B6 *1.
R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*17, CYP2B6*18, CYP2B6*19, CYP2B6*26;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;Associated  with  decreasedformation of  ➔ R-EDDP, S-EDDP;Metabolism/PK;"""CYP2B6.4>CYP2B6.1?CYP2B6.5?CYP2B6.17>CYP2B6.6?CYP2B6.7?CYP2B6.9?CYP2B6.19?C; YP2B6.26>>CYP2B6.16?CYP2B6.18"". ""CYP2B6.16 and CYP2B6.18 were essentially catalytically inactive""";CYP2B6 *5+ *17 + *6+ *7 + *9+ *19 + *26 + *18 is associated with decreased formation of R-EDDP and S-EDDP as compared to CYP2B6 *1.
;CYP2B6;rs70950385;CA/CA;Associated  with  decreased activity  of CYP2B6 ➔ ;Other;"""The rs70950385 (AG>CA) variant, predicted to create a microRNA binding site for miR-1275, was associated with 33% decreased CYP2B6 activity among normal metabolizers (AG/AG vs. CA/CA [p<0.05]). In vitro luciferase assays were used to confirm that the CA on the variant allele created a microRNA binding site causing a 11.3% decrease in activity compared to the AG allele when treated with miR-1275 (p=0.0035).""";Genotype CA/CA is associated with decreased activity of CYP2B6 as compared to genotype AG/AG.
EFAVIRENZ;CYP2B6;rs1969136524;C;Associated  with  decreasedclearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (Ile84Leu, Arg109Trp, Arg120Cys, Arg120Leu, Arg126Gln, Asp266Ala, and Ile486Phe) showed significantly lower CLint values (P<0.05)."" Table 1 shows rs1969136524 is 250A>C, I84L";Allele C is associated with decreased clearance of efavirenz as compared to allele A.
EFAVIRENZ;CYP2B6;rs772413158;A;Associated  with  decreasedclearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (Ile84Leu, Arg109Trp, Arg120Cys, Arg120Leu, Arg126Gln, Asp266Ala, and Ile486Phe) showed significantly lower CLint values (P<0.05)."" Table 1 shows rs772413158 is 377G>A, R126Q";Allele A is associated with decreased clearance of efavirenz as compared to allele G.
EFAVIRENZ;CYP2B6;rs752695347;T;Associated  with  decreasedclearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (Ile84Leu, Arg109Trp, Arg120Cys, Arg120Leu, Arg126Gln, Asp266Ala, and Ile486Phe) showed significantly lower CLint values (P<0.05)."" Table 1 shows rs752695347 is 358C>T, R120C";Allele T is associated with decreased clearance of efavirenz as compared to allele C.
EFAVIRENZ;CYP2B6;rs553968231;T;Associated  with  decreasedclearance of  ➔ EFAVIRENZ;Metabolism/PK;"""The kinetic parameters of wild-type CYP2B6 and 23 variants were determined in terms of the efavirenz 8-hydroxylation activity (; Table 4)"" ""seven variants (Ile84Leu, Arg109Trp, Arg120Cys, Arg120Leu, Arg126Gln, Asp266Ala, and Ile486Phe) showed significantly lower CLint values (P<0.05)."" Table 1 shows rs553968231 is 359G>T, R120L";Allele T is associated with decreased clearance of efavirenz as compared to allele G.
;CYP1A2;rs762551;A;Associated  with  increased  activity  of CYP1A2 ➔ ;;in smokers. This variant is called CYP1A2*1F.;Allele A is associated with increased activity of CYP1A2.
;CYP1A2;rs35694136;del;Associated  with  decreased activity  of CYP1A2 ➔ ;;in smokers. This variant is also called CYP1A2*1D.;Allele del is associated with decreased activity of CYP1A2.
DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*11;*11;Associated  with  decreasedclearance of  ➔ DACARBAZINE;Metabolism/PK;"In vitro study. The intrinsic clearance was measured as catalytic efficiencies. CYP1A2 was transitioned into PharmVar 12/2024. See ""Change log"" document on the top of the CYP1A2 PharmVar page (https://www.pharmvar.org/gene/CYP1A2). PharmGKB uses PharmVar core alleles. CYP1A2*1A is mapped under the *1 core allele.";CYP1A2 *11 is associated with decreased clearance of dacarbazine as compared to CYP1A2 *1.
;CYP1A2;rs762551;AA + AC;Associated  with  increased transcription of CYP1A2 ➔ ;Metabolism/PK;"but only in smokers. ""Significant contribution of ??163C?>?A to enhanced CYP1A2 inducibility was confirmed by an increase in CYP1A2 mRNA expression in smoker ??163A carriers. "" ""However, we first demonstrated that CYP1A2 mRNA expression rather than CYP1A2 genetic variability was associated with olanzapine concentration in patients."" ""Second, due to low frequency of CYP1A2*1F allele (0.4%) in the patients involved in the present study, the effect of CYP1A2*1F on CYP1A2 function in olanzapine metabolism was not assessed.""";Genotypes AA + AC is associated with increased transcription of CYP1A2 as compared to genotype CC.
DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*3;*3;Associated  with  decreasedclearance of  ➔ DACARBAZINE;Metabolism/PK;"In vitro study. The intrinsic clearance was measured as catalytic efficiencies. CYP1A2 was transitioned into PharmVar 12/2024. See ""Change log"" document on the top of the CYP1A2 PharmVar page (https://www.pharmvar.org/gene/CYP1A2). PharmGKB uses PharmVar core alleles. CYP1A2*1A (as included in the article) is mapped under the *1 core allele.";CYP1A2 *3 is associated with decreased clearance of dacarbazine as compared to CYP1A2 *1.
;CYP2A6;rs8192720;AA + AG;Associated  with  increased  expression of CYP2A6 ➔ ;;;Genotypes AA + AG are associated with increased expression of CYP2A6 in human liver samples.
;CYP2A6;rs8192725;AG + GG;Associated  with  increased  expression of CYP2A6 ➔ ;;mRNA levels, but not protein levels reached statistical significance.;Genotypes AG + GG are associated with increased expression of CYP2A6 in human liver samples.
;CYP2A6;rs28399433;AC + CC;Associated  with  decreased expression of CYP2A6 ➔ ;;Please note this variant was described as position -48 T>G in the TATA box of the cyp2a6 promoter.;Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.
;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;Associated  with  decreased expression of CYP2A6 ➔ ;;Paper originally identified the *4B allele. This was reassigned as *4 following CYP2A6's release in PharmVar.;CYP2A6 *4/*9 is associated with decreased expression of CYP2A6.
;CYP2B6;CYP2B6*1, CYP2B6*27;*27;Associated  with  decreased expression of CYP2B6 ➔ ;;An association with significantly decreased enzyme activity was also detected, with a significant reduction by more than 85% of enzyme activity as compared to CYP2B6*1. This is more pronounced than that observed for *6 (70% reduction). A patient with the *6/*27 genotype was noted to either have had a dose reduction or stopped therapy.;CYP2B6 *27 is associated with decreased expression of CYP2B6 as compared to CYP2B6 *1.
COUMARIN;CYP2A6;rs28399454;T;Associated  with  decreasedmetabolism of  ➔ COUMARIN;Metabolism/PK;rs28399454 is the defining variant of the CYP2A6*17 allele. Variant referred to as *17 in the paper and mapped to rs28399454 by PharmGKB.;Allele T is associated with decreased metabolism of coumarin as compared to allele C.
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4;*1/*4;Associated  with  decreasedclearance of  ➔ COUMARIN;Metabolism/PK;;CYP2A6 *1/*4 is associated with decreased clearance of coumarin as compared to CYP2A6 *1/*1.
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*9;*1/*9;Associated  with  decreasedclearance of  ➔ COUMARIN;Metabolism/PK;;CYP2A6 *1/*9 is associated with decreased clearance of coumarin as compared to CYP2A6 *1/*1.
;CYP2A6;CYP2A6*46;*46;Associated  with  increased  expression of CYP2A6 ➔ ;;Please note that this variant was described as a cyp2a6 gene conversion in the 3' UTR, and was not specifically described as *46.;CYP2A6 *46 is associated with increased expression of CYP2A6 in human liver samples.
;CYP2A6;CYP2A6*1, CYP2A6*4;*4;Associated  with  decreased expression of CYP2A6 ➔ ;;Compared to all *4 noncarriers. Please note, this allele was described in this study as *4, a cyp2a6 gene deletion.;CYP2A6 *4 is associated with decreased expression of CYP2A6 in human liver samples.
;CYP2A6;CYP2A6*46;*46;Associated  with  increased transcription of CYP2A6 ➔ ;;Compared to constructs with cyp2a6*1A or cyp2a7 3' UTR regions. mRNA stability was also increased compared to *1A. Defined in this paper as CYP2A6*1B, differing by two nucleotides (1695G>A and 1698A>C) from the cyp2a7 3'UTR . This allele has been subsequently reassigned as *46 by PharmVar.;CYP2A6 *46 is associated with increased transcription of CYP2A6.
;CYP2B6;rs3745274;TT;Associated  with  decreased expression of CYP2B6 ➔ ;Other;Liver samples with the TT genotype had reduced mRNA expression of CYP2B6. The T allele of rs3745274 is part of the CYP2B6*6 haplotype.;Genotype TT is associated with decreased expression of CYP2B6 as compared to genotypes GG + GT.
PROPOFOL;CYP2B6;rs553968231;T;Associated  with  decreasedclearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs553968231 is 359G>T, R120L";Allele T is associated with decreased clearance of propofol as compared to allele G.
PROPOFOL;CYP2B6;rs1969376664;T;Associated  with  decreasedclearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs1969376664 is 1456A>T, I486F";Allele T is associated with decreased clearance of propofol as compared to allele A.
PROPOFOL;CYP2B6;rs773494867;C;Associated  with  decreasedclearance of  ➔ PROPOFOL;Metabolism/PK;"""We determined the kinetic parameters regarding the propofol 4-hydroxylation activity of wild-type CYP2B6 and 23 variants (; Table 5)."" ""Furthermore, the CLint of A260V and V463M was significantly higher than that of the wild-type protein (P<0.05), whereas that of seven variants (T67M, I84L, R109W, R120C, R120L, D266A, and I486F) was significantly lower (P<0.05). "" Table 1 shows rs773494867 is 797A>C, D266A";Allele C is associated with decreased clearance of propofol as compared to allele A.
;CYP2A6;CYP2A6*46;*46;Associated  with  increased  expression of CYP2A6 ➔ ;;Compared to no *1B alleles. Higher mRNA and protein expression correlated with increased activity against coumarin. Defined in this paper as CYP2A6*1B, differing by two nucleotides (1695G>A and 1698A>C) from the cyp2a7 3'UTR . This allele has been subsequently reassigned as *46 by PharmVar.;CYP2A6 *46 is associated with increased expression of CYP2A6.
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*9, CYP2C19*10, CYP2C19*16, CYP2C19*19;*8 + *9 + *10 + *16 + *19;Associated  with  decreasedclearance of  ➔ 3-CYANO-7-ETHOXYCOUMARIN;Metabolism/PK;;CYP2C19 *8 + *9 + *10 + *16 + *19 are associated with decreased clearance of 3-cyano-7-ethoxycoumarin as compared to CYP2C19 *1.
NEBIVOLOL;CYP2C19;CYP2C19*1, CYP2C19*6, CYP2C19*18, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*30 + *31 + *32 + *33 + *6 + *18;Associated  with  decreasedclearance of  ➔ NEBIVOLOL;Metabolism/PK;Nebivolol 4-hydroxylation in insect microsomes. No information about cDNA reference. Variant constructs are single SNP constructs. Intrinsic clearance is Vmax/Km. Relative clearance for R73C (*30) is 14.42%,  H78Y (*31) is 21.99%, H99R (*32) is 42.65%, and D188N (*33) is 28.92% compared to *1 (no variants). *6 (R132Q) 0.94% and *18 (R329H) 34.19% of *1 (no variants in construct). The construct harboring I331V which is a *1 suballele (*1B) has a clearance of 51.93 of *1.;CYP2C19 *30 + *31 + *32 + *33 + *6 + *18 are associated with decreased clearance of nebivolol in Sf21 insect cells as compared to CYP2C19 *1.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;Associated  with  decreasedclearance of  ➔ MEPHENYTOIN;Metabolism/PK;The association is reported in comparison to *1B.;CYP2C19 *10 + *14 + *19 + *25 + *26 are associated with decreased clearance of mephenytoin in cos-7 cells as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*6;*6;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 6.89% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *6 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
FLUOXETINE;CYP2C19;rs550527959;T;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Caution: The variant might be together with rs4244285. Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. The article names the construct *2g(D360V), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for D360V is 30.24% compared to *1 (no variants).;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.
METHADONE;CYP2C19;rs1463550071;T;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for N403I was 43.56% of *1;Allele T is associated with decreased clearance of methadone as compared to allele A.
FLUOXETINE;CYP2C19;rs200346442;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R124Q is 9.75% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
FLUOXETINE;CYP2C19;rs200150287;G;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R125G is 17.31% compared to *1 (no variants).;Allele G is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.
FLUOXETINE;CYP2C19;rs118203756;C;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for G91R is 77.77% compared to *1 (no variants).;Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;Associated  with  increased sensitivity to ➔ FLUVOXAMINE, OMEPRAZOLE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *15 is associated with increased sensitivity to fluvoxamine and omeprazole as compared to CYP2C19 *1.
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;Associated  with  increased sensitivity to ➔ FLUVOXAMINE, OMEPRAZOLE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *18 is associated with increased sensitivity to fluvoxamine and omeprazole as compared to CYP2C19 *1.
CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;Associated  with  decreasedsensitivity to ➔ CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *18 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole and ticlopidine as compared to CYP2C19 *1.
FLUOXETINE;CYP2C19;rs778258371;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Caution: The variant might be together with rs4244285. Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. The article names the construct *2E(M271I), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for M271I is 32.38% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
CELECOXIB;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Associated  with  increased sensitivity to ➔ CELECOXIB;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *19 is associated with increased sensitivity to celecoxib as compared to CYP2C19 *1.
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;Associated  with  decreasedsensitivity to ➔ CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *16 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and ticlopidine as compared to CYP2C19 *1.
FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Associated  with  decreasedsensitivity to ➔ FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *19 is associated with decreased sensitivity to fluoxetine, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine and tranylcypromine as compared to CYP2C19 *1.
;CYP2C19;CYP2C19*1, CYP2C19*16;*16;Associated  with  decreasedformation of CYP2C19 ➔ ;Other;Relative expression levels of CYP2C19 holoprotein by reduced CO difference spectra were reduced for CYP2C19*16.;CYP2C19 *16 is associated with decreased formation of CYP2C19 in yeast microsomes as compared to CYP2C19 *1.
FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*11;*11;Associated  with  increased sensitivity to ➔ FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *11 is associated with increased sensitivity to fluconazole, fluvoxamine and sertraline as compared to CYP2C19 *1.
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Associated  with  decreasedsensitivity to ➔ FLUOXETINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *10 is associated with decreased sensitivity to fluoxetine as compared to CYP2C19 *1.
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;Associated  with  decreasedsensitivity to ➔ CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *9 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and troglitazone as compared to CYP2C19 *1.
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;Associated  with  increased sensitivity to ➔ FLUCONAZOLE, FLUVOXAMINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *9 is associated with increased sensitivity to fluconazole and fluvoxamine as compared to CYP2C19 *1.
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Associated  with  decreasedclearance of  ➔ OMEPRAZOLE;Metabolism/PK;"The corresponding variants were recreated by site-directed mutagenesis of CYP2C19 cDNA which was integrated into plasmids and transfected into DH5 alpha ""E.coli"" cells. CYP2C19 protein variants were eluted and tested for their effect on enzymatic activity.";CYP2C19 *10 is associated with decreased clearance of omeprazole as compared to CYP2C19 *1.
FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;Associated  with  decreasedsensitivity to ➔ FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *8 is associated with decreased sensitivity to fluconazole, fluoxetine, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine, tranylcypromine and troglitazone as compared to CYP2C19 *1.
FLUOXETINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;Associated  with  decreasedsensitivity to ➔ FLUOXETINE, TRANYLCYPROMINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *15 is associated with decreased sensitivity to fluoxetine and tranylcypromine as compared to CYP2C19 *1.
;CYP1A2;rs2069514;A;Associated  with  decreased activity  of CYP1A2 ➔ ;;in smokers from univariate analysis.p=0.496 in multivariate analysis. This variant is called CYP1A2*1C.;Allele A is associated with decreased activity of CYP1A2.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;Associated  with  decreasedclearance of  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;"Healthy volunteers (113 Vietnamese and 94 Korean) received a single 20 mg dose of omeprazole after overnight fasting. Blood samples were taken 3 hr after administration of omeprazole. Samples from volunteers with 1) 1/*2 or *1/*3 genotypes and 2) a metabolic ratio (MR) of omeprazole/ 5-hydroxyomeprazole that was higher than the average MR for *2/*2 or *3/*3 underwent direct DNA sequencing of CYP2C19 to search for novel variants responsible for the high MR. The corresponding variants were recreated by site-directed mutagenesis of CYP2C19 cDNA which was integrated into plasmids and transfected into DH5 alpha ""E.coli"" cells. CYP2C19 protein variants were eluted and tested for their effect on enzymatic activity.*Note: D256N has been designated CYP2C19*26 in the manuscript.";CYP2C19 *26 is associated with decreased clearance of mephenytoin and omeprazole as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*23;*23;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 31.4% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *23 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *23 + *25 + *26;Associated  with  decreasedclearance of  ➔ CLOPIDOGREL;Metabolism/PK;Please note the article separated *1A and *1B. All parameters were compared to CYP2C19*1B. The clearance of *1A was 115% compared to *1B.;CYP2C19 *10 + *14 + *19 + *23 + *25 + *26 are associated with decreased clearance of clopidogrel in cos-7 cell as compared to CYP2C19 *1.
FLUOXETINE;CYP2C19;rs370803989;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for D188N = *33 is 46.56% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
FLUOXETINE;CYP2C19;rs145328984;T;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R73C = *30 is 21.28% compared to *1 (no variants).;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.
FLUOXETINE;CYP2C19;rs763625282;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay, the article names the variant *3C (M136K). However it is not clear if the *3 signature SNP is included but the *3 signature SNP by itself results in not detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for M136K is 63.65% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.
FLUOXETINE;CYP2C19;rs147255955;T;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for L16F is 74.14% compared to *1 (no variants).;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.
FLUOXETINE;CYP2C19;rs3758581;G;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for I331V is 45.5% compared to *1 (no variants).;Allele G is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.
FLUOXETINE;CYP2C19;rs559628884;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for N277K is 63.06% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.
FLUOXETINE;CYP2C19;rs764137538;T;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R261W is 9.56% compared to *1 (no variants).;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.
FLUOXETINE;CYP2C19;rs1349931378;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for S303N is 39.59% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*33;*33;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 21.25% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *33 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
FLUOXETINE;CYP2C19;rs1463550071;T;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for N403I is 33.25% compared to *1 (no variants).;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.
METHADONE;CYP2C19;rs778258371;A;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other then the protein change (name of the variant) or cDNA *1 reference of wt.Relative intrinsic clearance for M271I was 20.23% of *1;Allele A is associated with decreased clearance of methadone as compared to allele G.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 24.59% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *18 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
METHADONE;CYP2C19;rs72552267;A;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for R132Q was 4.64% of *1;Allele A is associated with decreased clearance of methadone as compared to allele G.
METHADONE;CYP2C19;rs118203756;C;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for G91R was 50.33% of *1;Allele C is associated with decreased clearance of methadone as compared to allele G.
METHADONE;CYP2C19;rs764137538;T;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for R261W was 4.17% of *1;Allele T is associated with decreased clearance of methadone as compared to allele C.
METHADONE;CYP2C19;rs550527959;T;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for D360V was 21.2% of *1;Allele T is associated with decreased clearance of methadone as compared to allele A.
METHADONE;CYP2C19;rs1349931378;A;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for S303N was 32.05% of *1;Allele A is associated with decreased clearance of methadone as compared to allele G.
FLUOXETINE;CYP2C19;rs770829708;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Caution: The variant might be together with rs4244285. Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. The article names the construct *2F(D341N), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for D341N is 14.01% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
METHADONE;CYP2C19;rs1267723490;C;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for I327T was 20.95% of *1;Allele C is associated with decreased clearance of methadone as compared to allele T.
FLUOXETINE;CYP2C19;rs1267723490;C;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for I327N is 24.85% compared to *1 (no variants).;Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.
DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*2C;*2C;Associated  with  decreasedclearance of  ➔ DACARBAZINE;Metabolism/PK;In vitro study. The intrinsic clearance was measured as catalytic efficiencies.;CYP1A1 *2C is associated with decreased clearance of dacarbazine as compared to CYP1A1 *1.
DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*4;*4;Associated  with  decreasedclearance of  ➔ DACARBAZINE;Metabolism/PK;In vitro study. The intrinsic clearance was measured as catalytic efficiencies.;CYP1A1 *4 is associated with decreased clearance of dacarbazine as compared to CYP1A1 *1.
;CHD2;rs28458425;TT;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype TT is associated with increased transcription of ABCB1 as compared to genotypes AA + AT.
OXAZEPAM;;rs1976391;G;Associated  with  decreasedglucuronidation of  ➔ OXAZEPAM;Other;;Allele G is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele A.
;;rs247616;T;Associated  with  decreased expression of CETP ➔ ;Other;;Allele T is associated with decreased expression of CETP in HepG2 cells as compared to allele C.
;ABCA1;rs2515629;G;Associated  with  increased  expression of ABCA1 ➔ ;;;Allele G is associated with increased expression of ABCA1 in HapMap cells.
;ABCA1;rs4149297;G;Associated  with  increased  expression of ABCA1 ➔ ;;;Allele G is associated with increased expression of ABCA1 in HapMap cells.
;ABCA1;rs2472507;C;Associated  with  increased  expression of ABCA1 ➔ ;;;Allele C is associated with increased expression of ABCA1 in HapMap cells.
;ABCA12;rs10182702;C;Associated  with  increased  expression of ABCA12 ➔ ;;;Allele C is associated with increased expression of ABCA12 in HapMap cells.
;ABCA12;rs2888327;A;Associated  with  increased  expression of ABCA12 ➔ ;;;Allele A is associated with increased expression of ABCA12 in HapMap cells.
;ABCA8;rs11656365;T;Associated  with  decreased expression of ABCA8 ➔ ;;;Allele T is associated with decreased expression of ABCA8 in HapMap cells.
;ABCB1;rs1045642;AG + GG;Associated  with  increased  activity  of ABCB1 ➔ ;Metabolism/PK;Where activity level was measured by a Rhodamine 123 efflux assay. Please note alleles have been complemented to the plus chromosomal strand.;Genotypes AG + GG are associated with increased activity of ABCB1 in peripheral blood mononuclear cells as compared to genotype AA.
;;rs1976391;G;Associated  with  decreasedconcentrations of UGT1A1 ➔ ;Other;Significantly lower abundance of UGT1A1 protein was observed in human liver microsomes from individuals with the variant allele. Please note: the authors use the old rsID, rs111741722 (c.2950A>G) and associate it with UGT1A1, even though it may be associated with other UGT1A proteins. The association between age and protein abundance diminished in human liver microsome samples in cells carrying hetero- or homozygous variant alleles.;Allele G is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele A.
;ABCB1;rs1128503;AG + GG;Associated  with  increased  activity  of ABCB1 ➔ ;Metabolism/PK;Where activity level was measured by a Rhodamine 123 efflux assay. Please note alleles have been complemented to the plus chromosomal strand.;Genotypes AG + GG are associated with increased activity of ABCB1 in peripheral blood mononuclear cells as compared to genotype AA.
;ABCB1;rs1045642;AA;Associated  with  decreased expression of ABCB1 ➔ ;Other;When the SNP was analyzed as part of a haplotype with two other SNPS ( rs1128503 AA and rs203582 AA) the homozygous haplotype at all three SNPs was significantly associated with decreased expression of ABCB1 as compared to all other haplotypes.;Genotype AA is associated with decreased expression of ABCB1 as compared to genotypes AG + GG.
;ABCB1;rs1128503;AA;Associated  with  decreased expression of ABCB1 ➔ ;Other;When the SNP was analyzed as part of a haplotype with two other SNPS ( rs203582 AA and rs1128503 AA) the homozygous haplotype at all three SNPs was significantly associated with decreased expression of ABCB1 as compared to all other haplotypes.;Genotype AA is associated with decreased expression of ABCB1 as compared to genotypes AG + GG.
;ABCB1;rs2032582;AA;Associated  with  decreased expression of ABCB1 ➔ ;Other;When the SNP was analyzed as part of a haplotype with two other SNPS ( rs1128503 AA and rs1128503 AA) the homozygous haplotype at all three SNPs was significantly associated with decreased expression of ABCB1 as compared to all other haplotypes.;Genotype AA is associated with decreased expression of ABCB1 as compared to genotypes AC + CC.
;ABCB9;rs4148866;T;Associated  with  increased  expression of ABCB9 ➔ ;;;Allele T is associated with increased expression of ABCB9 in HapMap cells.
;ABCC10;rs2185631;A;Associated  with  decreased expression of ABCC10 ➔ ;;;Allele A is associated with decreased expression of ABCC10 in HapMap cells.
DOCETAXEL;ABCC10;rs2125739;TT;Associated  with  increased sensitivity to ➔ DOCETAXEL;Toxicity;;Genotype TT is associated with increased sensitivity to docetaxel in 18 NSCLC cell lines as compared to genotypes CC + CT.
;ABCC10;rs9394952;G;Associated  with  decreased expression of ABCC10 ➔ ;;;Allele G is associated with decreased expression of ABCC10 in HapMap cells.
;ABCC10;rs2487663;A;Associated  with  decreased expression of ABCC10 ➔ ;;;Allele A is associated with decreased expression of ABCC10 in HapMap cells.
;ABCC11;rs11861379;C;Associated  with  increased transcription of ABCC11 ➔ ;Metabolism/PK;;Allele C is associated with increased transcription of ABCC11 in human liver samples as compared to allele T.
;ABCB1;rs2032582;AC + CC;Associated  with  increased  activity  of ABCB1 ➔ ;Metabolism/PK;Where activity level was measured by a Rhodamine 123 efflux assay. Please note alleles have been complemented to the plus chromosomal strand.;Genotypes AC + CC are associated with increased activity of ABCB1 in peripheral blood mononuclear cells as compared to genotype AA.
;ABCC2;rs717620;T;Associated  with  increased transcription of ABCC2 ➔ ;;The ABCC2 -24C>T SNP, when introduced both as a single variant and as part of the -24C>T/-1019A>G/-1549G>A haplotype, showed a significant 35% increase in reporter activity compared with the reference ABCC2 promoter sequence (P<0.0001).;Allele T is associated with increased transcription of ABCC2 HepG2 liver cell line.
;;rs6822259;CC;Associated  with  increased  expression of UGT2B17 ➔ ;;;Genotype CC is associated with increased expression of UGT2B17 in normal breast tissue.
;;rs729559;GG;Associated  with  increased  expression of CYP2D6 ➔ ;Metabolism/PK;"""Following the conditional analysis, five SNPs, including the cis-variants rs1807493 and rs1062753, and the trans-variants rs4073010, rs729559, and rs80274432, emerged as independent variants significantly correlated with hepatic CYP2D6 protein expressions. Notably, four of these SNPs, except for rs80274432, also exhibited a significant association with CYP2D6 activities in human livers, suggesting their potential as novel and independent cis- and trans-variants regulating CYP2D6.""";Genotype GG is associated with increased expression of CYP2D6 in human liver s9 fractions as compared to genotypes AA + AG.
;;rs6539870;GG;Associated  with  increased  expression of IL1B ➔ ;Other;;Genotype GG is associated with increased expression of IL1B as compared to genotypes AA + AG.
;;rs478437;CC;Associated  with  increased  expression of USP7 ➔ ;Other;;Genotype CC is associated with increased expression of USP7 in lymphoblastoid cell lines as compared to genotypes CT + TT.
;;rs9999111;C;Associated  with  decreased expression of ABCG2 ➔ ;Other;SNPs in regulatory regions of the ABCG2 locus contribution to the variation in ABCG2 expression was assayed with a luciferase assay in HepG2 and HEK293 cells (in-vitro) and in a hydrodynamic tail vein assay (in-vivo luciferase assay).;Allele C is associated with decreased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele A.
;;rs149713212;A;Associated  with  decreased expression of ABCG2 ➔ ;Other;SNPs in regulatory regions of the ABCG2 locus contribution to the variation in ABCG2 expression was assayed with a luciferase assay in HepG2 and HEK293 cells (in-vitro) and in a hydrodynamic tail vein assay (in-vivo luciferase assay).;Allele A is associated with decreased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele G.
;;rs12508471;G;Associated  with  decreased expression of ABCG2 ➔ ;Other;SNPs in regulatory regions of the ABCG2 locus contribution to the variation in ABCG2 expression was assayed with a luciferase assay in HepG2 and HEK293 cells (in-vitro) and in a hydrodynamic tail vein assay (in-vivo luciferase assay).;Allele G is associated with decreased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele A.
ENDOXIFEN;;rs4386686;C;Associated  with  increased sensitivity to ➔ ENDOXIFEN;Toxicity;Sensitivity to endoxifen was assayed by dose dependent growth inhibition in vitro of cells administered increasing doses of endoxifen. The authors reported that 141 unique associations between SNPs, miRNA, mRNA expression that were significantly related to endoxifen sensitivity. Only rs4386686 was explicitly described in the paper.;Allele C is associated with increased sensitivity to endoxifen HapMal LCLs as compared to allele G.
;;rs4073010;TT;Associated  with  increased  expression of CYP2D6 ➔ ;Metabolism/PK;"""Following the conditional analysis, five SNPs, including the cis-variants rs1807493 and rs1062753, and the trans-variants rs4073010, rs729559, and rs80274432, emerged as independent variants significantly correlated with hepatic CYP2D6 protein expressions. Notably, four of these SNPs, except for rs80274432, also exhibited a significant association with CYP2D6 activities in human livers, suggesting their potential as novel and independent cis- and trans-variants regulating CYP2D6.""";Genotype TT is associated with increased expression of CYP2D6 in human liver s9 fractions as compared to genotypes CC + CT.
;;rs35283911;G;Associated  with  increased  expression of HP ➔ ;Other;"independent of HP CNV status. ""rs35283911 [G] was associated with higher HP gene expression (median RNA count G/G, 94.5; G/-, 68.8; and -/-, 25.7; P = 0.033).""";Allele G is associated with increased expression of HP as compared to allele del.
;;rs4386686;C;Associated  with  increased  expression of MIRLET7I ➔ ;Toxicity, Other;Increased MIRLET71 expression is associated with increased sensitivity to endoxifen (as assayed by growth inhibition in vitro of cells administered increasing doses of endoxifen).  The authors reported that 141 unique associations between SNPs, miRNA, mRNA expression that were significantly related to endoxifen sensitivity.  Only rs4386686 was explicitly described in the paper.;Allele C is associated with increased expression of MIRLET7I in HapMap LCLs as compared to allele G.
TAMOXIFEN;;rs478437;CC;Associated  with  increased sensitivity to ➔ TAMOXIFEN;Other;Cell lines with the CC genotype had a smaller percentage of viable cells remaining after a 10 uM endoxifen treatment, as compared to cell lines with the CT or TT genotype. This indicates higher cellular sensitivity. Endoxifen is a metabolite of tamoxifen.;Genotype CC is associated with increased sensitivity to tamoxifen in lymphoblastoid cell lines as compared to genotypes CT + TT.
;;rs2784917;AA;Associated  with  increased  expression of WNT5B ➔ ;Other;;Genotype AA is associated with increased expression of WNT5B as compared to genotypes AG + GG.
;;rs9999111;C;Associated  with  decreased expression of ABCG2 ➔ ;Other;;Allele C is associated with decreased expression of ABCG2 in human umbilical cord and T cells as compared to allele A.
;;rs10242455;AG;Associated  with  increased transcription of CYP3A5 ➔ ;Metabolism/PK;This SNP is in complete linkage with rs776746, the causative SNP of the well-investigated CYP3A5*3 splice variant.;Genotype AG is associated with increased transcription of CYP3A5 in human liver samples as compared to genotype AA.
;;rs446112;AA;Associated  with  increased  expression of AGPAT2 ➔ ;Other;;Genotype AA is associated with increased expression of AGPAT2 as compared to genotypes AG + GG.
;;rs10871454;C;Associated  with  increased transcription of VKORC1 ➔ ;Metabolism/PK;;Allele C is associated with increased transcription of VKORC1 in human liver samples as compared to allele T.
;;rs2487030;T;Associated  with  increased  expression of ABCA1 ➔ ;;;Allele T is associated with increased expression of ABCA1 in HapMap cells.
;;rs4355801;G;Associated  with  increased  expression of TNFRSF11B ➔ ;;;Allele G is associated with increased expression of TNFRSF11B lymphoblast cell lines.
;;rs4285917;G;Associated  with  decreased expression of ABCD2 ➔ ;;;Allele G is associated with decreased expression of ABCD2 in HapMap cells.
;;rs12195350;G;Associated  with  decreased expression of ABCC10 ➔ ;;;Allele G is associated with decreased expression of ABCC10 in HapMap cells.
;;rs4898437;C;Associated  with  increased  expression of ABCD1 ➔ ;;;Allele C is associated with increased expression of ABCD1 in HapMap cells.
;;rs4386686;C;Associated  with  decreased expression of TRAF1 ➔ ;Toxicity, Other;Decreased TRAF1 expression is associated with decreased sensitivity to endoxifen (as assayed by growth inhibition in vitro of cells administered increasing doses of endoxifen). The study confirmed this finding and reports that TRAF1 expression is also correlated with decreased sensitivity to endoxifen in 44 breast cancer cell lines. The authors reported that 141 unique associations between SNPs, miRNA, mRNA expression that were significantly related to endoxifen sensitivity.  Only rs4386686 was explicitly described in the paper.;Allele C is associated with decreased expression of TRAF1 in HapMap LCLs as compared to allele G.
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;Associated  with  increased clearance of  ➔ CLOPIDOGREL;Metabolism/PK;The association is reported in comparison to *1B. Please note the article separates *1A and *1B. While *28 has a clearance 141% of *1B, *1A has a clearance of 115% of *1B.;CYP2C19 *28 is associated with increased clearance of clopidogrel in cos-7 cells as compared to CYP2C19 *1.
;ABCC4;rs11568658;A;Associated  with  increased catalytic  activity  of ABCC4 ➔ ;Metabolism/PK;"rs numbers listed in figure 1 legend. When assayed with taurocholic acid. Variant described as  ""G187W (rs11568658)"", minor alleles curated from gnomad.  ""We observed slightly increased activity of G187W with; reduced TCA retention (18.5%) and no change of E2; 17?G compared to MRP4-wildtype. Considering only a trend towards reduced cell surface expression, enhanced intrinsic activity may be suspected. """;Allele A is associated with increased catalytic activity of ABCC4 as compared to allele C.
MERCAPTOPURINE;ABCC4;rs3765534;TT;Associated  with  increased sensitivity to ➔ MERCAPTOPURINE;Toxicity, Metabolism/PK;"this was due to reduced cell surface expression of the TT variant transporter. Authors state ""cells expressing the variant MRP4 allele were less able to exclude 6-MP metabolites compared to the reference MRP4 allele"". When expressed in HEK cells the T variant did not ""impair the membrane localization of the reference MRP4 allele and suggests that the variant MRP4 allele is unlikely to have a dominant negative role and impair function of the MRP4 reference allele.""";Genotype TT is associated with increased sensitivity to mercaptopurine in NA18967 cells as compared to genotype CC.
;CACNA1S;rs1800559;T;Associated  with  increased  activity  of CACNA1S ➔ ;Other;Dysgenic myotubes expressing the 1086H allele (T) were more sensitive to voltage-stimulated calcium release as compared to the 1086R allele (C). Maximal L-channel calcium conductance was 33% lower in 1086H vs the 1086R allele.;Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.
CAFFEINE;CACNA1S;rs1800559;T;Associated  with  increased sensitivity to ➔ CAFFEINE;Other;Dysgenic myotubes expressing the 1086H allele (T) had higher resting calcium concentrations as compared to the 1086R allele (C), but demonstrated a decrease in calcium release when stimulated with caffeine, indicating lower sarcoplasmic reticulum stores of calcium.;Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.
HALOTHANE, ISOFLURANE;CACNA1S;rs772226819;A;Associated  with  increased sensitivity to ➔ HALOTHANE, ISOFLURANE;Other;The 174W construct (A allele) was more sensitive to triggers halothane, and isoflurane as compared to the 174R (G allele) construct in dysgenic myotubes. Dysgenic myotubes expressing the 174W construct also had higher resting calcium concentrations and a greater depletion of sarcoplasmic reticulum calcium concentrations as compared to the 174R construct. The 174W allele had no significant effect on excitation-contraction coupling, or L-type calcium currents.;Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.
;CBR3;rs8133052;A;Associated  with  decreased expression of CBR3 ➔ ;;;Allele A is associated with decreased expression of CBR3 in breast tissue.
;CBR3;rs1056892;A;Associated  with  increased  expression of CBR3 ➔ ;;;Allele A is associated with increased expression of CBR3 in breast tissue.
;CBS;rs915854;C;Associated  with  increased  expression of PKNOX1 ➔ ;Other;assumed minor allele from gnomAD is risk allele.;Allele C is associated with increased expression of PKNOX1 as compared to allele T.
;CD38;rs1130169;T;Associated  with  decreased expression of CD38 ➔ ;;TT has lower expression than CT, which has lower expression than CC.;Allele T is associated with decreased expression of CD38.
;CDA;rs3215400;C/del + del/del;Associated  with  increased  expression of CDA ➔ ;Other;compared to CC. In vitro assays with PBMCs from healthy volunteers.;Genotypes C/del + del/del are associated with increased expression of CDA in PBMCs.
;CDA;rs2072671;CC;Associated  with  increased  expression of CDA ➔ ;Other;;Genotype CC is associated with increased expression of CDA in PBMCs.
DEXAMETHASONE;BCL2L11;rs2241843;AA;Associated  with  increased sensitivity to ➔ DEXAMETHASONE;Toxicity;Cells exposed to dexamethasone with the AA genotype were overrepresented among sensitive lymphoblastic cell lines (LCLs) compared to those with intermediate or resistant phenotype. Please note that alleles have been complemented to the plus chromosomal strand.;Genotype AA is associated with increased sensitivity to dexamethasone in lymphoblastic cell lines as compared to genotypes AC + CC.
;CDA;rs532545;CC;Associated  with  decreased activity  of CDA ➔ ;Other;;Genotype CC is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes CT + TT.
;CDA;rs2072671;AA;Associated  with  decreased activity  of CDA ➔ ;Other;and in multiple linear regression analysis this was significantly associated with predicting CDA enzyme activity (p=0.009), along with gender.;Genotype AA is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes AC + CC.
;CDA;rs1048977;TT;Associated  with  increased  expression of CDA ➔ ;Other;;Genotype TT is associated with increased expression of CDA in PBMCs.
;CDA;rs602950;AA;Associated  with  decreased activity  of CDA ➔ ;Other;;Genotype AA is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes AG + GG.
;CDA;rs602950;GG;Associated  with  increased  expression of CDA ➔ ;Other;with gene expression levels AA < AG < GG.;Genotype GG is associated with increased expression of CDA in PBMCs.
;CDA;rs3215400;del/del;Associated  with  increased  expression of CDA ➔ ;;;Genotype del/del is associated with increased expression of CDA in CEPH cell lines.
PALBOCICLIB;CDKN2A;rs759922342;C;Associated  with  increased sensitivity to ➔ PALBOCICLIB;Efficacy;effect described for H142R which maps to rs759922342T>C.;Allele C is associated with increased sensitivity to palbociclib in Nalm6 cells as compared to allele T.
REMIMAZOLAM;CES1;rs71647871;T;Associated  with  decreasedmetabolism of  ➔ REMIMAZOLAM;Metabolism/PK;"""Consistent with our previous reports for other CES1 substrates,; remimazolam was efficiently hydrolyzed in WT CES1 at a rate of 31.30 ¤ 2.52; nmol/min/mg protein, while no appreciable hydrolysis was detected in L40Ter or Vector; groups. Significant impairments were observed in the E220G (VE220G=9.98 ¤ 0.50; nmol/min/mg protein, P=0.0177), Q169P (VQ169P=7.22 ¤ 0.29 nmol/min/mg protein,; P=0.0116), and G143E groups (VG143E=5.96 ¤ 0.05 nmol/min/mg protein, P=0.0097). In; contrast, S75N significantly increased the remimazolam deactivation rate to nearly two-; fold that of the WT CES1 group (VS75N=61.03¤ 2.84 nmol/min/mg protein, P=0.0228)."" ""Consistent with the results obtained from CES1 variants transfected cells, the; remimazolam deactivation rates in G143E carriers were significantly lower than those in; the non-carriers (Figure 7, G143E carriers: 7.51 ¤ 3.14 VS non-carriers: 13.88 ¤ 6.53; nmol/mg protein/min, P=0.0164).""";Allele T is associated with decreased metabolism of remimazolam as compared to allele C.
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs201065375;A;Associated  with  decreasedmetabolism of  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Metabolism/PK;The SNP abolished CES1 enzyme activity when assayed with enalapril, clopidogrel, sacubitril.;Allele A is associated with decreased metabolism of clopidogrel, enalapril and sacubitril in HEK cells as compared to allele G.
;CETP;rs708272;GG;Associated  with  increased  expression of CETP ➔ ;Other;Baseline concentrations of CETP were measured in a subset of the cohort.;Genotype GG is associated with increased expression of CETP in plasma as compared to genotype AA.
;CDA;rs532545;TT;Associated  with  increased  expression of CDA ➔ ;Other;with gene expression levels CC < CT < TT.;Genotype TT is associated with increased expression of CDA in PBMCs.
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;Associated  with  increased concentrations of  ➔ MERCAPTOPURINE;Toxicity, Metabolism/PK;Bone marrow concentrations of mercaptopurine and its metabolites (thioguanine nucleotides, TGN and 6-Methylmercaptopurine Nucleotides, MMPN) were significantly higher in mice deficient for ABCC4 (KO) mice vs WT. Double KO mice (ABCC4 and TPMT KO) also had significantly higher concentrations of mercaptopurine and metabolites vs WT.;ABCC4 deficiency is associated with increased concentrations of mercaptopurine in mice.
DEXAMETHASONE;BCL2L11;rs724710;CC;Associated  with  increased sensitivity to ➔ DEXAMETHASONE;Toxicity;Cells exposed to dexamethasone with the CC genotype were overrepresented among sensitive lymphoblastic cell lines (LCLs) compared to those with intermediate or resistant phenotype.;Genotype CC is associated with increased sensitivity to dexamethasone in lymphoblastic cell lines as compared to genotypes CT + TT.
;ARNT;rs2134688;GG;Associated  with  decreasedconcentrations of CYP3A4 ➔ ;Metabolism/PK;;Genotype GG is associated with decreased concentrations of CYP3A4 protein in human liver microsomes as compared to genotypes AA + AG.
;ABCC4;rs11568684;C;Associated  with  increased catalytic  activity  of ABCC4 ➔ ;Metabolism/PK;"rs numbers listed in figure 1 legend. When assayed with taurocholic acid. Variant described as  ""K293E (rs11568684)"", minor alleles curated from gnomad.  ""Our results suggest moderately increased transport; activity for L18I, K293E, and R531Q without changes in expression suggesting altered intrinsic activity. """;Allele C is associated with increased catalytic activity of ABCC4 as compared to allele T.
;ABCC4;rs4773866;T;Associated  with  increased  expression of ABCC4 ➔ ;;;Allele T is associated with increased expression of ABCC4 in HapMap cells.
;ABCC9;rs704212;T;Associated  with  increased  expression of ABCC9 ➔ ;Other;in liver samples from patients undergoing laparoscopic gastric bypass operation.;Allele T is associated with increased expression of ABCC9 as compared to allele C.
;ABCD1, BCAP31;rs17091297;C;Associated  with  increased  expression of ABCD1 ➔ ;;;Allele C is associated with increased expression of ABCD1 in HapMap cells.
;ABCD2;rs4284427;C;Associated  with  decreased expression of ABCD2 ➔ ;;;Allele C is associated with decreased expression of ABCD2 in HapMap cells.
;ABCG2;rs2725263;C;Associated  with  increased  expression of ABCG2 ➔ ;Other;SNPs in regulatory regions of the ABCG2 locus contribution to the variation in ABCG2 expression was assayed with a luciferase assay in HepG2 and HEK293 cells (in-vitro) and in a hydrodynamic tail vein assay (in-vivo luciferase assay).;Allele C is associated with increased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele A.
;ACE;rs1799752;del;Associated  with  increased enzyme  activity  of ACE ➔ ;;This effect was seen in both genders.;Allele del is associated with increased enzyme activity of ACE.
;ADCYAP1;rs304400;AA;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG.
LOSARTAN;AGTR1;rs12721226;A;Associated  with  decreasedaffinity to ➔ LOSARTAN;Other;;Allele A is associated with decreased affinity to losartan in COS-1 cells.
;ATP2B1;rs12817819;CT + TT;Associated  with  decreased expression of ATP2B1 ➔ ;;Patients had mild-to-moderate hypertension, and were randomized to receive hydrochlorothiazide or atenolol.  Please note that alleles have been complemented to the plus chromosomal strand.;Genotypes CT + TT are associated with decreased expression of ATP2B1 as compared to genotype CC.
DOXORUBICINOL;AKR1A1;rs2229540;G;Associated  with  decreasedformation of  ➔ DOXORUBICINOL;Metabolism/PK;"Authors studied N52S where 52N maps to the rs2229540 A allele and 52S is the rs2229540 G allele. Authors state ""No DOXol metabolite was observed using the tagged N52S; allelic variant.""";Allele G is associated with decreased formation of doxorubicinol as compared to allele A.
DAUNORUBICINOL;AKR1A1;rs6690497;C;Associated  with  decreasedformation of  ➔ DAUNORUBICINOL;Metabolism/PK;Authors studied E55D where 55D maps to the rs6690497 C allele and 55E is the rs6690497 G allele.;Allele C is associated with decreased formation of daunorubicinol as compared to allele G.
DAUNORUBICINOL;AKR1A1;rs2229540;G;Associated  with  decreasedformation of  ➔ DAUNORUBICINOL;Metabolism/PK;Authors studied N52S where 52N maps to the rs2229540 A allele and 52S is the rs2229540 G allele.;Allele G is associated with decreased formation of daunorubicinol as compared to allele A.
EXEMESTANE;AKR1C3;rs62621365;T;Associated  with  decreasedaffinity to ➔ EXEMESTANE;Metabolism/PK;Recombinant expressed variant had a greater Km and Vmax than wild type.;Allele T is associated with decreased affinity to exemestane in human liver cytosol as compared to allele C.
DOXORUBICIN;AKR1C3;rs62621365;T;Associated  with  decreasedclearance of  ➔ DOXORUBICIN;Metabolism/PK;Also described as R258C;Allele T is associated with decreased clearance of doxorubicin as compared to allele C.
DOXORUBICIN;AKR1C3;rs34186955;T;Associated  with  decreasedclearance of  ➔ DOXORUBICIN;Metabolism/PK;Also described as P180S;Allele T is associated with decreased clearance of doxorubicin as compared to allele C.
DOXORUBICIN;AKR1C3;rs28943579;A;Associated  with  decreasedclearance of  ➔ DOXORUBICIN;Metabolism/PK;Also described as C145Y;Allele A is associated with decreased clearance of doxorubicin as compared to allele G.
EXEMESTANE;AKR1C4;rs11253043;A;Associated  with  decreasedaffinity to ➔ EXEMESTANE;Metabolism/PK;Recombinant expressed variant had a greater Km and Vmax than wild type.;Allele A is associated with decreased affinity to exemestane in human liver cytosol as compared to allele G.
;ALDH1A2;rs12915901;AA + AG;Associated  with  decreased expression of ALDH1A2 ➔ ;Other;"in subchondral bone samples with attached cartilage were collected from 40 patients with primary HOA who had undergone a trapeziectomy. ""Among the 40 patients included in the tissue expression analysis, there were 4 cases of genotype AA, 15 cases of genotype AG and 21 cases of genotype GG. As shown in Figure 1, the mRNA expression of ALDH1A2 was 1.31-folds higher in patients with genotype GG than in the patients with genotype AA/AG (0.000617 ¤ 0.000231 vs. 0.000471 ¤ 0.000198, p = .04).""";Genotypes AA + AG is associated with decreased expression of ALDH1A2 as compared to allele G.
;AMPH;rs12701634;CC;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype CC is associated with increased transcription of ABCB1 as compared to genotypes CT + TT.
DOXORUBICINOL;AKR1A1;rs6690497;C;Associated  with  decreasedformation of  ➔ DOXORUBICINOL;Metabolism/PK;Authors studied E55D where 55D maps to the rs6690497 C allele and 55E is the rs6690497 G allele.;Allele C is associated with decreased formation of doxorubicinol as compared to allele G.
;DPYD;rs2297595;C;Associated  with  decreased activity  of DPYD ➔ ;Metabolism/PK;Study evaluated the baseline plasma 5,6-dihydrouracil/uracil ratio (UH2/U) as a marker of DPD activity in the context of DPYD genotypes in healthy individuals. When the joint effect of this variant and rs1801265 (*9A) were analyzed a significant association was observed between the two variants and the UH2/U ratio, with carriers of the C allele showing a negative association with the ratio. HOWEVER, the authors state that baseline UH2/U ratio is a poor predictor of decreased DPD activity (though they note that it may be predictive during fluorouracil administration, such during cancer treatment). Please note that alleles have been complemented to the plus chromosomal strand.;Allele C is associated with decreased activity of DPYD.
;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Associated  with  decreased expression of CYP2C19 ➔ ;Other;A mutation for CYP2C19*1C (991A > G) was introduced using pcDNA3.1/CYP2C19*1A as a template, resulting in pcDNA3.1/CYP2C19*1C (*1B and *1C is used interchangeably in the article). Mutations for CYP2C19*19 (991A>G and 151A>G) was successively introduced using pcDNA3.1/CYP2C19*1C as a template. All CYP2C19 plasmids were sequenced to confirm successful mutagenesis. The cDNAs of CYP2C19*1C, CYP2C19*19 were subsequently subcloned into the pGYR1 yeast expression vector and heterologously expressed in yeast cells and proteins were purified from yeast microsomes.  Proteins levels were assayed by reduced CO difference spectra and immunoblot.;CYP2C19 *19 is associated with decreased expression of CYP2C19 as compared to CYP2C19 *1.
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;Associated  with  decreasedsensitivity to ➔ SERTRALINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *13 is associated with decreased sensitivity to sertraline as compared to CYP2C19 *1.
EBASTINE, TERFENADINE;CYP2J2;rs201379188;A;Associated  with  decreasedclearance of  ➔ EBASTINE, TERFENADINE;Metabolism/PK;alleles complemented. Relative clearance reported for R446W compared to CYP2J2.1 was 50% with ebastine and 1.8% with terfenadine.;Allele A is associated with decreased clearance of ebastine or terfenadine as compared to allele G.
TERFENADINE;CYP2J2;rs199717190;A;Associated  with  decreasedclearance of  ➔ TERFENADINE;Metabolism/PK;alleles complemented. Relative clearance reported for N374I compared to CYP2J2.1 was 100% with ebastine and 14% with terfenadine.;Allele A is associated with decreased clearance of terfenadine as compared to allele T.
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;Associated  with  decreasedclearance of  ➔ OXYCODONE;Metabolism/PK;These alleles showed decreased, but still detectable clearance of oxycodone compared to *1.;CYP3A4 *2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34 are associated with decreased clearance of oxycodone as compared to CYP3A4 *1.
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*17, CYP3A4*20, CYP3A4*21, CYP3A4*26, CYP3A4*30;*6 + *17 + *20 + *21 + *26 + *30;Associated  with  decreasedclearance of  ➔ OXYCODONE;Metabolism/PK;These alleles did not show any detectable enzymatic activity.;CYP3A4 *6 + *17 + *20 + *21 + *26 + *30 are associated with decreased clearance of oxycodone as compared to CYP3A4 *1.
SIROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Associated  with  decreasedclearance of  ➔ SIROLIMUS;Metabolism/PK;Microsomes carrying the *22 allele (3 heterozygotes and 1 homozygote) metabolized sirolimus at a significantly lower rate than non-carriers (n=27).;CYP3A4 *1/*22 + *22/*22 are associated with decreased clearance of sirolimus in human liver microsomes as compared to CYP3A4 *1/*1.
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*10, CYP3A4*14, CYP3A4*32;*3 + *10 + *14 + *32;Associated  with  increased clearance of  ➔ SILDENAFIL;Metabolism/PK;;CYP3A4 *3 + *10 + *14 + *32 is associated with increased clearance of sildenafil as compared to CYP3A4 *1.
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;Associated  with  decreasedclearance of  ➔ IBRUTINIB;Metabolism/PK;;CYP3A4 *2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32 is associated with decreased clearance of ibrutinib as compared to CYP3A4 *1.
;CYP3A4;rs2242480;TT;Associated  with  decreased activity  of CYP3A4 ➔ ;Metabolism/PK;Patients with the *36/*36 showed deceased activity of CYP3A4 when using midazolam as a probe drug. The publication reports the finding for CYP3A4*1G. PharmVar re-assigned CYP3A4*1G to CYP3A4*36. Previously, this annotation used CYP3A4*36 which has been retired by PharmVar. All references to *36 have been replaced by rs2242480 alleles.;Genotype TT is associated with decreased activity of CYP3A4 as compared to genotypes CC + CT.
TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*15, CYP3A4*31;*2 + *3 + *11 + *15 + *31;Associated  with  increased clearance of  ➔ TESTOSTERONE;Metabolism/PK;in vitro, mean ¤ SD of three independent experiments.;CYP3A4 *2 + *3 + *11 + *15 + *31 is associated with increased clearance of testosterone as compared to CYP3A4 *1.
TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*10, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33, CYP3A4*34;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;Associated  with  decreasedclearance of  ➔ TESTOSTERONE;Metabolism/PK;in vitro, mean ¤ SD of three independent experiments.;CYP3A4 *5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34 is associated with decreased clearance of testosterone as compared to CYP3A4 *1.
LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16, CYP3A4*24;*2 + *5 + *9 + *16 + *24;Associated  with  decreasedclearance of  ➔ LIDOCAINE;Metabolism/PK;in vitro, mean ¤ SD of three independent experiments.;CYP3A4 *2 + *5 + *9 + *16 + *24 is associated with decreased clearance of lidocaine as compared to CYP3A4 *1.
MIDAZOLAM;CYP3A4;rs12721627;C;Associated  with  decreasedclearance of  ➔ MIDAZOLAM;Metabolism/PK;;Allele C is associated with decreased clearance of midazolam.
FENTANYL;CYP3A4;rs2242480;T/T;Associated  with  decreasedmetabolism of  ➔ FENTANYL;Metabolism/PK;The publication reports the finding for CYP3A4*1G. PharmVar re-assigned CYP3A4*1G to CYP3A4*36. Previously, this annotation used CYP3A4*36 which has been retired by PharmVar. All references to *36 have been replaced by rs2242480 alleles.;Genotype T/T is associated with decreased metabolism of fentanyl in human liver microsomes as compared to genotypes C/C + C/T.
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;Associated  with  decreasedclearance of  ➔ REGORAFENIB;Metabolism/PK;*2, *7, *8, *11, *12, *13 and *17 were markedly decreased (less than 25% of *1).;CYP3A4 *2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34 is associated with decreased clearance of regorafenib as compared to CYP3A4 *1.
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33;*11 + *18 + *33;Associated  with  increased clearance of  ➔ TICAGRELOR;Metabolism/PK;"""CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%?75.11% relative clearance) compared to that of wild-type""";CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;Associated  with  decreasedclearance of  ➔ TICAGRELOR;Metabolism/PK;"""CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%?75.11% relative clearance) compared to that of wild-type""";CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.
LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*12;*12;Associated  with  decreasedclearance of  ➔ LURASIDONE;Metabolism/PK;Lurasidone metabolized by 24 variants of recombinant human CYP3A4 in vitro showed that the intrinsic clearance (Vmax/Km) of CYP3A4.12 was significantly decreased.;CYP3A4 *12 is associated with decreased clearance of lurasidone as compared to CYP3A4 *1.
LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*15, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;Associated  with  increased clearance of  ➔ LURASIDONE;Metabolism/PK;Lurasidone metabolized by 24 variants of recombinant human CYP3A4 in vitro showed that the intrinsic clearance (Vmax/Km) of CYP3A4.15, .19, .23, .24, .28, .29, .32, and .33 were significantly increased.;CYP3A4 *15 + *19 + *23 + *24 + *28 + *29 + *32 + *33 is associated with increased clearance of lurasidone as compared to CYP3A4 *1.
SAXAGLIPTIN;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;Associated  with  decreasedclearance of  ➔ SAXAGLIPTIN;Metabolism/PK;*2, *7, *8, *9, *11, *12, *13, *17, *20, *23, *24, *32  and *34 had markedly decreased clearance of 25% or less than *1.;CYP3A4 *2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34 is associated with decreased clearance of saxagliptin as compared to CYP3A4 *1.
EBASTINE, TERFENADINE;CYP2J2;rs759510111;A;Associated  with  increased clearance of  ➔ EBASTINE, TERFENADINE;Metabolism/PK;alleles complemented. Relative clearance reported for T470I compared to CYP2J2.1 was 600% with ebastine and 200% with terfenadine.;Allele A is associated with increased clearance of ebastine or terfenadine as compared to allele G.
EBASTINE;CYP2J2;rs757528200;(CTC)1;Associated  with  decreasedclearance of  ➔ EBASTINE;Metabolism/PK;Relative clearance reported for 173_173del compared to CYP2J2.1 was 43% with ebastine.;Allele (CTC)1 is associated with decreased clearance of ebastine as compared to allele CTCCTC.
;CYP2E1;CYP2E1*7A, CYP2E1*7B;*7B;Associated  with  increased transcription of CYP2E1 ➔ ;Metabolism/PK;"and compared to ""wild type"".";CYP2E1 *7B is associated with increased transcription of CYP2E1 in HepG2 cells as compared to CYP2E1 *7A.
;CYP2E1;CYP2E1*7, CYP2E1*7A;*7A;Associated  with  increased transcription of CYP2E1 ➔ ;Metabolism/PK;"The 3 haplotypes containing this variant had significantly greater activity than the ""wild type"". This variant is in an Sp1 binding site. Authors stated: ""So we infer that Sp1 may play an important role in increasing CYP2E1 promoter activity. However, the binding efficiency change caused by a single nucleotide mutation might not be enough to alter overall promoter activity."" It is unclear if the ""wild type"" promoter contained the VNTR element of *1C or *1D.";CYP2E1 *7A is associated with increased transcription of CYP2E1.
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;Associated  with  decreasedmetabolism of  ➔ N-DESMETHYLTAMOXIFEN;Metabolism/PK;"""the relative Kcat/Km values for desmethyltamoxifen were only 30?35% for both CYP2D6.2 and CYP2D6.35 and 48% for CYP2D6.28, as compared to CYP2D6.1, indicating reduced catalytic efficiency for this substrate (Table 2)"" ""it is evident that CYP2D6*2 encodes an enzyme with reduced activity for certain substrates, such as risperidone and desmethyltamoxifen. However, CYP2D6.2 does not impact the CYP2D6-mediated metabolism of bufuralol (Table 2), dextromethorphan,10 and codeine"" ""In conclusion, there is compelling evidence to support the inclusion of CYP2D6*2 and CYP2D6*35 as reduced-function alleles in future pharmacogenomic guidelines for specific drug substrates""";CYP2D6 *2 + *28 + *35 is associated with decreased metabolism of N-desmethyltamoxifen in HEK293 cells as compared to CYP2D6 *1.
BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;Associated  with  decreasedclearance of  ➔ BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;Metabolism/PK;The *17 construct (T107I, R296C and S486T) was expressed in insect cells and the kinetic parameters Km and Vmax were determined for dextromethorphan and bufuralol compared to *1 construct. (Insect cells expression resulted in 2-3-fold lower Km and 10-20-fold higher Vmax than COS-7 cells expression.);CYP2D6 *17 is associated with decreased clearance of bufuralol, debrisoquine or dextromethorphan in microsomes from baculovirus-transfected cells as compared to CYP2D6 *1.
;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;Associated  with  decreased expression of CYP2D6 ➔ ;Metabolism/PK;"""reduced CYP2D6 protein levels in heterozygous individuals with the CYP2D6*3, CYP2D6*4, and CYP2D6*5 gene deletion variants"" in human liver microsomes from postmortem.";CYP2D6 *1/*4 is associated with decreased expression of CYP2D6 as compared to CYP2D6 *1/*1.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*169;*169;Associated  with  decreasedclearance of  ➔ DEXTROMETHORPHAN;Metabolism/PK;"Wild-type CYP2D6.1 and variants were expressed in 293FT cells. Michaelis Menten kinetics for wild-type CYP2D6.1 and variants were determined for dextromethorphan O-demethylation. V402L had significantly lower CLint values than that of CYP2D6.1. Kinetic parameters for dextromethorphan O-demethylation: CLint (Vmax/Km) (mL/min/pmol CYP2D6) (% of wild-type) CYP2D6.1 = 0.43 ¤ 0.04; 0.04 ¤ 0.00 (8.33) P < 0.05 compared to CYP2D6.1 by Dunnett T3 test. PharmVar *169 defined by 3830G>C (rs1602566413, V402L).";CYP2D6 *169 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1.
DEXTROMETHORPHAN;CYP2D6;rs76187628;G;Associated  with  increased clearance of  ➔ DEXTROMETHORPHAN;Metabolism/PK;"Wild-type CYP2D6.1 and variants were expressed in 293FT cells. Michaelis Menten kinetics for wild-type CYP2D6.1 and variants were determined for dextromethorphan O-demethylation. Kinetic parameters for dextromethorphan O-demethylation: CLint (Vmax/Km) (mL/min/pmol CYP2D6) (% of wild-type) CYP2D6.1 = 0.43 ¤ 0.04; V104A = 0.55 ¤ 0.01 (128) P < 0.05 compared to CYP2D6.1 by Dunnett T3 test.";Allele G is associated with increased clearance of dextromethorphan as compared to allele A.
;CYP2D6;CYP2D6*1, CYP2D6*169;*169;Associated  with  decreased expression of CYP2D6 ➔ ;Metabolism/PK;Wild-type CYP2D6.1 and variants were expressed in 293FT cells. Expression levels (pmol CYP2D6/mg microsomal protein). PharmVar *169 defined by 3830G>C (rs1602566413, V402L).;CYP2D6 *169 is associated with decreased expression of CYP2D6 as compared to CYP2D6 *1.
;CYP2D6;rs76187628;G;Associated  with  increased  expression of CYP2D6 ➔ ;Metabolism/PK;"Wild-type CYP2D6.1 and variants were expressed in 293FT cells. Expression levels (pmol CYP2D6/mg microsomal protein). ""Our ndings indicate that expression levels of V104A were significantly increased when compared to wild-type CYP2D6.1""";Allele G is associated with increased expression of CYP2D6 as compared to allele A.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;Associated  with  decreasedclearance of  ➔ DEXTROMETHORPHAN;Metabolism/PK;The dextromethorphan O-demethylation activities were measured for *2 (R296C, S486T) construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. Relative clearance as % of wild-type: *2: 43.85. One-way analyses of variance with Dunnett?s tests.;CYP2D6 *2 is associated with decreased clearance of dextromethorphan in insect microsomes as compared to CYP2D6 *1.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Associated  with  decreasedclearance of  ➔ DEXTROMETHORPHAN;Metabolism/PK;The dextromethorphan O-demethylation activities were measured for *10 (P34S, S486T) construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. Relative clearance as % of wild-type: *10: 4.57. One-way analyses of variance with Dunnett?s tests.;CYP2D6 *10 is associated with decreased clearance of dextromethorphan in insect microsomes as compared to CYP2D6 *1.
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*9, CYP3A4*19, CYP3A4*34;*3 + *4 + *9 + *19 +*34;Associated  with  increased clearance of  ➔ IBRUTINIB;Metabolism/PK;*19 and *34 had markedly increased activity with greater than 200% relative clearance of *1.;CYP3A4 *3 + *4 + *9 + *19 +*34 is associated with increased clearance of ibrutinib as compared to CYP3A4 *1.
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;Associated  with  decreasedmetabolism of  ➔ RISPERIDONE;Metabolism/PK;"""In the case of risperidone, CYP2D6.2, CYP2D6.28, and CYP2D6.35 displayed significantly higher Km values than CYP2D6.1. The relative Kcat/Km values demonstrated that the catalytic efficiencies of CYP2D6.2 and CYP2D6.35 for risperidone were reduced by approximately 80%, compared to CYP2D6.1 (Table 2)"" ""it is evident that CYP2D6*2 encodes an enzyme with reduced activity for certain substrates, such as risperidone and desmethyltamoxifen. However, CYP2D6.2 does not impact the CYP2D6-mediated metabolism of bufuralol (Table 2), dextromethorphan,10 and codeine"" ""In conclusion, there is compelling evidence to support the inclusion of CYP2D6*2 and CYP2D6*35 as reduced-function alleles in future pharmacogenomic guidelines for specific drug substrates""";CYP2D6 *2 + *28 + *35 is associated with decreased metabolism of risperidone in HEK293 cells as compared to CYP2D6 *1.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*26;*26;Associated  with  decreasedclearance of  ➔ DEXTROMETHORPHAN;Metabolism/PK;microsomes from transfected insect cells: Intrinsic clearance was 0.76 ul/pmol P450/min for *26 and 1.22 ul/pmol P450/min for *1.  Differences in Vmax and Km were each significant.;CYP2D6 *26 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1.
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs750996195;T;Associated  with  decreasedclearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Metabolism/PK;The 1) bufuralol 1?-hydroxylation and 2) dextromethorphan O-demethylation activities were measured for the E215K construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1 (wild type). Relative clearance as % of wild-type: 1) 78.81 and 2) 38.60. One-way analyses of variance with Dunnett?s tests.;Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;Associated  with  decreasedclearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Metabolism/PK;"The *17 construct (T107I, R296C and S486T) was expressed in cos-7 cells and the kinetic parameters Km and Vmax were determined for dextromethorphan and bufuralol compared to *1 construct. dextromethorphan: Km 2 fold increase to *1; Vmax 33% reduction. bufuralol: Km no effect compared to *1; Vmax 45% decrease compared to *1. Resulting in about 25 % (p<0.01) reduction in intrinsic clearance for dextromethorphan and 37% (p<0.02) for bufuralol for *17 compared to *1. CYP2D6 cDNA with *17=T105I, R296C; S486T variations. The intrinsic clearance for these substrates are also lower from *17 compared to *2 (p<0.05).";CYP2D6 *17 is associated with decreased clearance of bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*14;*14;Associated  with  decreasedclearance of  ➔ BUFURALOL;Metabolism/PK;cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The intrinsic clearance measured as bufuralol 1'-hydroxylation (Clins=Vmax/Km) was lower for the *14B construct compared to *1, p<0.01 (Km value significantly higher in *14B compared to *1 and Vmax insignificant lower). *14B is re-assigned to *14 with the Nov 2018 PharmVar update.;CYP2D6 *14 is associated with decreased clearance of bufuralol in COS-7 cells as compared to CYP2D6 *1.
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*53;*53;Associated  with  increased clearance of  ➔ N-DESMETHYLTAMOXIFEN;Metabolism/PK;"CYP2D6 cDNA was cloned and expressed in COS-7 cells to compare to constructs for CYP2D6*7, 10, 12, 14, 17, 18, 29, 30, 31, 35, 36, 37, 40, 46, 47, 50, 51, 52, 54, 55, 57, 61, 62, 63, 64, 65, 71, 72 constructs. Assaying the *53 (F120I; A122S) construct yielded in a decreased Km (p<0.05) and increased Vmax (p<0.005) compared to *1, which led to an increased intrinsic clearance of 2786% compared to the results with the *1 construct.";CYP2D6 *53 is associated with increased clearance of n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.
DAPOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;Associated  with  decreasedclearance of  ➔ DAPOXETINE;Metabolism/PK;"The dapoxetine-demethylation and oxidation activities were measured for *2 (R296C, S486T); *10 (P34S, S486T); *87 (A5V); *88 (V104A); *91 (C161S); *93 (T249P); *95(R388H); *97 (F457L); *98 (H463D) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. Relative clearance for dapoxetine demethylation/oxidation reaction as % of wild-type: *2: 49.63/58.45; *10: 25.31/29.51; *87: 68.37/50.34; *88: 88.12/77.44; *93: 20.44/27.56; *95: 73.39/49.26; *97: 72.34/43.90; *98: 76.30/37.73. Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.";CYP2D6 *2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98 is associated with decreased clearance of dapoxetine as compared to CYP2D6 *1.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*53;*53;Associated  with  increased clearance of  ➔ BUFURALOL;Metabolism/PK;cDNA construct was transiently expressed in cos 7 cells and compared to the wild type construct. The bufuralol 1'-hydroxylation activity and dextromethorphan O-demethylation activity with the CYP2D6*53 construct were similar compared to the *1 construct.  CYP2D6*53 construct had a Km values lower than *1 (p<0.005). and Vmax levels greater than *1. The intrinsic clearance (Clint=Vmax/Km) was 4 times higher for the *53 construct comparing to *1 (p<0.05).;CYP2D6 *53 is associated with increased clearance of bufuralol in COS-7 cells as compared to CYP2D6 *1.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Associated  with  decreasedclearance of  ➔ DEXTROMETHORPHAN;Metabolism/PK;65% decreased intrinsic clearance in liver samples with 100 TT genotype vs 100 CC genotype.;CYP2D6 *10/*10 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1/*1.
;CYP2E1;rs2515641;T;Associated  with  decreased expression of CYP2E1 ➔ ;Other;in untreated cells.;Allele T is associated with decreased expression of CYP2E1 as compared to allele C.
;ZBED5;rs10840501;GG;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes AA + AG.
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15, CYP3A4*28, CYP3A4*31;*14 + *15 + *28 + *31;Associated  with  increased clearance of  ➔ REGORAFENIB;Metabolism/PK;;CYP3A4 *14 + *15 + *28 + *31 is associated with increased clearance of regorafenib as compared to CYP3A4 *1.
LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*14, CYP3A4*15, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;Associated  with  increased clearance of  ➔ LIDOCAINE;Metabolism/PK;in vitro, mean ¤ SD of three independent experiments.;CYP3A4 *11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34 is associated with increased clearance of lidocaine as compared to CYP3A4 *1.
CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;Associated  with  increased clearance of  ➔ CABOZANTINIB;Metabolism/PK;;CYP3A4 *14 + *15 is associated with increased clearance of cabozantinib as compared to CYP3A4 *1.
VITAMIN E;CYP4F2;rs2108622;T;Associated  with  increased steady-state level of  ➔ VITAMIN E;Metabolism/PK;The T allele is significantly associated with increased plasma vitamin E (alpha-tocopherol) at week 48 but not at week 96 in pediatric patients receiving vitamin E (alpha-tocopherol) supplements.;Allele T is associated with increased steady-state level of vitamin e as compared to allele C.
;CYP4F2;rs2189784;A;Associated  with  increased  expression of CYP4F2 ➔ ;Other;The AA geotype was associated with increased expression of CYP4F2 mRNA when assessed in liver cells extracted from patients undergoing liver surgery. R sq.= 7.9%;Allele A is associated with increased expression of CYP4F2 as compared to allele G.
;CYP4F2;rs2189784;A;Associated  with  decreased expression of CYP4F12 ➔ ;Other;The A allele was associated with decreased expression of CYP4F12 mRNA when assessed in liver cells extracted from patients undergoing liver surgery. R sq.= 8.36%;Allele A is associated with decreased expression of CYP4F12 as compared to allele G.
;CYP4F2;rs2108622;CT;Associated  with  increased concentrations of CYP4F2 ➔ ;Other;"Men had higher CYP4F2 enzyme concentrations (median 3.6 ng/ml) vs. women (median 2.85 ng/ml; P = 0.043). CYP4F2 concentration was higher in clopidogrel vs, ticagrelor (median 3.6 ng/ml vs. 2.3 ng/ml, P = 0.056, respectively). CYP4F2 CT was also associated with higher concentrations of CYP4F2 vs CC (median 4.3 ng/ml vs. median 2.4 ng/ml, P = 0.009).";Genotype CT is associated with increased concentrations of CYP4F2 as compared to genotype CC.
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;CT + TT;Associated  with  increased concentrations of  ➔ VITAMIN K AND ANALOGUES;Other, Metabolism/PK;There was a significant difference in the genotype frequencies between patients with  vitamin K <10 pg/ml (CT + TT 76.2%) and vitamin K > 10 pg/ml (CC 45.4%).;Genotypes CT + TT is associated with increased concentrations of Vitamin K as compared to genotype CC.
;CYP4F2;rs2108622;T;Associated  with  increased  expression of CYP4F2 ➔ ;Other;The TT allele was associated with increased expression of CYP4F2 mRNA when assessed in liver cells extracted from patients undergoing liver surgery. R sq.= 12.6%;Allele T is associated with increased expression of CYP4F2 as compared to allele C.
;CYP4F2;rs2108622;T;Associated  with  increased  expression of CYP4F11 ➔ ;Other;The TT allele was associated with increased expression of CYP4F11 mRNA when assessed in liver cells extracted from patients undergoing liver surgery. R sq. = 13.7%;Allele T is associated with increased expression of CYP4F11 as compared to allele C.
;DCK;rs2306744;T;Associated  with  increased  expression of DCK ➔ ;Other;The authors tested differences in the association of different compound haplotypes and dCK expression in vitro and in vivo. This was done two ways. The first was with a luciferase assay in Cos7 cells transfected with a plasmid containing the different haplotypes. The second was with blood samples from AML patients and qRT-PCR to test expression of DCK.;Allele T is associated with increased expression of DCK as compared to allele C.
;DHRS4L1;rs10147475;GG;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes AA + AG.
VITAMIN E;CYP4F2;rs2108622;T;Associated  with  increased steady-state level of  ➔ VITAMIN E;Metabolism/PK;The T allele is significantly associated with increased plasma vitamin E (alpha-tocopherol) at week 48 but not at week 96 in adult patients receiving vitamin E (alpha-tocopherol) supplements.;Allele T is associated with increased steady-state level of vitamin e as compared to allele C.
;DISP1;rs61840266;TT;Associated  with  increased transcription of ABCC1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype TT is associated with increased transcription of ABCC1 as compared to genotypes AA + AT.
;DPYD;rs568132506;A;Associated  with  decreasedcatalytic  activity  of DPYD ➔ ;Other;This variant is also called p.P86L and is found in East African population. It is associated with significantly reduced DPYD activity (0.03 of normal activity) and may contribute to 5-Fluorouracil sensitivity in East African population.;Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.
;DPYD;rs760663364;A;Associated  with  decreasedcatalytic  activity  of DPYD ➔ ;Other;This variant is also called p.A513V and is found in East African population. It is associated with significantly reduced DPYD activity (0.82 of normal activity) and may contribute to 5-Fluorouracil sensitivity in East African population.;Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.
FLUOROURACIL;DPYD;rs1801159;CC;Associated  with  decreasedclearance of  ➔ FLUOROURACIL;Toxicity, Metabolism/PK;"The elimination rate constant (Ke) for 5-fluorouracil was significantly lower in patients with the CC genotype compared to the TT (""wildtype') genotype. Genotype CC was referred to as ""DPYD*5 mutant genotype"" in this study.";Genotype CC is associated with decreased clearance of fluorouracil as compared to genotype TT.
;DPYD;rs3918290;CT;Associated  with  decreased activity  of DPYD ➔ ;Other;"A British family with 19 members was assessed. The CT genotype was present in 10 members, absent in 6, and not determined in 3. DPYD activity was also determined for each family member. Statistical analysis showed that individuals with the CT genotype had significantly reduced DPYD activity (mean: 58+/-19) as compared to those who did not (mean=87+/-18). In this paper, rs3918290 is described as ""the presence of a G to A point mutation at the 5'-splicing site consensus sequence (GT to AT) that leads to skipping of the entire exon preceding the mutation during pre-RNA transcription and processing"". Note that alleles have ben complemented to the positive strand.";Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.
;DPYD;rs1801158;CT;Associated  with  decreasedcatalytic  activity  of DPYD ➔ ;Other;Healthy individuals. Carriers of the *4 allele (n=4) were found to have a median DPD activity that was 13.5% of the average activity, a significant difference.;Genotype CT is associated with decreased catalytic activity of DPYD as compared to genotype CC.
;DPYD;rs547099198;A;Associated  with  decreasedcatalytic  activity  of DPYD ➔ ;Other;This variant is also called p.T793I and is found in East African population. It is associated with significantly reduced DPYD activity (0.25 of normal activity) and may contribute to 5-Fluorouracil sensitivity in East African population.;Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.
;DPYD;rs67376798;AT;Associated  with  decreasedcatalytic  activity  of DPYD ➔ ;Other;Healthy individuals. Carriers of the AT genotype (n=2) were found to have a median DPD activity that was 21.1% of the average activity, a significant difference.;Genotype AT is associated with decreased catalytic activity of DPYD in peripheral blood mononuclear cells.
;DPYD;rs1801265;G;Associated  with  decreased activity  of DPYD ➔ ;Other;"The DPYD*9A allele (c.85T>C) was expressed in mammalian cells (HEK293 Flp-In) and protein expression and activity as compared to wild-type DPYD was analyzed. Cells with the DPYD*9A allele (G) had significantly lower activity as compared to wild-type (A). However, when DPYD activity was assessed within a healthy cohort of 100 individuals (allele frequency = 0.25), there was only a tendency toward lower activity (p=0.1115). Text from the discussion section:""the analysis of recombinantly-expressed DPYD mutants showed that only a mildly-reduced DPD activity, ranging from 68% to 84% of that of the wild-type DPD enzyme, was observed for the DPD mutants carrying the p.C29R, p.M166V, p.G401R, p.S534N and p.V732I mutations.To date, weak or conflicting data exists as to whether the p.C29R, p.M166V, p.S534N and p.V732I mutations confer an increased risk to patients to develop severe 5FU-associated toxicity.""";Allele G is associated with decreased activity of DPYD as compared to allele A.
;DPYD;rs1801160;T;Associated  with  decreased activity  of DPYD ➔ ;Other;"The DPYD*6 allele (c.2194G>A) was expressed in mammalian cells (HEK293 Flp-In) and protein expression and activity as compared to wild-type DPYD was analyzed. Cells with the DPYD*6 allele (T) had significantly lower activity as compared to wild-type. However, when DPYD activity was assessed within a healthy cohort of 100 individuals (allele frequency = 0.025), there was only a tendency toward lower activity (p=0.1908). Text from the discussion section:""the analysis of recombinantly-expressed DPYD mutants showed that only a mildly-reduced DPD activity, ranging from 68% to 84% of that of the wild-type DPD enzyme, was observed for the DPD mutants carrying the p.C29R, p.M166V, p.G401R, p.S534N and p.V732I mutations.To date, weak or conflicting data exists as to whether the p.C29R, p.M166V, p.S534N and p.V732I mutations confer an increased risk to patients to develop severe 5FU-associated toxicity.""";Allele T is associated with decreased activity of DPYD as compared to allele C.
;DISP1;rs17535305;GG;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes CC + CG.
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs777560972;A;Associated  with  decreasedclearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Metabolism/PK;The 1) bufuralol 1?-hydroxylation and 2) dextromethorphan O-demethylation activities were measured for the E215K construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1 (wild type). Relative clearance as % of wild-type: 1) 32.47 and 2) 71.30. One-way analyses of variance with Dunnett?s tests.;Allele A is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele G.
;CYP4F11;rs1060467;A;Associated  with  increased  expression of CYP4F2 ➔ ;Other;The AA genotype was associated with increased expression of CYP4F2 mRNA when assessed in liver cells extracted from patients undergoing liver surgery. R sq. = 7.2%;Allele A is associated with increased expression of CYP4F2 as compared to allele G.
;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Associated  with  decreased expression of CYP3A5 ➔ ;Other;Expression levels of CYP3A5 was significantly higher in graft livers that carried the CYP3A5*1 allele than in those that had the CYP3A5*3/*3 genotype.;CYP3A5 *3/*3 is associated with decreased expression of CYP3A5 graft liver cell as compared to CYP3A5 *1.
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;Associated  with  increased clearance of  ➔ BREXPIPRAZOLE;Metabolism/PK;;CYP3A4 *14 + *15 is associated with increased clearance of brexpiprazole as compared to CYP3A4 *1.
ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*12, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;Associated  with  decreasedmetabolism of  ➔ ALECTINIB;Metabolism/PK;"""The catalytic activities of the 12 variants in CYP3A4.4, 0.7, 0.8, 0.12, 0.14, 0.16, 0.17, 0.18, 0.19, 0.20, 0.23, and 0.24 were typically lower than that of CYP3A4.1. Patients with these variants were poor metabolizers. Compared with other variant carriers, we should pay more attention to the occurrence of DDI when using alectinib. Among them, the catalytic activity of CYP3A4.20 was the lowest, only 2.63% of that of CYP3A4.1""";CYP3A4 *4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of alectinib as compared to CYP3A4 *1.
METHADONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*24, CYP3A4*29, CYP3A4*31;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;"""The apparent Km, Vmax, and CLint of N-demethylation of MTD by wild-type CYP3A4*1 was 6.62??M, 267.233?pmol/min/pmol, and 0.0313??L/min/?mol, respectively. Compared to CYP3A4*1, seven variants exhibited significant increases in Vmax or Km (CYP3A4*2, *11, *14, *17, *18, *23, *24). Thus, 12 variants exhibit decreased CLint (2.68%?73.61%), especially CYP3A4*5, *16, *17, *24, and *29 with >50% reduction in CLint compared to wild-type CYP3A4*1. On the other hand, CYP3A4*11, *32, and *34 exhibited higher clearance than wild-type CYP3A4*1 due to the increased Vmax and similar Km (132.03%?149.71%). Additionally, six variants (CYP3A4*4, *9, *10, *23, *28, *33) demonstrated CLint values to comparable to wild-type CYP3A4*1. Enzymatic kinetic parameters of CYP3A4*30 could not be detected, indicating that its enzymatic activity was too weak to result in any MTD N-demethylation.""";CYP3A4 *2 + *3 + *5 + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31 is associated with decreased clearance of methadone as compared to CYP3A4 *1/*1.
METHADONE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*32, CYP3A4*34;*11 + *32 + *34;Associated  with  increased clearance of  ➔ METHADONE;Metabolism/PK;"""The apparent Km, Vmax, and CLint of N-demethylation of MTD by wild-type CYP3A4*1 was 6.62??M, 267.233?pmol/min/pmol, and 0.0313??L/min/?mol, respectively. Compared to CYP3A4*1, seven variants exhibited significant increases in Vmax or Km (CYP3A4*2, *11, *14, *17, *18, *23, *24). Thus, 12 variants exhibit decreased CLint (2.68%?73.61%), especially CYP3A4*5, *16, *17, *24, and *29 with >50% reduction in CLint compared to wild-type CYP3A4*1. On the other hand, CYP3A4*11, *32, and *34 exhibited higher clearance than wild-type CYP3A4*1 due to the increased Vmax and similar Km (132.03%?149.71%). Additionally, six variants (CYP3A4*4, *9, *10, *23, *28, *33) demonstrated CLint values to comparable to wild-type CYP3A4*1. Enzymatic kinetic parameters of CYP3A4*30 could not be detected, indicating that its enzymatic activity was too weak to result in any MTD N-demethylation.""";CYP3A4 *11 + *32 + *34 is associated with increased clearance of methadone as compared to CYP3A4 *1/*1.
;CYP3A4;rs35599367;A;Associated  with  decreased expression of CYP3A4 ➔ ;Other;CYP3A4*22 (rs35599367 T) is associated with a two-fold or greater increase in formation of a nonfunctional CYP3A4 alternative splice variant with partial intron 6 retention in human liver;Allele A is associated with decreased expression of CYP3A4 as compared to genotype GG.
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*39, CYP3A4*40, CYP3A4*41, CYP3A4*42, CYP3A4*43, CYP3A4*44, CYP3A4*46;*39 + *40 + *41 + *42 + *43 + *44 + *46;Associated  with  decreasedclearance of  ➔ MIDAZOLAM;Metabolism/PK;;CYP3A4 *39 + *40 + *41 + *42 + *43 + *44 + *46 is associated with decreased clearance of midazolam by recombinant protein expressed in yeast as compared to CYP3A4 *1.
MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*10, CYP3A4*15, CYP3A4*16;*3 + *4 + *5 + *10 +*15 + *16;Associated  with  increased clearance of  ➔ MACITENTAN;Metabolism/PK;*5 was markedly increased, 500% compared to *1.;CYP3A4 *3 + *4 + *5 + *10 +*15 + *16 is associated with increased clearance of macitentan as compared to CYP3A4 *1.
;CYP3A4;rs4986909;A;Associated  with  decreasedsteady-state level of CYP3A4 ➔ ;;In a bacterial heterologous expression system, there was no detectable P450 holoprotein with this variant.  In vitro.;Allele A is associated with decreased steady-state level of CYP3A4.
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*31, CYP3A4*34;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;Associated  with  decreasedclearance of  ➔ VANDETANIB;Metabolism/PK;;CYP3A4 *5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34 is associated with decreased clearance of vandetanib as compared to CYP3A4 *1.
;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Associated  with  decreased expression of CYP3A5 ➔ ;Other;CYP3A5 mRNA expression was significantly higher in those carrying the CYP3A5*1 allele than in those who had the CYP3A5*3/*3 genotype (P<0.0001, Mann-Whitney U-test);CYP3A5 *3/*3 is associated with decreased expression of CYP3A5 intestinal cell as compared to CYP3A5 *1.
CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;Associated  with  decreasedclearance of  ➔ CABOZANTINIB;Metabolism/PK;*2, *7, *8, *12, *16 and *17 had markedly decreased clearance of less than 25% of *1.;CYP3A4 *2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34 is associated with decreased clearance of cabozantinib as compared to CYP3A4 *1.
AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;Associated  with  increased clearance of  ➔ AMIODARONE;Metabolism/PK;in vitro recombinant protein.;CYP3A4 *2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34 is associated with increased clearance of amiodarone as compared to CYP3A4 *1.
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*24, CYP3A4*28, CYP3A4*29;*2 + *5 + *24 + *28 + *29;Associated  with  decreasedclearance of  ➔ SILDENAFIL;Metabolism/PK;*24 had especially low activity with clearance of less than 2% of *1, the others ranged from 25-75% of *1.;CYP3A4 *2 + *5 + *24 + *28 + *29 is associated with decreased clearance of sildenafil as compared to CYP3A4 *1.
;CYP3A4;CYP3A4*8;*8;Associated  with  decreasedsteady-state level of CYP3A4 ➔ ;;In a bacterial heterologous expression system, there was no detectable P450 holoprotein with this variant. In vitro.;CYP3A4 *8 is associated with decreased steady-state level of CYP3A4.
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*18, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;Associated  with  decreasedclearance of  ➔ BREXPIPRAZOLE;Metabolism/PK;these had between 30-76% of relative clearance compared to *1;CYP3A4 *3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34 is associated with decreased clearance of brexpiprazole as compared to CYP3A4 *1.
;CYP3A4;CYP3A4*12;*12;Associated  with  decreasedenzyme  activity  of CYP3A4 ➔ ;;In a bacterial heterologous expression system, this variant displayed a significantly altered testosterone metabolite profile and a four-fold increase in the Km value for 1'-OH midazolam formation.  In vitro.;CYP3A4 *12 is associated with decreased enzyme activity of CYP3A4.
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*7, CYP3A4*8, CYP3A4*17, CYP3A4*20;*2 + *7 + *8 + *17 + *20;Associated  with  decreasedclearance of  ➔ BREXPIPRAZOLE;Metabolism/PK;this set were markedly decreased compared to *1 with relative clearance less than 30% of *1.;CYP3A4 *2 + *7 + *8 + *17 + *20 is associated with decreased clearance of brexpiprazole as compared to CYP3A4 *1.
;CYP3A4;CYP3A4*11;*11;Associated  with  decreasedsteady-state level of CYP3A4 ➔ ;;In vitro (In a bacterial heterologous expression system).;CYP3A4 *11 is associated with decreased steady-state level of CYP3A4.
AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;Associated  with  decreasedclearance of  ➔ AMIODARONE;Metabolism/PK;in vitro recombinant protein.;CYP3A4 *17 + *24 is associated with decreased clearance of amiodarone as compared to CYP3A4 *1.
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Associated  with  increased metabolism of  ➔ MIDAZOLAM;Metabolism/PK;The ratio of 1'-OH midazolam (MDZ) to 4-OH MDZ was dependent upon CYP3A5 genotype with livers from individuals with the CYP3A5*1*1 genotype with the highest ratios (2.75 6 ¤ 0.58) and CYP3A5*3*3 genotypes having the lowest ratios (1.03 ¤ 0.45).;CYP3A5 *1/*1 is associated with increased metabolism of midazolam in fetal liver microsomes as compared to CYP3A5 *3/*3.
MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*33, CYP3A4*34;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;Associated  with  decreasedclearance of  ➔ MACITENTAN;Metabolism/PK;;CYP3A4 *9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34 is associated with decreased clearance of macitentan as compared to CYP3A4 *1.
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs138417770;T;Associated  with  decreasedclearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Metabolism/PK;The 1) bufuralol 1?-hydroxylation and 2) dextromethorphan O-demethylation activities were measured for the E215K construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1 (wild type). Relative clearance as % of wild-type: 1) 14.45 and 2) 14.3. One-way analyses of variance with Dunnett?s tests.;Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs371793722;G;Associated  with  decreasedclearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Metabolism/PK;The 1) bufuralol 1?-hydroxylation and 2) dextromethorphan O-demethylation activities were measured for the E215K construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1 (wild type). Relative clearance as % of wild-type: 1) 58.96 and 2) 50.06. One-way analyses of variance with Dunnett?s tests.;Allele G is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele A.
;CYP2D6;rs1058164;G;Associated  with  decreased expression of CYP2D6 ➔ ;Other;unclear what strand this is reported on.;Allele G is associated with decreased expression of CYP2D6 as compared to allele C.
METHADONE;CYP2C19;rs181297724;C;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for A161P was 9.95% of *1;Allele C is associated with decreased clearance of methadone as compared to allele G.
METHADONE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*29 + *30 + *31 + *32 + *33;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;"CYP2C19 proteins were produced in 293FT cells expressing different variant constructs.; Km and Vmax were measure for the N-demethylation reaction of methadone. Intrinsic clearance is calculated Vmax/Km. *29 + *30 + *31 + *32 + *33 had a decrease in Vmax but similar or non-significant higher Km which caused a change in clearance. *29 9.75% of wt,  *30 16.03% of wt, *31 23.76% of wt, *32 37.96% of wt, *33 23.07% of wt.; In previous publication using this system *3 (W212X) and 35FS had no protein expressed. *29 (K28I) showed a strong decrease in CYP2D6 expression. In addition CYP2C19*30(R73C), CYP2C19*33(D188N) had a lesser decreased expression of CYP2C19 protein.";CYP2C19 *29 + *30 + *31 + *32 + *33 is associated with decreased clearance of methadone as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;rs778258371;A;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Caution: The variant might be together with rs4244285. No information about the gene construct generation used for the assay. The article names the construct *2E(M271I), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for M271I  was 21.38% of wild-type (no variant). CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;Allele A is associated with decreased clearance of voriconazole in insect microsomes as compared to allele G.
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for H99R is 34.93% compared to *1 (no variants).;CYP2C19 *32 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Caution: The annotation encompasses several constructs named as *2 sub alleles due to different variants.  Those amino acid changes might or not be together with rs4244285 and /or rs12769205 in the construct. No information about the gene construct generation used for the assay is reported, although the table 1 states the splicing in the effect column. However, if all construct had the same splicing variant the range of clearance is unexpected and the variants are located after the splicing event in the sequence. For those amino acid changes currently exists no rsID to use to annotate. The article names the construct *2H (H396D), *2J (K421Q) however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity, while *3C has a detectable clearance. Intrinsic clearance is Vmax/Km. For K421Q, voriconazole clearance was 20.78% of *1 (no variant). For H396D, metabolite concentrations of voriconazole were below the detection limit, so kinetic parameters could not be determined, indicating null function.;CYP2C19 *2 is associated with decreased clearance of voriconazole in insect microsomes as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Metabolite concentrations of voriconazole were below the detection limit, so kinetic parameters could not be determined, indicating null function. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *3 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
METHADONE;CYP2C19;rs138142612;A;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for R329H was 35.6% of *1;Allele A is associated with decreased clearance of methadone as compared to allele G.
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*24;*24;Associated  with  decreasedclearance of  ➔ MEPHENYTOIN, OMEPRAZOLE;Metabolism/PK;CYP2C19*24 (991 A>G, 1004 G>A) variants were introduced into full-length CYP2C19 WT cDNA and both expressed independently in E.coli. Protein expressions of CYP2C19 WT and variants in E. coli cells were measured by immunoblotting. The total specific CYP contents determined were 43.2 ¤ 10.2 (WT), and 15.9 ¤ 9.7 (CYP2C19*24) pmol/mg protein. Bacterial membrane protein containing 991 A>G and 1004 G>A resulted in higher Km and lower Vmax values for S-Mephenytoin 4'-Hydroxylation resulting in a reduced intrinsic clearance of 11% compared to *1. For the Omeprazole 5'-Hydroxylation, Km and Vmax values could not be determined for CYP2C19*24 due to its low catalytic activity.;CYP2C19 *24 is associated with decreased clearance of mephenytoin and omeprazole in E.coli as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 26.57% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *32 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for K28I is 43.04% compared to *1 (no variants).;CYP2C19 *31 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*11, CYP2C19*23;*11 + *23;Associated  with  increased formation of  ➔ 16ALPHA-HYDROXYTESTOSTERONE;Metabolism/PK;;CYP2C19 *11 + *23 is associated with increased formation of 16alpha-hydroxytestosterone as compared to CYP2C19 *1.
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;Associated  with  increased formation of  ➔ 11ALPHA-HYDROXYTESTOSTERONE;Metabolism/PK;;CYP2C19 *9 + *11 + *23 is associated with increased formation of 11alpha-hydroxytestosterone as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 83.78% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *29 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for K28I is 43.04% compared to *1 (no variants).;CYP2C19 *29 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 18.36% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *31 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*30;*30;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 12.17% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;CYP2C19 *30 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.
SIPONIMOD;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3/*3 + *2/*2;Associated  with  decreasedmetabolism of  ➔ SIPONIMOD;Metabolism/PK;"HLM incubations from CYP2C9*3/*3 and CYP2C9*2/*2 donors showed ~ 10- and 3-fold decrease in siponimod metabolism as compared to *1/*1. ""In silico simulation predicted a significant reduction in siponimod clearance in the CYP2C9*2/*2 and CYP2C9*3/*3 genotypes based on the in vitro metabolism data"",  ""the predicted mean area under the curve (AUC) is 2.7-, 3.0- and 4.5-fold higher in the CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, respectively, compared with the CYP2C9*1/*1 genotype"". Individual liver microsomes from 16 donors of 3 genotypes were included in the analysis.";CYP2C9 *3/*3 + *2/*2 are associated with decreased metabolism of siponimod as compared to CYP2C9 *1/*1.
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*13;*13;Associated  with  decreasedclearance of  ➔ DICLOFENAC;Metabolism/PK;measured by rate of formation of 4'-hydroxydiclofenac.;CYP2C9 *13 is associated with decreased clearance of diclofenac in yeast expression system as compared to CYP2C9 *1.
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Associated  with  decreasedclearance of  ➔ DICLOFENAC;Metabolism/PK;measured by rate of formation of 4'-hydroxydiclofenac.;CYP2C9 *3 is associated with decreased clearance of diclofenac in yeast expression system as compared to CYP2C9 *1.
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Associated  with  decreasedclearance of  ➔ TOLBUTAMIDE;Metabolism/PK;;CYP2C9 *1/*3 is associated with decreased clearance of tolbutamide as compared to CYP2C9 *1/*1.
ANDROSTENEDIONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;Associated  with  increased formation of  ➔ ANDROSTENEDIONE;Metabolism/PK;;CYP2C19 *9 + *11 + *23 is associated with increased formation of androstenedione as compared to CYP2C19 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*52;*52;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *52 had a relative clearance of 0.2% compared to *1.;CYP2C9 *52 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
METHADONE;CYP2C19;rs749678783;C;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for M255T was 23.51% of *1;Allele C is associated with decreased clearance of methadone as compared to allele T.
METHADONE;CYP2C19;rs770829708;A;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for D341N was 10.1% of *1;Allele A is associated with decreased clearance of methadone as compared to allele G.
FLUOXETINE;CYP2C19;rs72552267;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R132Q is 37.45% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
METHADONE;CYP2C19;rs200150287;G;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for R125G was 35.53% of *1;Allele G is associated with decreased clearance of methadone as compared to allele C.
FLUOXETINE;CYP2C19;rs749678783;C;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for M255T is 29.96% compared to *1 (no variants).;Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.
FLUOXETINE;CYP2C19;rs138142612;A;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for R329H is 37.84% compared to *1 (no variants).;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
FLUOXETINE;CYP2C19;rs181297724;C;Associated  with  decreasedclearance of  ➔ FLUOXETINE;Metabolism/PK;Formation of norfluoxetine from fluoxetine in insect microsomes. No information about the gene construct generation used for the assay. Intrinsic clearance is Vmax/Km. Relative clearance for A161P is 23.94% compared to *1 (no variants).;Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.
FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;rs181297724;C;Associated  with  decreasedsensitivity to ➔ FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine. Construct included A161P and I331V but not *2 key SNP.";Allele C is associated with decreased sensitivity to fluoxetine, ketoconazole, sertraline or ticlopidine as compared to allele G.
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;rs181297724;C;Associated  with  increased sensitivity to ➔ FLUVOXAMINE, OMEPRAZOLE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine. Construct included A161P and I331V but not *2 key SNP.";Allele C is associated with increased sensitivity to fluvoxamine or omeprazole as compared to allele G.
FLUOXETINE;CYP2C19;rs17878459;C;Associated  with  decreasedsensitivity to ➔ FLUOXETINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine. The construct includes E92D and I331V.";Allele C is associated with decreased sensitivity to fluoxetine as compared to allele G.
CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;CYP2C19;rs17878459;C;Associated  with  increased sensitivity to ➔ CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine. The construct includes E92D and I331V.";Allele C is associated with increased sensitivity to celecoxib, fluconazole or fluvoxamine as compared to allele G.
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;Associated  with  increased clearance of  ➔ MEPHENYTOIN;Metabolism/PK;Please note, the association is reported for *1B, which has the I331V variant.;CYP2C19 *23 is associated with increased clearance of mephenytoin in cos-7 cell as compared to CYP2C19 *1.
FLUVOXAMINE;CYP2C19;rs3758581;G;Associated  with  increased sensitivity to ➔ FLUVOXAMINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";Allele G is associated with increased sensitivity to fluvoxamine as compared to allele A.
VORICONAZOLE;CYP2C19;rs763625282;A;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Caution: M136K amino acid change might or not be together with W212X. No information about the gene construct generation used for the assay, the article names the variant *3C (M136K). In table 1 it lists W212X as effect for *3C. However it is not clear if the *3 signature SNP (W212X) is included in the *3C M136K construct since the *3 signature SNP construct by itself results in not detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for M136K is 24.63% compared to *1 (no variants).;Allele A is associated with decreased clearance of voriconazole in insect microsomes as compared to allele T.
VORICONAZOLE;CYP2C19;rs3758581;G;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Clearance was 33.84% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;Allele G is associated with decreased clearance of voriconazole in insect microsomes as compared to allele A.
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Associated  with  decreasedaffinity to ➔ OMEPRAZOLE;Metabolism/PK;Comparison was to construct the has Ile331Val. Article states CYP2C19.1B having Ile331Val-however, according to definition would be *1C.  The kinetic parameter K(m) of CYP2C19*19 was assessed and compared to CYP2C19*1B.;CYP2C19 *19 is associated with decreased affinity to omeprazole as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;rs770829708;A;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Caution: The variant might be together with rs4244285. No information about the gene construct generation used for the assay. The article names the construct *2F(D341N), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for D341N was 15.25% of wild-type. CYP2C19 variants expressed in Sf21 insect cells using baculovirus-mediated expression system.;Allele A is associated with decreased clearance of voriconazole n insect microsomes as compared to allele G.
CELECOXIB, FLUCONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;Associated  with  increased sensitivity to ➔ CELECOXIB, FLUCONAZOLE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *14 is associated with increased sensitivity to celecoxib and fluconazole as compared to CYP2C19 *1.
FLUOXETINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;Associated  with  decreasedsensitivity to ➔ FLUOXETINE, SERTRALINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *14 is associated with decreased sensitivity to fluoxetine and sertraline as compared to CYP2C19 *1.
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;Associated  with  increased sensitivity to ➔ FLUCONAZOLE, FLUVOXAMINE;Metabolism/PK;"The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. ""Sensitivity"" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.";CYP2C19 *13 is associated with increased sensitivity to fluconazole and fluvoxamine as compared to CYP2C19 *1.
VORICONAZOLE;CYP2C19;rs181297724;C;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Caution: The variant might be together with rs4244285. No information about the gene construct generation used for the assay. The article names the construct *2C(A161P), however it is not clear if it carries other *2 variants such as the signature splice variant or rs12769205 the other splice variant in *2. There is no comparison *2 construct without additional amino acid changes. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance was 24.59% compared to *1 (no variants).;Allele C is associated with decreased clearance of voriconazole in insect microsomes as compared to allele G.
METHADONE;CYP2C19;rs200346442;A;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Insect microsomes expressing the CYP2C19 alleles were incubated with 50-2000‘M methadone. No information about the constructs other than the protein change (name of the variant) or cDNA *1 reference of wt. Relative intrinsic clearance for R124Q was 1.48% of *1;Allele A is associated with decreased clearance of methadone as compared to allele G.
VORICONAZOLE;CYP2C19;rs550527959;T;Associated  with  decreasedclearance of  ➔ VORICONAZOLE;Metabolism/PK;Caution: The variant might be together with rs4244285. No information about the gene construct generation used for the assay. The article names the construct *2G(D360V), however it is not clear if it carries other *2 variants such as the signature splice variant. There is no comparison *2 construct. However there is a *3 construct that results in no detectable enzyme activity. Intrinsic clearance is Vmax/Km. Relative clearance for D360V was 5.61% compared to *1 (no variants).;Allele T is associated with decreased clearance of voriconazole in insect microsomes as compared to allele A.
;CYP2C19;rs7902257;A;Associated  with  decreased expression of CYP2C19 ➔ ;Other;This variant was detected in a group of Xhosa volunteers from S. Africa. Dual luciferase assays were used to determine the effect of the *allele on CYP2C19 gene expression. The promoter construct contained reference for ss230394406 (C), ss230394407 (C), rs17878739 (T), rs3814637 (C), and rs7902257(A) for the *1.006 (formerly *27) variant. The construct only included the promoter region of CYP2C19*1.006. The rs7902257 A containing construct showed a significant decrease in fold induction when compared to the G containing construct.;Allele A is associated with decreased expression of CYP2C19 in HepG2 cells as compared to allele G.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*51;*51;Associated  with  increased clearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *51 had a relative clearance of 479.0% compared to *1.;CYP2C9 *51 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.
;CYP2C9;rs4918758;C;Associated  with  decreasedtranscription of CYP2C9 ➔ ;Other;Promoter activity was measured in a luciferase assay using HepG2 cells transfected with a luciferase (Luc) construct harboring the promoter SNPs of CYP2C9, and bgalactosidase expression plasmid. The construct carrying both the rs4918758 (-1188) C and rs9332094 (-1766) C allele had five-fold reduction in activity compared to the construct with T alleles at both positions (wild-type sequence of -1766T/-1188T), p<0.01.;Allele C is associated with decreased transcription of CYP2C9 as compared to allele T.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*33;*33;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *33 had a relative clearance of 0.4% compared to *1.;CYP2C9 *33 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*13;*13;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *13 had a relative clearance of 11.7% compared to *1.;CYP2C9 *13 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*16;*16;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *16 had a relative clearance of 14.0% compared to *1.;CYP2C9 *16 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*45;*45;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *45 had a relative clearance of 2.0% compared to *1.;CYP2C9 *45 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
;CYP2D6;rs16947;AA + AG;Associated  with  decreased expression of CYP2D6 ➔ ;Other;rs16947 was significantly associated with a 2.4-fold decrease (P = 0.011) in CYP2D6 mRNA levels in a multiple linear regression analyses adjusted by rs5758550/rs133333 genotype.;Genotypes AA + AG are associated with decreased expression of CYP2D6 in human liver cells as compared to genotype GG.
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*22, CYP2D6*26, CYP2D6*48;*22 + *48;Associated  with  increased clearance of  ➔ PRIMAQUINE;Metabolism/PK;*22, construct containing 82C>T variation in cDNA and *48, containing 972C>T variation in cDNA had increased intrinsic clearance compared to a cDNA construct containing no variation. *22 = 192%' *48 + 162%;CYP2D6 *22 + *48 are associated with increased clearance of primaquine in 293FT cells as compared to CYP2D6 *1.
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*89, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;Associated  with  decreasedclearance of  ➔ METHADONE;Metabolism/PK;Variants were introduced into CYP2D6 cDNA and expressed in insect cells. The intrinsic clearance (Vmax/Km) was reduced for the N-demethylation of methadone.;CYP2D6 *2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98 are associated with decreased clearance of methadone as compared to CYP2D6 *1.
;CYP2D6;CYP2D6*1, CYP2D6*92, CYP2D6*96;*92 + *96;Associated  with  decreased activity  of CYP2D6 ➔ ;Metabolism/PK;*92 (1995delC) and *96 (3895C>T) were introduced into CYP2D6 cDNA and expressed in insect cells. The activity of these constructs did not allow for determination kinetic parameters (Km and Vmax) for the transformation of tamoxifen.;CYP2D6 *92 + *96 are associated with decreased activity of CYP2D6 as compared to CYP2D6 *1.
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;Associated  with  decreasedclearance of  ➔ VENLAFAXINE;Metabolism/PK;"The reaction of venlafaxine to O-desmethylvenlafaxine (5?500ù‘M substrate (three variants was adjusted to 1000ù‘M) venlafaxine) was measured for *2 (R296C, S486T); *10 (P34S, S486T); *87 (A5V); *88 (V104A); *89 (L142S); *90 (K147R); *91 (C161S); *93 (T249P); *94 (D337G); *95(R388H); *97 (F457L); *98 (H463D) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. Relative clearance as % of *1: *2: 28.3; *10: 2.9; *87: 38.3; *88: 49.4; *89: 71.1 ;*90: 75.1; *91: 37.90; *93: 0.2; *94: 71.9; *95: 47.7; *97: 44.2; *98: 56.6. One-way analyses of variance with Dunnett?s tests.Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.";CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of venlafaxine as compared to CYP2D6 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*36;*36;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *36 had a relative clearance of 0.1% compared to *1.;CYP2C9 *36 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*98;*10 + *87 + *90 + *93 + *95 + *98;Associated  with  decreasedclearance of  ➔ GEFITINIB;Metabolism/PK;"Recombinant microsomes expressing CYP2D6 variants generated in Spodoptera frugioerda 21 (Sf21) insect cells were used. Gefitinib and its metabolite O-desmethyl gefitinib were analyzed by an ultra-performance liquid chromatography-tandem mass spectrometry system.; Variants Vmax (pmol/min/pmol P450) Km (‘M) Ksi (‘M) Clint (Vmax/Km) Relative clearance (% of wild type); CYP2D6.1 1.25¤0.02 6.94¤0.44 158.10¤31.16 0.18¤0.01 100.00; CYP2D6.2 (R296C; S486T) 0.82¤0.14 19.61¤4.69** 31.61¤6.97** 0.04¤0.00** 23.43**; CYP2D6.10 (P34S; S486T) 0.09¤0.00** 16.83¤1.53* 41.86¤1.73** 0.01¤0.00** 3.11**; CYP2D6.87 (A5V) 1.31¤0.03 11.02¤0.42 62.21¤4.16** 0.12¤0.00** 65.82**; CYP2D6.90 (K147R) 1.83¤0.08* 15.17¤0.40 74.55¤6.36** 0.12¤0.00** 66.97**; CYP2D6.93 (T249P) 0.07¤0.00** 10.61¤0.43 88.43¤15.92** 0.01¤0.00** 3.68**; CYP2D6.95 (R388H) 1.27¤0.02 14.46¤0.59 88.79¤2.62** 0.09¤0.00** 48.82**; CYP2D6.98 (H463D) 7.86¤0.37** 96.63¤5.08** 5.92¤0.30** 0.08¤0.00** 45.13**";CYP2D6 *10 + *87 + *90 + *93 + *95 + *98 are associated with decreased clearance of gefitinib as compared to CYP2D6 *1.
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;Associated  with  decreasedclearance of  ➔ BUFURALOL;Metabolism/PK;"The bufuralol 1?-hydroxylation activities were measured for *2 (R296C, S486T); *10 (P34S, S486T); *87 (A5V only, and missing the *100C>T of the *87 allele); *88 (V104A); *89 (L142S); *90 (K147R); *91 (C161S only, and missing the 2988G>A splice variant of the *91 allele); *93 (T249P); *94 (D337G only,  missing the 100C>T of the *94 allele); *95(R388H only, missing the 100C>T of the *95 allele); *97 (F457L); *98 (H463D) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. Relative clearance as % of wild-type: *2: 40.4; *10: 1.34; *87: 34.47; *88: 47.1; *90: 81.98; *91: 46.59; *93: 0.4; *94: 74.56; *95: 53.56; *97: 36.55; *98: 31.59. One-way analyses of variance with Dunnett?s tests. The bufuralol 1?-hydroxylation activity was measured for the *134 (rs76088846) and *153 (rs567606867) construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1 (wild type). Relative clearance as % of wild-type: *134 = 49.74 and *153 = 0.23.";CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153 are associated with decreased clearance of bufuralol in insect microsomes as compared to CYP2D6 *1.
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;Associated  with  decreasedclearance of  ➔ RISPERIDONE;Metabolism/PK;"The the conversion of risperidone to 9-OH risperidone was measured for *2 (R296C, S486T); *10 (P34S, S486T); *87 (A5V); *88 (V104A); *89 (L142S); *90 (K147R); *91 (C161S); *93 (T249P); *94 (D337G); *95(R388H); *97 (F457L); *98 (H463D) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. Relative clearance as % of *1: *2: 26.56; *10: 2.01; *87: 43.30; *88: 75.86; *89: 87.56; *90: 78.40; *91: 85.37; *93: 9.62; *94: 78.92; *95: 46.85; *97: 53.99; *98: 64.47 No information about *1 construct but might be cDNA.Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.";CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of risperidone as compared to CYP2D6 *1.
CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;Associated  with  decreasedclearance of  ➔ CITALOPRAM;Metabolism/PK;Variants were introduced into CYP2D6 cDNA and expressed in insect cells. The variants showed a reduced intrinsic clearance for both demethylation and oxidation of citalopram compared to *1. Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.;CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98 are associated with decreased clearance of citalopram as compared to CYP2D6 *1.
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;Associated  with  decreasedclearance of  ➔ ATOMOXETINE;Metabolism/PK;"Recombinant human CYP2D6 expressed in microsomes from insect cells. in vitro assay measuring the enzymatic activity using atomoxetine as substrate. intrinsic clearance is Vmax/Km. Star alleles exhibited decreased Vmax or increased Km. Variants that define the star alleles are not reported. E.g. not clear what variants were used to construct *2. *91 probably is based on 1736G>C (C161S) not including the 2989G>A (splicing defect) that is part of *91; 100C>T might be not included in the *87, *94, and *95 construct. *10 showed 4.3 % of wt, *2 54.32 % of wt.";CYP2D6 *90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10 are associated with decreased clearance of atomoxetine as compared to CYP2D6 *1.
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*98;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;Associated  with  decreasedclearance of  ➔ TAMOXIFEN;Metabolism/PK;Variants were introduced in the CYP2D6 cDNA and expressed in insect cells. *2 (R296C and S486T): 43% of *1, *10 (P34S and S486T): 23% of *1, *87: 49% of *1, *90: 57% of *1, *91: 42% of *1, *93: 13% of *1, *95: 39% of *1, *98: 49% of *1. Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.;CYP2D6 *2 + *10 + *87 + *90 + *91 + *93 + *95 + *98 are associated with decreased clearance of tamoxifen as compared to CYP2D6 *1.
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*93, CYP2D6*94, CYP2D6*95;*10 + *93 + *94 + *95;Associated  with  decreasedclearance of  ➔ TOLTERODINE;Metabolism/PK;"In-vitro assay. The the conversion of tolterodine to 5-Hydroxymethyl tolterodine was measured for *10 (P34S, S486T); *93 (T249P); *94 (D337G); *95(R388H) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. *94 an d*95 constructs missing 100C>T variant that is part of both haplotype definitions.";CYP2D6 *10 + *93 + *94 + *95 are associated with decreased clearance of tolterodine as compared to CYP2D6 *1.
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;Associated  with  decreasedclearance of  ➔ DEXTROMETHORPHAN;Metabolism/PK;"The dextromethorphan O-demethylation activities were measured for *87 (A5V only, and missing the *100C>T of the *87 allele); *90 (K147R); *91 (C161S only, and missing the 2988G>A splice variant of the *91 allele); *93 (T249P); *94 (D337G only, missing the 100C>T of the *94 allele); *95(R388H only, missing the 100C>T of the *95 allele; *97 (F457L); *98 (H463D) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1. Relative clearance as % of wild-type: *87: 47.31; *90: 58.94; *91: 41.13; *93: 1.3; *94: 67.03; *95: 30.24; *97: 44.7; *98: 14.3. One-way analyses of variance with Dunnett?s tests. The dextromethorphan O-demethylation activity was measured for the *134 (rs76088846) and *153 (rs567606867) construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1 (wild type). Relative clearance as % of wild-type: *134 = 47.20 and *153 = 1.45.";CYP2D6 *87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153 are associated with decreased clearance of dextromethorphan in insect microsomes as compared to CYP2D6 *1.
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;Associated  with  decreasedclearance of  ➔ AMITRIPTYLINE;Metabolism/PK;The variants were introduced into CYP2D6 cDNA and expressed in insect cells. The variants showed a decreased intrinsic clearance (Vmax/Km).Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.;CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of amitriptyline as compared to CYP2D6 *1.
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs745746329;T;Associated  with  decreasedclearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Metabolism/PK;The 1) bufuralol 1?-hydroxylation and 2) dextromethorphan O-demethylation activities were measured for the E215K construct in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1 (wild type). Relative clearance as % of wild-type: 1) 58.38 and 2) 54.86. One-way analyses of variance with Dunnett?s tests.;Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.
OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;Associated  with  decreasedclearance of  ➔ OLANZAPINE;Metabolism/PK;"The the conversion of olanzapine to 2-hydroxymethylolanzapine was measured for *2 (R296C, S486T); *10 (P34S, S486T); *87 (A5V); *88 (V104A); *89 (L142S); *90 (K147R); *91 (C161S); *93 (T249P); *94 (D337G); *95(R388H); *97 (F457L); *98 (H463D) constructs in insect cells. The intrinsic clearance was calculated as Vmax/Km. The relative clearance is in relation to *1.  No information about *1 construct but might be cDNA. Clearance in % *10: 5.2 *87: 26.0 *88: 78.9 *90: 75.8 *91: 75.7 *93: 17.7 *95: 68.4 *97: 75.3. Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.";CYP2D6 *10 + *87 + *88 + *90 + *91 + *93 + *95 + *97 are associated with decreased clearance of olanzapine as compared to CYP2D6 *1.
;CYP2C9;rs9332094;C;Associated  with  decreasedtranscription of CYP2C9 ➔ ;Other;Promoter activity was measured in a luciferase assay using HepG2 cells transfected with a luciferase (Luc) construct harboring the promoter SNPs of CYP2C9, and bgalactosidase expression plasmid. The construct carrying both the rs4918758 (-1188) C and rs9332094 (-1766) C allele had five-fold reduction in activity compared to the construct with T alleles at both positions (wild-type sequence of -1766T/-1188T), p<0.01.;Allele C is associated with decreased transcription of CYP2C9 as compared to allele T.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*37;*37;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *37 had a relative clearance of 37.7% compared to *1.;CYP2C9 *37 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*42;*42;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *42 had a relative clearance of 0.1% compared to *1.;CYP2C9 *42 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
;CYP2C9;rs7089580;AT + TT;Associated  with  increased  expression of CYP2C9 ➔ ;Other;in human liver tissues.;Genotypes AT + TT is associated with increased expression of CYP2C9 as compared to genotype AA.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*55;*55;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *55 had a relative clearance of 32.0% compared to *1.;CYP2C9 *55 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*56;*56;Associated  with  increased clearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *56 had a relative clearance of 643.2% compared to *1.;CYP2C9 *56 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*53;*53;Associated  with  increased clearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *53 had a relative clearance of 448.0% compared to *1.;CYP2C9 *53 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*50;*50;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *50 had a relative clearance of 39.8% compared to *1.;CYP2C9 *50 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*54;*54;Associated  with  increased clearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *54 had a relative clearance of 388.3% compared to *1.;CYP2C9 *54 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*19;*19;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *19 had a relative clearance of 3.4% compared to *1.;CYP2C9 *19 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*31;*31;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *31 had a relative clearance of 51.4% compared to *1.;CYP2C9 *31 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
LOSARTAN;CYP2C9;rs1057910;C;Associated  with  decreasedclearance of  ➔ LOSARTAN;Metabolism/PK;Statistically significant 2- to 3-fold lower rates of E-3174 formation were evident in microsomes from CYP2C9*1/*3   individuals and a 9-fold lower rate was observed in liver microsomes from a single CYP2C9*3/*3 individual compared with CYP2C9*1/*1.;Allele C is associated with decreased clearance of losartan.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*41;*41;Associated  with  increased clearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *41 had a relative clearance of 365.6% compared to *1.;CYP2C9 *41 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*27;*27;Associated  with  increased clearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *27 had a relative clearance of 179.0% compared to *1.;CYP2C9 *27 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*14;*14;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *14 had a relative clearance of 13.3% compared to *1.;CYP2C9 *14 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*62;*62;Associated  with  decreasedclearance of  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;Metabolism/PK;Recombinant wild-type CYP2C9 and 3 CYP2C9 variants (*2, *3, *62) were assayed in-vitro with tolbutamide, losartan and diclofenac and the clearance rate Clint (Vmax/ Km) was determined. tolbutamide = 0.00096 ¤ 0.00023 (7.48%), losartan = 0.15 ¤ 0.02 (0.83%), diclofenac = 0.72 ¤ 0.13 (32.68%). CYP2C9*62 is the 8576C > T (R125C).;CYP2C9 *62 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Associated  with  decreasedclearance of  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;Metabolism/PK;Recombinant wild-type CYP2C9 and 3 CYP2C9 variants (*2, *3, *62) were assayed in-vitro with tolbutamide, losartan and diclofenac and the clearance rate Clint (Vmax/ Km) was determined. tolbutamide = 0.010 ¤ 0.0017 (80.4%), losartan = 10.15 ¤ 1.03 (54.85%), diclofenac = 1.46 ¤ 0.086 (68.46%).;CYP2C9 *2 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Associated  with  decreasedclearance of  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;Metabolism/PK;Recombinant wild-type CYP2C9 and 3 CYP2C9 variants (*2, *3, *62) were assayed in-vitro with tolbutamide, losartan and diclofenac and the clearance rate Clint (Vmax/ Km) was determined. tolbutamide = 0.0027 ¤ 0.00032 (21.45%), losartan = 1.29 ¤ 0.13 (7.01%), diclofenac = 1.05 ¤ 0.11 (48.85%).;CYP2C9 *3 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*47;*47;Associated  with  increased clearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *47 had a relative clearance of 470.3% compared to *1.;CYP2C9 *47 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*49;*49;Associated  with  increased clearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *49 had a relative clearance of 249.8% compared to *1.;CYP2C9 *49 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *3 had a relative clearance of 13.5% compared to *1.;CYP2C9 *3 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*43;*43;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *43 had a relative clearance of 2.7% compared to *1.;CYP2C9 *43 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*39;*39;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *39 had a relative clearance of 1.1% compared to *1.;CYP2C9 *39 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;Associated  with  decreasedclearance of  ➔ PHENYTOIN;Metabolism/PK;In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *8 had a relative clearance of 6.2% compared to *1.;CYP2C9 *8 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.
;ZNF890P;rs62442010;AA;Associated  with  increased transcription of ABCB1 ➔ ;Other;"Authors observed increases in ABCB1, ABCC1, ABCC2 and ABCG2 transcripts and consider this a ""functional expression cluster"". Regulators of this cluster may therefore be important for treatment resistance.";Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AC + CC.
